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With the rise in obesity, there has been an increased interest in foods which may 
beneficially affect appetite. Resistant starch (RS) and whole grains (of which RS 
is a main dietary fibre component) have been proposed to affect satiety and 
therefore may be beneficial in weight management. There is little direct evidence 
confirming this in humans. Whilst animal data suggest a positive effect of RS on 
appetite, the few existing human intervention studies provide inconsistent 
findings. For whole grains the majority of evidence is from epidemiological work 
as opposed to intervention studies. Therefore a series of studies was conducted 
to investigate effects of RS and whole grains on appetite and food intake.
Two studies were conducted using RS. The first investigated the acute (24 
hours) effects of 48 g RS in healthy adult males compared with an energy and 
available carbohydrate matched placebo. Following RS there was a significantly 
lower energy intake compared with placebo. There was also a significantly lower 
postprandial insulin response with RS, possibly explained by increased hepatic 
insulin clearance determined by a higher C-peptide to insulin ratio. In the second 
study 40 g RS consumed daily for 4 weeks was compared with the placebo, in 
overweight and obese participants. Effects on food intake were assessed and a 
frequently sampled intravenous glucose tolerance test (FSIVGTT) was 
conducted. This study found no effect on either appetite or energy intake, but did 
find significantly higher glucose, insulin and C-peptide concentrations, measured 
during the FSIVGTT, with the RS compared with the placebo, possibly explained
Abstract
by an improved first-phase insulin response. This finding did not translate into 
differences in parameters obtained from modelling the FSIVGTT data, but this 
and the lack of appetite and food intake differences could be explained by the 
small participant numbers.
Two intervention studies were conducted with whole grains incorporated into 
bread rolls. The first, a crossover study, involved 3 weeks’ daily consumption of 
48 g milled whole grain or control, in young healthy adults. Whilst no significant 
difference was found between interventions in energy intake or subjective 
appetite ratings, a significantly lower systolic blood pressure was observed with 
the milled whole grains. The second was an 8 week parallel study (48 g intact or 
48 g milled whole grains or control) in overweight and obese adults. No 
significant difference was found between groups on energy intake, subjective 
appetite ratings, cholesterol or postprandial metabolite concentrations.
RS appears to be a possible satiating ingredient when consumed acutely and, 
whilst this was not confirmed in our chronic study, effects may have been 
masked by small participant numbers. A novel finding from our RS studies was 
an effect on the insulin response. These studies suggest that RS could have a 
beneficial role in weight management and favourable metabolic effects. Our 
whole grain interventions appear not to agree with epidemiological work that 
suggests a beneficial role on appetite, but there maybe effects on blood 
pressure regulation. In all instances further investigations are required in other 
population groups, with more participants and for longer time periods.
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Chapter 1
Introduction
C hapter 1
The following chapter describes the background literature relating to the 
conducted research. The chapter includes introductory information on appetite, 
physiological regulation of food intake and the role of insulin, as well as a 
summary of current literature on the effects of consumption of resistant starch 
and whole grains on appetite, weight regulation and insulin responses.
1.1. Obesity
Obesity has become a global epidemic and rates are increasing in economically 
less developed countries, as well as in the most developed (World Health 
Organisation (WHO), 2000a). In a report by the National Audit Office (2001) 
proportions of the population in England (from data collected in 1998), who are 
obese (body mass index, BMI >30 kg/m2) or overweight (BMI >25 kg/m2), were 
reported to be over half of women and approximately two thirds of men, with one 
in five adults being obese. It was stated in this report that if levels of obesity 
increased at the rates observed at the time of the report, then by 2010 over a 
quarter of adults would be obese (National Audit Office (NAO), 2001).
Obesity has been linked to an increased risk of developing other diseases 
including cardiovascular disease (CVD), osteoarthritis, respiratory diseases, 
type 2 diabetes mellitus (T2DM), gastrointestinal diseases, liver diseases, gall 
bladder disease, reproductive disorders and some cancers (National Audit 
Office (NAO), 2001, World Health Organisation (WHO), 2000b, World Health 
Organisation (WHO), 2000a). Indeed it has been stated that obesity is the main
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modifiable risk factor for development of T2DM, and the relative risk rises with 
increasing BMI (World Health Organisation (WHO), 2000a). Central obesity is 
considered more hazardous to health, due to fat accumulation around organs, 
and increases co-morbidity risk (Haslam and James, 2005). Central obesity, 
more than peripheral obesity, is a significant contributor to the development and 
progression of insulin resistance and the metabolic syndrome (World Health 
Organisation (WHO), 2000b). Several mechanisms have been proposed as to 
how the increased risk of insulin resistance due to central obesity arises. These 
include the presence of the high levels of internal fat itself, but also to the 
secretion of inflammatory cytokines (for example tumour necrosis factor alpha 
(TNFa) and interleukins 1 and 6 (IL1 and IL6) from the adipose tissue (Haslam 
and James, 2005). It has been shown that weight loss, even modest amounts, 
can be of benefit to many of the associated conditions (World Health 
Organisation (WHO), 2000b).
1.1.1. Energy balance
Energy intake and expenditure are key factors that regulate body weight and a 
prolonged imbalance between these two factors results in weight gain or loss. 
Energy balance is closely maintained even within large variations in energy 
intake and expenditure (Murphy and Bloom, 2004). However, over recent years, 
changes in lifestyle have resulted in an increase in energy intake (due to more 
readily available food and higher energy density foods) and decreased energy 
expenditure (more labour saving devices and less physical activity). Both of
3
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these contribute to an obesogenic environment. Only a small imbalance 
between intake and expenditure over several years would lead to obesity.
1.2. Appetite
1.2.1. Definitions
Appetite is the desire or physical craving to eat and is typically separated into 
three parts -  hunger, satiation and satiety. In a review by Mattes et al (2005) 
hunger is defined as “sensations that promote food consumption”, satiation as 
“sensations that govern meal size and duration”, and satiety as “sensations that 
determine the inter-meai period of fasting”. Therefore satiation and satiety are 
important for determining energy intake. All these aspects of appetite are closely 
regulated by physiological factors, but are also influenced by external cues 
(including activity levels, availability of food, the presence or absence of other 
people and the hedonic properties of the food itself), psychological factors (such 
as learnt habits and beliefs) and emotional factors (for example response to 
stress or happiness) (Mattes et al., 2005, Flint et al., 2000).
Appetite is difficult to quantify as it is subjective and varies greatly between 
individuals, as well as being influenced by many factors (both external and 
internal) and therefore there is no easy direct assessment; nevertheless indirect 
measures have been developed (Mattes et al., 2005). The most frequently used 
indirect methods involve monitoring food intake (for example, through dietary 
records, food frequency questionnaires or ad libitum test meals), using
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biomarkers (for example monitoring changes to concentrations of gut hormones) 
and the use of questionnaires (for example those that require subjects to rate 
how they feel in response to a meal) (Mattes et al., 2005).
1.2.2. Physiological regulation
1.2.2.1. Short-term regulation
Appetite is regulated by many physiological factors that interact, including 
involvement of the hypothalamus and hormones released from the gut (Bloom et 
al., 2005). The latter act on areas of the brain including the hypothalamus (the 
main site of action), the brainstem and the vagus nerve (Bloom et al., 2005, 
Druce et al., 2004) and subsequently modulate appetite regulation.
The hypothalamus is vital for appetite regulation and the subsequent control of 
food intake (Dhillo, 2007); it receives peripheral signals from the digestive tract 
(gut peptides) and adipose tissue (through signalling molecules, including leptin 
and insulin) (Figure 1.1) (Murphy and Bloom, 2004, Wynne et al., 2005). There 
are several different areas (nuclei) in the hypothalamus, of which the arcuate 
nucleus (ARC) is thought to be the most important in appetite regulation (Dhillo, 
2007, Heijboer et al., 2006), due to the area having an incomplete blood brain 
barrier. The ARC is essential for interpreting peripheral signals, which act on 
receptors and consequently cause the release of neuropeptides (Bloom et al., 
2005, Murphy and Bloom, 2004, Wynne et al., 2005). There are two classes of 
neurones in the ARC, those that stimulate food intake (neuropeptide Y (NPY)
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and agouti-related peptide (AgRP)) and those that inhibit food intake (pro­
opiomelanocortin (POMC) and cocaine- and amphetamine-regulated transcript 
(CART)) (Heijboer et al., 2006, Wynne et al., 2005).
Figure 1.1: Peripheral factors (short and long term) involved in appetite regulation acting on 
the hypothalamus. Taken from Wynne et al (2005). Long-term factors in red, short-term 
factors in green
Gut hormones that regulate food intake are both anorexigenic (increase satiety) 
and orexigenic (promote hunger). The hormone ghrelin is unique in being 
orexigenic and is often termed the “hormone of hunger” (Druce et al., 2004, 
Wynne et al., 2005, Murphy and Bloom, 2004). Anorexigenic hormones are 
released postprandially; they act by both direct and indirect mechanisms and 
promote feelings of satiety. These hormones include cholecystokinin (CCK), 
glucagon-like peptide 1 (GLP-1), oxyntomodulin (Oxm), peptide YY (PYY) and 
pancreatic polypeptide (PP) (Bloom et al., 2005).
Ghrelin is primarily secreted from endocrine cells in the stomach (De Vriese and 
Delporte, 2007). The form in which ghrelin is secreted is distinctive as it is made
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up of 28 amino acids with an octanoyl group added, which allows ghrelin to exert 
its actions (De Vriese and Delporte, 2007). In addition to increasing food intake, 
ghrelin has other functions in the body including stimulation of growth hormone 
release and increasing gastric emptying, and it has been shown to decrease the 
secretion of gastric acid in rodent models (Druce et al., 2004, De Vriese and 
Delporte, 2007). Plasma concentrations of ghrelin are highest when an 
individual is fasting and fall during a meal in response to changes to glycaemia 
(De Vriese and Delporte, 2007); lower fasting concentrations of ghrelin are 
typically found in obesity (De Vriese and Delporte, 2007) and, as individuals 
loose weight, ghrelin concentrations rise, which partially accounts for problems 
associated with sustaining weight loss (Druce et al., 2004).
CCK is released rapidly postprandially, primarily from enteroendocrine cells of 
the duodenum and jejunum, due to the presence of amino acids and fatty acids 
(Coll et al., 2007, Holt et al., 1992). CCK concentrations stay high for up to five 
hours (Bloom et al., 2005, Wynne et al., 2005). The release of CCK causes, in 
addition to effects on appetite, gall bladder contraction, inhibition of gastric 
emptying, stimulation of gastric motility, and exocrine pancreatic secretions 
(Bloom et al., 2005, Holt et al., 1992, Wynne et al., 2005). Administration of CCK 
in humans has been shown to reduce both meal size and duration (Holt et al., 
1992). It has been reported that CCK may influence body weight due to 
interaction with leptin and subsequent enhancement of the effects of leptin (as 
discussed below, section 1.2.2.2).
7
C hapter 1
GLP-1 and Oxm are synthesised from the processing of the progiucagon gene 
in the gut (Druce et al., 2004, Small and Bloom, 2004); glucagon is also 
synthesised from the proglucagon gene in the pancreas and is the principle 
product of proglucagon processing (Bloom et al., 2005). GLP-1 and Oxm are 
released from endocrine L cells in the small intestine (Coll et al., 2007), 50% of 
GLP-1 is released from the small intestine and 50% from the large intestine 
(Robertson et al., 1999). Oxm promotes satiety and causes decreased secretion 
of gastric acid, delayed gastric emptying and has a role in the control of weight 
(Bloom et al., 2005, Coll et al., 2007). Oxm concentrations increase following 
food intake (Druce et al., 2004) and the associated decrease in food intake 
observed may be partially explained due to inhibition of ghrelin (Bloom et al., 
2005). GLP-1 is secreted in response to absorbed nutrients (glucose, fat and 
protein) and causes a reduction in food intake and enhanced satiety (Adam and 
Westerterp-Plantenga, 2005, Bloom et al., 2005). Postprandial release of GLP-1 
also delays gastric emptying, reduces secretion of gastric acid and inhibits 
glucagon release (Druce et al., 2004, Adam and Westerterp-Plantenga, 2005, 
Murphy and Bloom, 2004). In humans the greatest concentration of GLP-1 (and 
the biologically active form) is GLP-17-36 (Girard, 2008). Studies have shown that 
GLP-1 concentrations are lower in obesity and therefore it has been suggested 
that administration of GLP-1 may enhance satiety and cause weight loss (Bloom 
et al., 2005, Wynne et al., 2005). GLP-1 is also an incretin (Dhillo, 2007). 
Incretins are gut hormones that increase the insulin response by stimulating 
insulin secretion and therefore play a role in blood glucose regulation (Girard,
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2008, Kim and Egan, 2008). The insulin produced due to the action of incretins 
may account for at least 50% of the insulin released in response to oral glucose 
intake (Kim and Egan, 2008). Once GLP-1 has been released it travels in the 
circulation and binds with a specific receptor (GLP-1 R) on the a and (3 cells in 
the Islets of Langerhans (Girard, 2008), which increases intracellular cAMP 
(cyclic adenosine monophosphate) and calcium concentrations, in turn 
activating other signalling pathways (Kim and Egan, 2008). Receptor binding 
and signalling pathway activation results in increased insulin secretion, inhibition 
of glucagon release and increase in (3-cell proliferation and survival (Girard, 
2008, Kim and Egan, 2008). GLP-17.36 is rapidly broken down to an inactive form 
due to the action of protease enzymes (such as dipeptidyl-peptidase-lV (DPP- 
IV)) (Dhillo, 2007, Wynne et al., 2005). Therefore due to the incretin actions of 
GLP-1, strategies using analogues of GLP-17-36, that are resistant to DPP, are 
being trialled for use in treatment of T2DM (Coll et al., 2007, Dhillo, 2007, 
Wynne et al., 2005).
PYY is secreted from L cells in the distal intestine (predominately the ileum and 
colon). PYY is secreted in 2 forms, PYYi-36 and PYY3.36, the most active of 
which is PYY3.36. It has been shown to reduce food intake and promote satiety 
(Bloom et al., 2005). Concentrations of PYY rise rapidly following a meal (Druce 
et al., 2004, Coll et al., 2007) in proportion to energy consumed and 
concentrations stay high for about six hours (Bloom et al., 2005, McGowan and 
Bloom, 2004). PYY concentrations also rise following high fat intake and in the
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presence of gastric acid and CCK (McGowan and Bloom, 2004). PYY is 
released quickly following ingestion but before nutrients arrive at the distal 
portion of the intestine, suggesting neuronal and upper gastrointestinal tract 
involvement (Wynne et al., 2005, McGowan and Bloom, 2004). A further PYY 
release occurs once the nutrients reach the colon, approximately 4 - 5  hours 
after the meal (Druce et al., 2004). PYY has been proposed to act as an “ileal 
brake” which may contribute to satiety and feelings of fullness (Druce et al.,
2004). PYY has other documented effects apart from inhibition of food intake, 
which include slowing gastric emptying and delaying exocrine secretions from 
the pancreas and gall bladder (Bloom et al., 2005, Druce et al., 2004).
PP is released from endocrine F-cells that are located near to the pancreatic 
islets (Coll et al., 2007). PP concentrations rise proportionally to the amount of 
food consumed and concentrations stay high for approximately six hours (Bloom 
et al., 2005, Murphy and Bloom, 2004, Wynne et al., 2005). PP is not only 
released relative to calorie intake, but also by gastric distension, in response to 
blood glucose concentrations and due to the presence of other gut hormones 
(Murphy and Bloom, 2004). Its actions in addition to those on food intake include 
inhibition of pancreatic exocrine secretion, gastrointestinal motility and gall 
bladder contraction. When PP has been administered to normal weight 
individuals, subsequent food intake was reduced until the following morning 
(Druce et al., 2004).
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1.2.2.2. Long-term regulation
Other factors are also important in appetite regulation and reflect longer-term 
energy stores rather than short-term effects to ingested nutrients. Leptin is a 
hormone that is released from adipocytes and circulates in the blood at 
concentrations that are proportional to body fat mass (Druce et al., 2004, 
Murphy and Bloom, 2004, Wynne et al., 2005). Leptin has been found to reduce 
food intake (Druce et al., 2004) and its concentrations are seen to fall during 
starvation (Small and Bloom, 2004). Once released it stimulates anorexigenic 
neurons and causes negative feedback inhibiting the orexigenic actions (Druce 
et al., 2004, Dhillo, 2007); this causes food consumption to be inhibited and 
prevents further body fat mass increase. When leptin is deficient it results in 
obesity in both humans and rats (Murphy and Bloom, 2004). However, leptin 
concentrations in obesity do not appear to be deficient, and indeed plasma 
concentrations are high (due to the high levels of adipose tissue), suggesting 
that in obesity individuals may be resistant to the actions of leptin (Murphy and 
Bloom, 2004) and therefore the potential of leptin as a treatment for obesity is 
limited (Dhillo, 2007). Insulin also acts as a long-term energy signal and is 
discussed in more detail below (section 1.3).
1.3. Insulin
1.3.1. Mechanism of action
Insulin is a small peptide secreted from the p-cells of the Islets of Langerhans in 
the pancreas and is co-secreted (in identical amounts) with connecting peptide
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(C-peptide), both of which are part of the same original molecule, proinsulin. 
These two peptides are removed from the body by different routes, insulin 
predominantly by the liver and C-peptide by the kidneys (Rossell et al., 1983). 
As such, insulin and C-peptide have different half lives (5 minutes and 30 
minutes respectively) and therefore C-peptide concentrations are normally 5 
times higher than insulin in the periphery. Of the insulin that arrives at the liver 
via the portal system, approximately 50% is removed during 1st pass transit 
(Polonsky and Rubenstein, 1984), and thus C-peptide is often used as a 
surrogate marker of insulin secretion (Hills and Brunskill, 2009, Toffolo et al., 
1995). Measurements of insulin and C-peptide concentrations taken 
concomitantly can provide information on both insulin secretion and hepatic 
clearance (Cobelli et al., 2007, Faber et al., 1981). Hepatic insulin clearance 
calculated as the ratio of C-peptide to insulin, should still be interpreted with 
caution due to many other factors that may influence or confound the findings 
(Polonsky and Rubenstein, 1984).
Whilst it has been considered that C-peptide does not have an active role in 
metabolism and is inert, only acting to stabilise and ensure the correct formation 
of insulin molecules, emerging evidence now contradicts this assumption (Hills 
and Brunskill, 2009, Wahren, 2004). C-peptide may act at a cellular level, by 
binding to cell membrane receptors and activating signalling pathways. It may 
also exert an independent beneficial effect on the nephropathy and neuropathy 
found in diabetes (Hills and Brunskill, 2009, Wahren, 2004).
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Insulin secretion is pulsatile and biphasic. In the first phase, insulin is released 
rapidly due to increases in blood glucose concentrations and in the second 
phase insulin has a slower sustained release (Gerich, 2002). Insulin has many 
actions, both those that promote and those that inhibit metabolism. Inhibiting 
actions include gluconeogenesis (production of glucose from other substances), 
glycogenolysis (glycogen breakdown), lipolysis (fat breakdown), ketogenesis 
(production of ketones) and proteolysis (protein breakdown). Enhancements 
include glucose uptake into muscle and adipose tissue, glycogen synthesis and 
protein synthesis. Of insulin’s actions perhaps the most fundamental is glucose 
uptake into cells (Trout et al., 2007).
Blood glucose concentrations are tightly regulated and maintained at 
approximately 5 mmol/l. During fasting, in normal conditions, insulin 
concentrations are low and blood glucose concentrations are maintained 
through the release of glucagon (from the a-cells of the Islets of Langerhans), 
which activates enzymes (such as glucose 6-phosphatase) that produce glucose 
from glycogenolysis and gluconeogenesis. After ingestion of macronutrients, 
insulin concentrations rise and the release of glucose from the liver is down- 
regulated, resulting in conservation of body stores and the use of exogenous 
carbohydrate for metabolism (Figure 1.2). In the postprandial phase glucose 
uptake can be both insulin-dependent and independent. Different isoforms of the 
glucose transporters are expressed in different areas of the body, for example 
GLUT2 is expressed mainly in the liver, GLUT4 in muscles and fat, GLUT1 in
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the brain, kidney and colon, GLUT5 in the jejunum and GLUT3 in many areas 
including the brain and kidney (Bell et al., 1990). The insulin-dependent uptake 
in muscle and fat involves insulin binding to cellular membrane receptors (insulin 
receptor substrates (for example IRS-1)) and activating intracellular signalling 
pathways, which ultimately results in the translocation of GLUT4 to the 
membrane surface (Bell et al., 1990, Trout et al., 2007). GLUT2, unlike GLUT4, 
is continually expressed on the membrane surface to allow bi-directional 
movement of glucose in the liver (Bell et al., 1990). The main sites of action of 
insulin are the liver, muscle and adipose tissues.
S ystem ic
1.3.2. insulin sensitivity
insulin sensitivity is defined as the ability of insulin to control blood glucose 
concentrations, through glucose uptake into tissues and the inhibition of hepatic 
glucose output (Trout et al., 2007).
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Insulin resistance arises due to the inability of insulin to execute its actions at a 
given insulin concentration (Wallace and Matthews, 2002), and higher insulin 
concentrations are therefore required to maintain normal glucose concentrations 
(Trout et al., 2007). Over long periods of time the insulin produced may become 
inadequate to maintain the normal glucose concentrations (due to [3-cells no 
longer maintaining sufficient secretion), which would result in high glucose 
concentrations, and, if this is prolonged, could progress to T2DM. The 
progression of increased insulin resistance and the effects on insulin production 
and blood glucose concentrations are shown in Figure 1.3.
Time
»
Insulin 
Resistance
Insulin 
Production
— Glucose 
Concentration
Non- Pre- Type 2
diabetes diabetes diabetes
Figure 1.3: Progression of insulin resistance over time and the effects on insulin production 
and glucose concentrations. Greater production of insulin is required overtime to maintain 
blood glucose concentrations, due to increasing insulin resistance. This eventually leads to 
reduced insulin secretion and subsequently higher glucose concentrations observed in Type 2 diabetes.
Insulin resistance is associated with other pre-disposing factors such as an 
increased waist circumference (a marker of visceral obesity), hypertension and
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dyslipidaemia. When several of these factors appear concomitantly it is defined 
as the Metabolic or Insulin Resistance Syndrome. There are different definitions 
of the Metabolic Syndrome; however, one commonly cited was put forward by 
the European Group for the Study of Insulin Resistance (EGIR). The EGIR 
definition of the metabolic syndrome is designed for non-diabetic individuals and 
is described by the presence of insulin resistance or high fasting insulin 
concentration (concentrations in the highest 25% of the population), which would 
equate to being a concentration greater than 60 pmol/l. This needs to be present 
in combination with two other factors from: fasting hyperglycaemia (greater than 
6.1 mmol/l in an individual without diabetes), hypertension (£140/90 mmHg or 
treated hypertension), dyslipidaemia (triglycerides (TG) >2.0 mmol/l or HDL- 
cholestero! <1.0 mmol/l or treated dyslipidaemia) or central obesity (waist 
circumference £94 cm for men and £80 cm for women) (Balkau and Charles, 
1999). Another frequently used definition is the US National Cholesterol 
Education Program Adult Treatment Panel III definition (National Institutes of 
Health, 2001). This definition is predominately lipid based and requires three or 
more of the following factors to be present: abdominal obesity (assessed by 
waist circumference £102 cm in men or £88 cm in women), high TG 
concentrations (£1.695 mmol/l (£150 mg/dl)), low high-density lipoprotein (HDL) 
(<1.036 mmol/l (<40 mg/dl) in men and <1.295 mmol/l (<50 mg/dl) in women), 
hypertension (£130/85 mmHg) or hyperglycaemia (£6.1 mmol/l (£110 mg/dl)) 
(National Institutes of Health, 2001).
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Several techniques are used to measure insulin sensitivity, some of which are 
discussed in more detail below. The “gold standard” technique is the 
euglycaemic-hyperinsulinaemic clamp, described by DeFronzo et al (DeFronzo 
et al., 1979). This method investigates glucose uptake directly in the steady 
state and as such the data do not require modelling. Limitations of the technique 
include risk of hypoglycaemia, lack of metabolic flexibility (as humans live in a 
non-steady state) and the relative invasiveness, intensity and cost of the 
technique (Trout et al., 2007, Wallace and Matthews, 2002). It is also not 
possible from this technique to measure (B-cell function (Cobelli et al., 2007). As 
the clamp is considered to be the gold standard, other methods have been 
validated against it with varying precision and these are discussed below.
The most common alternative to the clamp is the intravenous glucose tolerance 
test (IVGTT). The frequently sampled IVGTT (FSIVGTT) involves a short (few 
minutes) intravenous infusion of glucose at a steady rate for a set time with 
collection of frequent blood samples to measure changes to glucose and insulin 
concentrations. This has also been modified to include a short (normally 5 
minutes) infusion of insulin to enhance the individual’s own insulin response 
(Trout et al., 2007, Finegood et al., 1990) and this modification has been shown 
to improve the estimation of insulin sensitivity (Yang et al., 1987). Many different 
protocols are used for the IVGTT and there is little standardisation between 
groups, making comparisons between studies difficult (Wallace and Matthews,
2002). In a review by Bingley et al (1992) a standard protocol, not involving
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insulin infusion, was proposed. The IVGTT has the advantage that it provides 
information not only on insulin sensitivity, but also on [3-cell function (Bergman,
2005). Data from an IVGTT require modelling to provide indices of insulin 
sensitivity. The most validated model is the “Minmod”, a minimal model 
technique developed by Bergman et al (1981) and this software is extensively 
used; it has been stated to have become “in effect, the “industry standard” for 
analysing frequently sampled intravenous glucose tolerance test (FSIVGTT) 
data” (Boston et al., 2003). This model calculates (3-cell function and insulin 
sensitivity from an IVGTT (both the insulin modified and non-modified versions) 
and involves two mathematical models, the first of which is a model of insulin 
kinetics (looking at first and second phase of the (3-cell response) and the 
second, a model of glucose kinetics (measuring insulin sensitivity) (Bergman et 
al., 1981).
The acute insulin response (first phase) observed in the first 8 - 1 0  minutes is 
widely reported from IVGTT (Mari et al., 2008, Cobelli et al., 2007). In the first 10 
minutes after the glucose has been administered, there is a peak of blood 
glucose concentrations, as the infused glucose mixes in the circulation, and an 
initial peak in insulin concentrations due to activation of the [3-cells (Trout et al., 
2007). Up to 20 minutes after the glucose administration, the glucose disposal is 
proposed to be glucose-mediated and after 20 minutes is said to be insulin- 
mediated (Trout et al., 2007). During the insulin modified IVGTT there are two 
insulin peaks, one is the endogenously produced insulin and the second is due
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to the infused insulin. The sensitivity value for the IVGTT is derived from the 
glucose concentrations in relation to concentrations of insulin. This technique 
has been reported to be reproducible; it is less invasive, requires less 
investigator skill (Trout et al., 2007) and correlates well with the clamp (Beard et 
al., 1986). However, the IVGTT is time consuming and the results are 
dependent on the minimal modelling software used and on interpretation 
(Wallace and Matthews, 2002).
The oral glucose tolerance test (OGTT) has also been used to measure insulin 
sensitivity. The test involves an oral dose of 75 g of glucose and then collection 
of blood samples for 2 hours. This test is used clinically to determine an 
individual’s glycaemic status and WHO criteria have been developed for 
diagnostic purposes. Clinically samples are taken at time zero and 120 minutes, 
but increased information can be obtained by frequent sampling. This test is 
limited by poor reproducibility and can be affected by gastric emptying rate 
(Trout et al., 2007); however it can give an indication of whole body insulin 
sensitivity (Matsuda and DeFronzo, 1999).
Measures of postprandial oral insulin sensitivity have also been developed to 
calculate the insulin sensitivity to a meal (Caumo et al., 2000). A value of insulin 
sensitivity is given based on area under the curve (AUC) calculations for insulin 
and glucose concentrations and involves minimal modelling of glucose kinetics 
and a mathematical equation of how quickly glucose is absorbed and appears in
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the blood following oral consumption (Caumo et al., 2000). Caumo et al (2000) 
evaluated the postprandial oral insulin sensitivity value against the sensitivity 
value obtained in the same subjects by an insulin-modified FSIVGTT. The study 
found that the two insulin sensitivity values obtained were well correlated (rs = 
0.89, p= <0.01), although the actual values obtained were significantly different 
(p=<0.001) with the oral test value being approximately twice as high as the 
value from the IVGTT. Another study has shown that whilst the insulin sensitivity 
values obtained from the oral insulin sensitivity test are correlated with the 
insulin sensitivity from an IVGTT, the results were also twice as high and results 
regarding (3-cell function were less comparable (Steil et al., 2004). Flowever, the 
studies concluded that the oral insulin sensitivity test could still be used to 
assess changes to insulin sensitivity (Steil et al., 2004, Caumo et al., 2000), 
especially when other types of test may not be possible due to cost or practical 
reasons (Caumo et al., 2000). Postprandial tests are also useful when gut 
function or the incretin response is likely to be of importance.
Measurements of insulin sensitivity have also been calculated from fasting blood 
samples. The most established and validated is the homeostasis model 
assessment (HOMA). HOMA provides an estimate of insulin sensitivity (HOMA 
%S) and p-celi function (HOMA %B) compared with a young healthy reference 
population (Wallace and Matthews, 2002, Matthews et al., 1985). It uses a 
computer mathematical model, derived from measures of fasting insulin and 
glucose concentrations (taken at the same time) in individuals with different
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degrees of insulin resistance and (3-cell function; from this a subject’s %S and 
%B can be estimated (Matthews et al., 1985). Values obtained from HOMA have 
been shown to correlate well with the clamp (Bonora et al., 2000, Matthews et 
al., 1985). Fasting insulin concentrations are also used in isolation as a marker 
of insulin sensitivity and it is assumed that any fasting insulin concentration 
greater than 60 pmol/l (representing the top tertile of the general population) 
would indicate insulin resistance; this value has been shown to correlate with 
other factors of the metabolic syndrome. However, a limitation of the method is 
the assay methodology. Fasting insulin concentrations form the basis of the 
EGIR Criteria for insulin resistance. Both of these fasting measures rely on the 
accuracy of a single sample which may be affected by stress or the pulsate 
nature of insulin release and it has been proposed that more than one sample 
should be taken to account for these effects (Matthews et al., 1985, Wallace and 
Matthews, 2002).
1.3.3. Role of insulin in weight and appetite
Fasting insulin concentrations are correlated with the degree of obesity (Meistas 
et al., 1983). Postprandial insulin concentrations have also been shown to be 
higher in individuals with obesity (Meistas et al., 1983). It has been proposed 
that the high insulin concentrations observed in obesity could be due to 
increased insulin secretion, decreased clearance or a combination (Meistas et 
al., 1983, Rossell et al., 1983, Faber et al., 1981) and that insulin resistance 
could play a key role.
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Insulin has a role comparable to leptin in appetite regulation (long-term signals) 
as both increase with body adipose tissue mass (Murphy and Bloom, 2004, 
Wynne et al., 2005). However, the primary difference between leptin and insulin 
is the postprandial variation in insulin concentrations (Wynne et al., 2005). There 
are insulin receptors in the hypothalamus and insulin has been shown to 
stimulate POMC gene expression and inhibit NPY mRNA expression directly 
(Heijboer et al., 2006) causing a reduction in food intake (Murphy and Bloom, 
2004, Wynne et al., 2005). The lack of association between insulin 
concentrations and appetite in the obese could therefore potentially be 
explained by central insulin resistance.
There are conflicting data as to whether glucose and/or insulin are involved in 
short-term appetite regulation. A recent meta-analysis looking at the association 
between insulin and appetite in single meal interventions in both normal and 
overweight subjects (Flint et al., 2007) found that insulin was indeed associated 
with appetite regulation in normal weight subjects, but this association was 
absent in overweight subjects and a similar effect was not observed with 
glucose. Flint et al (2007) proposed mechanisms by which insulin may affect 
appetite, including direct insulin action on the hypothalamus or indirectly via 
gastrointestinal hormones.
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1.3.4. Glvcaemic index
The glycaemic index (Gl) was first defined by Jenkins et al (1981). Gl refers to a 
food rather than to an individual and so differs from the glycaemic response, 
which is the change in blood glucose concentrations of an individual in response 
to a food. Gl is therefore defined as a measure of how much 50 g of the 
available carbohydrate portion of a food raises the blood glucose concentration 
of an individual and is calculated using the incremental AUC (iAUC). This is then 
expressed as a percentage of the blood glucose response to 50 g of glucose in 
the same individual, again calculated using iAUC. Therefore Gl allows a 
quantitative comparison of blood glucose responses following ingestion of 
equivalent amounts of digestible carbohydrate from different foods. Foods are 
then classified based on their glycaemic response, with low Gl foods being 
classified as foods that are digested and absorbed slowly, whilst high Gl foods 
are those that are rapidly digested and absorbed (Brouns et ai., 2005). Gl values 
are classified as: low Gl < 55, intermediate Gl between 55 and 70 and high Gl > 
70 (Bornet et al., 2007).
High Gi foods not only cause a higher glycaemic response, but also elicit higher 
insulinaemic responses compared with low Gl (Ludwig, 2000). The higher insulin 
responses observed following high Gl foods have been reported to potentially 
promote weight gain (Ludwig, 2000). Gl is often used as a surrogate marker for 
the insulin response, as it is easier to measure than insulin concentration, even
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though it is actually the insulin response which is of more metabolic importance 
due to the associated health problems associated with hyperinsulinaemia.
Whilst the available carbohydrate portion of a food primarily determines the GI, 
other factors also exert an influence. These include the amount of fructose, 
lactose, soluble fibre, protein and fat that are present within the food (Bornet et 
al., 2007, Ludwig, 2000). The degree of food processing and particle size of a 
food can also affect GI, where the more processed a grain, the higher the GI 
(Englyst et al., 2003). When foods are combined, as typically consumed within a 
meal, the GI of each food is altered due to the presence of factors other than the 
food itself in the meal (Bornet et al., 2007). However, whilst there is lack of 
agreement between studies as to whether the GI of a meal can be predicted 
from the GI of each individual food, this is commonly used (Bornet et al., 2007). 
Wolever et al (2006) concluded from their study that the GI of individual foods is 
a “significant determinant of the glycaemic effect of mixed meals in normal 
subjects” when properly applied. In the review by Brouns et al (2005) it is 
recommended that the GI of a meal is based on the GI of the individual food 
(that has been measured, not taken from tables) and its contribution to the meal 
to provide an overall GI for the meal.
Another term used is the glycaemic load (GL). GL is defined as the GI of a food 
multiplied by the amount (in grams) of carbohydrate present and then divided by 
100, and is used as a measure of the glycaemic effect of a meal. It is thought to
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be a more sensitive measure of the effect of the available carbohydrate on the 
blood glucose response as it considers the amount of food being consumed 
(Lunn and Buttriss, 2007).
It has been proposed that low Gl foods and low GL meals, may have a 
beneficial role on risk factors for chronic diseases, especially T2DM, due to their 
influence on the glycaemic response (Bornet et al., 2007, Brouns et al., 2005) 
and therefore there is much debate about the Gl concept. Another mechanism 
by which low Gl foods could be beneficial is the effect of the glycaemic response 
on an attenuated postprandial insulin response (Liljeberg et al., 1999).
Brouns et al (2005) reviewed the methodology used for Gl to provide a standard 
protocol. The review provides a list of recommendations for the methodology, 
some of which are summarised below. Ten people (healthy males and females) 
should be used to provide reasonable precision, with tests taking place after an 
overnight fast (between 10 and 14 hours) and each individual consuming an 
evening meal, of their choice, but the same prior to each test. The reference 
food that is recommended is glucose, although the review states that other 
foods (in particular white bread) can be used, but must be calibrated against 
glucose. When glucose is used it is recommended that the 50 g is dissolved in 
250 ml of water and consumed within 10 minutes. As the reference food is used 
to determine the Gl of the test food it is desirable that this is repeated for each 
individual to reduce variation and therefore the paper recommends the reference
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food is repeated at least once to obtain an average value. Glucose 
measurement is recommended on fingertip capillary blood (either whole blood or 
plasma). Insulin concentrations are not needed for routine Gl measurements, 
but are recommended for completeness. Blood samples should be collected on 
fasting and then 15, 30, 45, 60, 90, 120 minutes from time zero, which is 
considered as after the first bite/sip of the food/drink being tested. The iAUC 
(ignoring areas below baseline) is the recommended AUC calculation.
Bornet et al (2007) conducted a systematic review on the effect of Gl on satiety 
and weight regulation. This review found that in short-term studies satiety was 
higher following low Gl foods/meals compared with high Gl foods/meals. 
However, results from long-term studies are less conclusive. The role of Gl as a 
predictor of appetite and satiety has since been reviewed by Niwano et al 
(2009). They also found that evidence from short-term studies indicated that 
both the glycaemic and insulinaemic responses were related to appetite and 
satiety, and reactive hypoglycaemia (blood glucose concentrations falling below 
baseline in response to food) appeared to indicate an earlier return of hunger. 
This review also found that the relationship between the glycaemic and 
insulinaemic responses were less established from long-term studies and further 
well-designed studies were required. A crossover study conducted for 12 weeks, 
where high or low Gl foods were incorporated into normal diets, found no effect 
of the lower Gl on energy intake, satiety or body weight in obese/overweight 
women (Aston et al., 2008). In this study effects on satiety were assessed at the
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end of the 12 week intervention periods, using ad libitum meals and visual 
analogue scales for subjective measures, and, as is acknowledged by the 
authors, the lack of findings on the test days may have been due to effects of 
chronic consumption. However, an eight day crossover study, where high or low 
GI foods were consumed at all meals in a laboratory setting to investigate the 
effects of GI and GL, also found no significant differences in ratings of appetite 
or food intake between the diets and no significant difference in glycaemic or 
insulinaemic responses (Alfenas and Mattes, 2005). Therefore this suggests that 
overall the data relating to GI and appetite are inconclusive.
1.4. Fibre
1.4.1. Types of fibre
In 2008 a definition for dietary fibre (DF) was agreed by the Codex Alimentarius 
Commission (Codex Committee on Nutrition and Foods for Special Dietary Uses 
-  CCNFSDU), where carbohydrate polymers of ten or more monomers, which 
are not hydrolysed in the small intestine by enzymes, are considered to be DF. 
They must be edible carbohydrate polymers that occur naturally in foods, or are 
carbohydrate polymers taken from raw foods (enzymatically, physically or 
chemically), or are synthetic carbohydrate polymers. The latter two need to have 
been shown to have a physiological benefit and need to be verified by scientific 
evidence (Cummings et al., 2009). Until this definition there were several 
conflicting definitions that considered different components as DF, although the
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majority of definitions considered components that are indigestible in the small 
intestine as being part of DF (Buttriss and Stokes, 2008).
DF has historically been divided into two classes depending on solubility in 
water, thus classified as either soluble or insoluble. Insoluble DF includes 
resistant starch, cellulose, hemicellulose and lignins, whilst soluble DF includes 
glucans, pentose and oligosaccharides (Lunn and Buttriss, 2007). Soluble DF is 
predominately found in vegetables, fruits, oats and barley, and insoluble DF, in 
whole grains (especially wheat and rice) and fibrous parts of plants, although 
most DF-containing foods are comprised of a mixture of both types. The two 
types have different properties in the body. Soluble DF absorbs water during 
transit in the gastrointestinal tract and forms viscous gels, whereas insoluble DF 
increases bulk and softens stools (Lunn and Buttriss, 2007). Flowever, some 
newly classified DF, such as resistant starch and inulin, do not fit easily in this 
classification and can exhibit a mixture of effects. As the terms soluble and 
insoluble do not completely reflect the physiological properties of all DF, they 
now tend to be classified as viscous or non-viscous DF, although many 
published studies still refer to the solubility. DF can also be classified as 
fermentable or non-fermentable, where the distinction is whether or not the DF 
reaches the colon, where the colonic microflora ferment the DF to produce 
products such as gases and short-chain fatty acids (SCFA).
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Soluble DF has been linked to lowering of postprandial glucose concentrations 
and positive effects on blood lipid concentrations, which may be mediated 
through delayed gastric emptying and subsequent slowing of nutrient absorption 
in the small intestine. However, epidemiological evidence suggests that it may in 
fact be the insoluble DF, such as those found in whole grains, that are linked to 
positive health effects (Weickert and Pfeiffer, 2008, Jenkins et al., 2000), for 
example a reduced risk for many chronic diseases including CVD, cancers 
(especially of the gastrointestinal tract), T2DM and obesity.
In a review of carbohydrates and DF by Lunn and Buttriss (2007) it is stated that 
high DF intakes are linked to five primary physiological benefits: improved 
gastrointestinal health, improved glucose and insulin responses, reduced CVD 
risk factors, reduced risk of development of some cancers and increased satiety. 
However, different DF may result in different physiological effects and an 
individual DF source may not exhibit all of the benefits.
In the United Kingdom (UK) the current recommendation for DF intake, 18 g per 
day, was set in 1991 (Department of Health, 1991). The definition was based on 
measurement of non-starch polysaccharides (NSP) by the Englyst method, as 
NSP was thought to contribute the most quantitatively to DF, could be measured 
with good precision and was chemically identifiable (Lunn and Buttriss, 2007). 
According to the method used by the Association of Official Analytical Chemists 
(AOAC) total DF would be approximately 24 g, which is more in line with the
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recommendations of many other countries (Buttriss and Stokes, 2008). The 
AOAC method incorporates a greater range of components, including resistant 
starch, sugar alcohols and the short-chain oligosaccharides, which are not 
accounted for in the Englyst method. The AOAC method is now commonly used 
by the food industry for labelling purposes (Lunn and Buttriss, 2007).
Whether 18 or 24 g as a recommendation is taken, the average intake of DF in 
the UK is well below either of these, at approximately 13 g per day (Buttriss and 
Stokes, 2008).
1.4.2. Effects of fibre on weight and appetite
DF may be beneficial in weight regulation. This diverse group of carbohydrates 
has been proposed to increase satiety (Slavin and Green, 2007) and this may 
therefore be one mechanism by which DF impacts on energy balance.
Studies have investigated the interaction between DF and weight, some of 
which were reviewed by Slavin (2005). This review found that from observational 
studies there was an inverse relationship between DF intake and body weight. 
However, this review also found that evidence from intervention studies was less 
consistent when DF foods or supplements were investigated. Experimental 
studies using different types of DF have found variable results, with some DF 
exhibiting satiating qualities and others not. Delargy et al (1995) performed two 
studies, one investigating the effects of high versus low DF and the other,
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varying ratios of insoluble (wheat bran) and soluble (psyllium gum) DF, on food 
intake and satiety. These studies found that higher DF intakes were associated 
with reduced energy intake at the next meal, although daily energy intake was 
not significantly different between the amount or ratios of DF; but there were 
slight effects on desire to eat after the high insoluble DF meal.
Pereira and Ludwig (2001) reviewed mechanisms by which DF may affect 
weight. Several mechanisms were discussed and divided into intrinsic, hormonal 
and colonic effects. Some of the mechanisms proposed included both the lower 
energy density (intrinsic effect) of DF and the fermentation of DF (colonic effect), 
which produces SCFA that may stimulate the satiety hormone GLP-1. This 
review also discussed other mechanisms including the role of other hormones 
(such as insulin, which is lowered due to slowed carbohydrate absorption) and 
effects on gut hormones involved in appetite (Pereira and Ludwig, 2001). Other 
mechanisms have also been proposed, including delayed gastric emptying, that 
may then prolong the feeling of fullness or slowed nutrient absorption, 
particularly glucose, which in turn may prolong satiety (Slavin, 2005, Mattes et 
al., 2005, Pereira and Ludwig, 2001).
1.4.3. Effects of fibre on insulin
Soluble DF forms gels, which have a beneficial effect on glucose and insulin 
responses due to reduced absorption rates, although results from long-term 
intervention studies are mixed (Venn and Mann, 2004). Other studies have
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shown that in fact it may be the insoluble DF that has beneficial effects on 
insulin responses and therefore may have a positive role in T2DM control 
(Wolever, 2000, Weickert and Pfeiffer, 2008).
In a study by Weickert et al (2005) the short-term effects of insoluble DF on 
glucose were assessed. The study was a randomised crossover study where 
subjects consumed three portions of macronutrient matched breads, either 
control white bread, or bread supplemented with purified insoluble DF (10.5 g 
wheat fibre, 10.6 g oat fibre or 10.4 g resistant starch) for one day and on the 
following day the control bread was taken. Effects on blood metabolites were 
assessed on both days. Overall on the day it was consumed the insoluble DF 
enhanced the insulin response and, on the following day, after the control meal 
the postprandial glucose measurements were significantly lower. A further study 
by Weickert et al (2006) investigated the effects of insoluble DF intake on insulin 
sensitivity, assessed using an euglycaemic-hyperinsulinaemic clamp. This was a 
three day randomised crossover study, in which subjects consumed three 
portions of either control white bread or bread enriched by an insoluble oat fibre. 
The study found an improvement in insulin sensitivity from the insoluble DF 
intake.
The beneficial effects of insoluble DF on glucose and insulin responses may be 
mediated through the production of SCFA from fermentation of DF (Weickert 
and Pfeiffer, 2008). Several mechanisms have been proposed as to how
32
C hapter 1
increased SCFA may affect glucose and insulin responses. The increased 
SCFA may decrease hepatic production of glucose and therefore alter insulin 
requirements (Weickert and Pfeiffer, 2008). Increased SCFA (particularly 
acetate) have been shown to reduce free fatty acid concentrations (Crouse et 
al., 1968), which are known to inhibit insulin mediated glucose uptake (Boden et 
al., 1994) and increase ectopic TG storage, therefore improving insulin 
sensitivity. Increased SCFA from fermentation of DF may also increase 
production of GLP-1 (as shown in animal models) which, due to the incretin 
actions of GLP-1, could affect insulin secretion (Pereira and Ludwig, 2001).
There is also evidence to suggest that DF may influence insulin sensitivity 
(Slavin and Green, 2007, Weickert and Pfeiffer, 2008) and this may be 
independent from any effects on body weight or appetite. Weickert and Pfeiffer 
(2008) reported that, based on the studies they reviewed, diets high in insoluble 
DF were associated with a reduced risk of T2DM and this could be mediated by 
improved insulin sensitivity, although the exact mechanism is still unclear.
1.5. Resistant starch
1.5.1. Definition
Resistant starch (RS) is a fermentable carbohydrate, which is not digested or 
absorbed in the small intestine, but passes to the colon where it is fermented by 
colonic bacteria to produce SCFA (including butyrate, acetate and propionate), 
organic acids (lactic acid) and some gasses (hydrogen, methane and carbon
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dioxide) (Champ, 2004). RS has been defined as "the sum of starch and 
products of starch degradation not absorbed in the small intestine o f healthy 
individuals” (Asp, 1992). RS, a non-viscous insoluble DF, is a high-amylose 
starch which is more resistant to digestion than amylopectin (rapidly digestible) 
(Nugent, 2005) and has been proposed to have effects similar to other DF, such 
as improved bowel function and reduced risk of some cancers, particularly of the 
bowel and lower gastrointestinal tract (Goldring, 2004).
RS is subdivided into 4 categories, RS1, RS2, RS3 and RS4. RS1 refers to RS 
where the granules of starch are surrounded by intact cell walls, making the 
starch physically inaccessible, and is found in grains, seeds and tubers (Brown, 
2004, Tapsell, 2004). RS2 refers to starches which are resistant to the action of 
amylase due to the structure of the granule and are found in foods such as 
unripe green bananas and raw potatoes (Brown, 2004, Tapsell, 2004). A form of 
RS2, high-amylose maize starch, is distinctive from other types of RS as it 
retains its resistant properties during food processing (Brown, 2004). RS3 is 
formed upon retrogradation of starches (as in cooked and cooled potatoes or 
pasta, and stale bread) and RS4 starch granules have been chemically or heat 
modified by manufacturers so that their digestibility is decreased and they resist 
digestion by enzymes; this enables them to be added to processed foods 
(Brown, 2004, Tapsell, 2004). The resistance of the starches can be affected by 
factors such as processing, cooking and chewing (Nugent, 2005).
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RS may be a useful way to increase DF intake at a population level, as it is easy 
to incorporate into food without adverse effects to either taste or texture (Brown, 
2004), which from a food industry perspective is extremely important. The safety 
of high consumption of RS was reviewed by Goldring (2004), who stated that 
whilst allergic reactions have been observed with other DF (such as inulin), 
there are no similar reported reactions with RS. However, some studies have 
reported increased flatulence, bloating and mild laxative effects, whereas other 
studies have not found effects of intakes up to 60 g per day.
Most of the studies that have involved supplementation with RS to assess its 
physiological effects have used RS2 and RS3 in their investigations.
1.5.2. Intake levels of resistant starch
The RS intake in the UK is low and was reported to be approximately 2.76 g per 
day (Tomlin and Read, 1990) although this estimate is now two decades old. 
There are differences between countries in RS intake, which can be accounted 
for by differences in habitual diets. Currently there are no dietary 
recommendations for the amount of RS specifically that should be consumed 
within the diet, although it is included in the 24 g DF recommendation by AOAC 
method.
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1.5.3. Health benefits of resistant starch
Many potential physiological effects of RS have been suggested, including 
improvements in bowel health, in glucose and insulin responses and blood lipid 
concentrations, as well as increases in satiety (Nugent, 2005, Higgins, 2004). 
Changes and improvements in these and other physiological effects may all 
therefore have a beneficial role in several chronic diseases, including obesity, 
CVD, T2DM, metabolic syndrome and some cancers (Nugent, 2005, Higgins, 
2004).
1.5.4. Effects of resistant starch on weight and appetite
Many studies investigating the effects of RS have measured body weight as an 
outcome measure; some of these (Muir et al., 2004, de Roos et al., 1995, 
Heijnen et al., 1996, Phillips et al., 1995) have reported that subjects’ body 
weight remained stable throughout the study. However, in many of the studies, 
subjects were asked to keep their diets constant or follow their normal dietary 
pattern, in order to assess other primary outcome measures (Phillips et al., 
1995, Muir et al., 2004, Heijnen et al., 1996), which may account for the lack of 
change in body weight. In the study by de Roos et al (1995) the subjects were 
able to eat freely and yet body weight still remained constant. Similarly, in a 
study in overweight and obese subjects that investigated the effects of RS 
supplementation on blood lipids, glucose and insulin, no change in body weight 
was observed (Park et al., 2004). Another study found that after 
supplementation with 30 g RS for 4 weeks there was no change in body weight
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or BMI, but that there was a small significant increase in lean body mass 
(Robertson et al., 2005).
Although the evidence for an effect of RS consumption on body weight is limited, 
different mechanisms have been proposed as to how RS may result in weight 
loss. These include lower energy intakes due to RS having a lower energy value 
per gram compared with rapidly digestible starch (RDS) (Raben et al., 1994, 
Champ, 2004, Nugent, 2005). It has also been stated that RS has similar 
properties to other DF (Phillips et al., 1995) and therefore may effect satiety and 
weight regulation, but further well controlled long-term interventions are 
required.
A review by Tapsell (2004) examined the effects of RS on the metabolic 
syndrome. It was stated that it is possibly the effects on slower absorption of 
glucose and the subsequent effects on lowering insulin concentrations that may 
affect hunger, fat storage and weight regulation.
RS may also affect weight regulation due to direct effects on appetite. Several 
mechanisms have been proposed, but the actual mechanism, if any, is not 
known. The production of SCFA from colonic fermentation of RS may cause an 
increase in the production of GLP-1, or a decrease in the release of glucose 
from the liver, which in turn may alter the requirement for insulin and therefore
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indirectly affect satiety (Pereira, 2002). RS may also affect appetite through 
mechanisms similar to those of other DF, as discussed previously.
Animal studies consistently show positive effects of RS on appetite, and rodent 
studies have also demonstrated effects of RS on gut hormone release (Keenan 
et al., 2006, Zhou et al., 2006, Zhou et al., 2008). These results have yet to be 
fully demonstrated in humans.
A human study by de Roos et al (1995) investigated the effect of one week 
supplementation with 30 g RS2, or 30 g RS3, or glucose, incorporated into 
habitual diets. Overall the study found that supplementation with either type of 
RS had little effect on appetite or food intake, (although subjects reported being 
slightly more satiated with RS2) and caused no change to energy or 
macronutrient intake.
A study by Raben et al (1994) investigated the effects of acute ingestion of RS 
compared with digestible starch, both mixed into an artificially sweetened fruit 
syrup. The study found postprandial glucose, insulin, gastric-inhibitory 
polypeptide (GIP) and GLP-1 concentrations were significantly lower after RS 
compared with the digestible starch, and that feelings of fullness and satisfaction 
were greater with digestible starch than RS. However, the interpretation was 
confounded as the texture of the drinks was different (the digestible starch was 
thick whilst the RS was liquid) which may have resulted in differences in gastric-
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emptying, and the fact that postprandial measures were only taken for 5 hours 
and the RS may need longer to have an effect.
In a study by van Amelsvoort and Weststrate (1992) the effects of different ratios 
of amylose to amylopectin in meals were assessed. It was found that 
immediately after consumption the high amylose was more satiating and that the 
effect lasted for up to 6 hours; although results may have been adversely 
affected by palatability. In a further study by Weststrate and van Amelsvoort 
(1993) there were no significant differences between different ratios of amylose 
and amylopectin in subjective appetite ratings.
A study by Robertson et al (2005) investigated the effects of four week 
supplementation with RS on insulin sensitivity (assessed using an euglycaemic- 
hyperinsulinaemic clamp and by postprandial oral insulin sensitivity using the 
minimal model method described by Caumo et al (2000)). As part of the 
outcome measures from the study, effects on ghrelin, GLP-1 and leptin were 
measured. The study found no significant difference on GLP-1 or leptin between 
the RS and placebo, but did find a significant increase in fasting concentrations 
of ghrelin.
Combining data there appears to be no effect or only a weak link between RS 
intake and satiety in the short term although further research is required 
(Higgins, 2004, Nugent, 2005).
39
C hapter 1
1.5.5. Effects of resistant starch on insulin
As discussed above, viscous DF is thought to lower insulin and glucose 
concentrations when consumed acutely. As RS is a non-viscous DF it would not 
be expected to affect these postprandial responses. Some studies have shown 
that RS consumption causes reduced glycaemic and insulinaemic responses 
when it has been used as a replacement for normal flour or other carbohydrates. 
However, in some of these studies (Raben et al., 1994, Park et al., 2004) the 
substitution with RS has resulted in differences in the amount of available 
(glycaemic) carbohydrate, GL and energy between the supplements, which 
could explain the effects observed on lower insulin and glucose responses
A study by Robertson et al (2003) matched the amount of available 
carbohydrate between the RS supplement and the placebo. This study found 
that, after one day’s consumption of 60 g RS compared with an available 
carbohydrate matched placebo, postprandial glucose and insulin concentrations 
were lower, in response to a standard fibre-free meal. There was also a higher 
insulin sensitivity (assessed by postprandial oral insulin sensitivity using the 
minimal model method described by Caumo et al (2000)) following the RS than 
the placebo.
A study by Behall and Hallfrisch (2002) looked at ratios of amylose in breads 
and the amount required to affect glucose and insulin concentrations. This study 
found that 50% (equivalent of approximately 8 g RS) or more amylose was
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required to affect the glucose concentrations and 60% (equivalent of 
approximately 11.5 g RS) or more to affect insulin concentrations. In a study by 
Behall and Howe (1995) the effects of 14 week consumption of high versus low 
amylose on insulin, glucose and TG concentrations were assessed. It was found 
that the insulin response was lower following high amylose than low amylose, 
but the glucose responses were similar. The study also found that the TG 
concentrations were lower with the high amylose starch.
In a study by van Amelsvoort and Westsrate (1992) the effects of amylose to 
amylopectin ratios in meals were assessed; they found lower glucose and 
insulin concentrations following the high amylose meals in the first hour after 
consumption, but the glucose concentrations between 2 and 6 hours post meal 
were higher with the high amylose starch. Another study by Weststrate and van 
Amelsvoort (1993) also investigated the effects of the different ratios of amylose 
and amylopectin, on postprandial insulin and glucose concentrations. They 
found that in response to the test breakfasts there were no significant 
differences between the supplements for glucose or insulin concentrations, 
although these were slightly lower with the high amylose. After the test lunches 
the glucose concentrations were significantly lower with the high amylose than 
the low amylose, but there were no significant differences between the starches 
for the insulin concentrations. A further study was conducted by Heijnen et al 
(1995) where the effects of different ratios of amylose and amylopectin, in 
different food matrices, on glucose and insulin concentrations were assessed.
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They found that in drinks the glucose and insulin responses were lower with the 
high amylose ratio, the glucose responses were lower in puddings with high 
amylose and there were similar effects on glucose and insulin when the different 
ratios were mixed into breads. Overall this study found that different physio- 
chemical properties of foods, into which amylose is mixed, impact on the 
subsequent effects observed on postprandial glucose and insulin 
concentrations.
Studies have investigated the effects of RDS and slowly digestible starch (SDS) 
on glucose and insulin responses. SDS, similarly to RDS, is digested completely 
in the small intestine (unlike RS), but the digestion of SDS is slower than that of 
RDS (Cummings and Englyst, 1995, Englyst et al., 1996). One study gave 
participants (healthy and those with T2DM) 50 g of each of the starches, on 2 
different occasions, and collected blood samples over a 6 hour postprandial 
period (Seal et al., 2003). The study found higher glucose and insulin 
concentrations with the RDS compared with the SDS in both participant groups. 
Those with T2DM also attended for an additional study visit where the SDS dose 
was increased to 89.7 g in order to try and match the glycaemic response 
observed with the RDS. Whist the glycaemic response with the greater dose of 
SDS was higher than the lower dose of SDS, it was still lower than RDS, 
although these differences were not significant (Seal et al., 2003). In a study by 
Ells et al (2005) the effects of RDS and SDS on glucose and insulin were also 
compared. In this study participants consumed 75 g of each starch and attended
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for a 6 hour postprandial study day, at the start (to assess acute changes) and 
end of the 14 days (to assess adaptation to 75 g/day), where the starch was 
consumed at a breakfast test meal. This study found significantly greater 
changes in glucose and insulin concentrations after the RDS compared with the 
SDS, although the 14 day adaptation period did not alter the findings.
The study by de Roos et al (1995), investigated the effects of one week 
supplementation with 30 g RS2, or 30 g RS3, or glucose, incorporated into 
habitual diets. Urine was also collected to assess C-peptide concentrations as a 
marker of insulin secretion. The study found that C-peptide concentrations were 
significantly lower following RS3 than either the RS2 or glucose, but were 
highest following the week’s supplementation with glucose, which the authors 
suggest shows that RS decreases insulin secretion.
The study by Robertson et al (2005) with four weeks’ supplementation of RS 
compared with an energy and carbohydrate matched placebo found an 
improvement in insulin sensitivity (measured by postprandial oral insulin 
sensitivity using the minimal model method described by Caumo et al (2000) 
and an euglycaemic-hyperinsulinaemic clamp) with RS compared with placebo.
Nugent (2005) reviewed studies that had investigated the effect of RS on insulin 
and glucose responses and found mixed results, with some showing decreased 
glucose and insulin responses and some no effects, although it was noted that
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there was no evidence for a detrimental effect of RS consumption on either 
insulin or glucose. The review also stated that it is difficult to compare the 
different studies as they have used different protocols and have used test meals 
that have varied in macronutrient content and amounts of available carbohydrate 
and DF, all of which may impact on insulin and glucose responses.
Higgins (2004) also reviewed effects of RS on insulin and glucose responses 
and looked at both acute and chronic effects. The acute studies reviewed 
showed mixed findings, for which proposed reasons included different types of 
RS being used in the studies, the macronutrient and DF content of tests meals 
being different and the effects of processing of the starch in the test meal. 
However, overall Higgins concluded that RS causes a small decrease in 
postprandial glucose responses and a greater effect on postprandial insulin 
concentrations. From the review of the chronic studies it was indicated that 
whilst it appears that RS improves insulin sensitivity in rodent studies, there 
were less available data for an effect in humans.
1.6. Whole grains
1.6.1. Definition
Whole grains are comprised of three layers; the bran, germ and endosperm. 
Each of these layers has a different nutritional composition with the presence of 
both nutrients and non-nutrients. The bran contains DF, B vitamins, 
phytonutrients (for example flavonoids and indoles) and some proteins; the
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endosperm is mostly made up of starch, with some proteins and a small amount 
of vitamins and minerals; the germ contains minerals (including iron and zinc), 
vitamin E, B vitamins and phytochemicals (Lang and Jebb, 2003). Commonly, 
when whole grains are milled the bran and germ layers (most nutrient dense 
parts) are removed leaving just the endosperm that is predominately digestible 
starch and thus of less nutritional value (Slavin, 2004, Smith et al., 2003). 
Although many refined flours are fortified to replace some of the lost nutrients, it 
is unclear whether this would provide the same effects as when the nutrients are 
present together in whole grains in natural amounts (Smith et al., 2003). The 
structure of a whole grain is shown in Figure 1.4.
Figure 1.4: Structure of a whole grain. Taken from Slavin (2004).
A grain can be termed a ‘whole grain’ even after processing, if all three layers 
are present in the proportions they are normally found in the native whole grain. 
The most often used and accepted definition of a whole grain, as stated by the
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American Association of Cereal Chemists (AACC) (1999) is: “Whole grains shall 
consist o f the intact, ground, cracked or flaked caryopsis, whose principal 
anatomical components -  the starchy endosperm, germ and bran -  are present 
in the same relative proportions as they exist in the intact c a ry o p s is Similarly, 
in the UK, the Institute of Grocery Distribution (IGD) (2008) whole grain Working 
Group recently defined whole grains as including those which have been 
processed in some manner, as long as the three main components are present 
in their normal proportions. The IGD (2008) definition states that a whole grain is 
“the edible entire grain after removal o f inedible parts such as the hull and 
glume. It must include the entire germ, endosperm and bran”.
The definition for a wholegrain food that is most commonly used is the one by 
the USA Food and Drug Administration (FDA) (1999), where in order for a food 
product to be considered a wholegrain food, the whole grains must make up 
51% or more, by weight of the portion that is typically consumed. The IGD 
(2008) recommend that, in order to claim that a product contains whole grains 
on the food label, it must contain at least 8 g whole grain per serving of the food.
1.6.2. Intake levels of whole grains
The consumption of whole grains in the UK is low. In a review by Lang et al 
(2003) intakes of whole grains in the UK were assessed, from two National 
surveys, the Dietary and Nutritional Survey of British Adults (aged 16-64 years) 
in 1986-87 and the National Diet and Nutrition Survey (in adults aged 65 and
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more) in 1994-95. From both surveys it appeared that a third of the UK adults 
surveyed did not consume whole grains daily and that 90% of those questioned 
consumed less than 3 servings per day. They also found that whole grain-intake 
increased with age and was higher in non-smokers and those with non-manual 
jobs. Whole grain-intake in British Adults in 1986-87 has also been compared 
with more recent intake data, from the National Diet and Nutrition Survey 2000- 
2001, by Thane et al (2007). This study found that whole grain-intake actually 
decreased from a median intake of 16 g per day (in 1986-87) to 14 g per day (in 
2000-01). Interestingly, the proportion of adults consuming no whole grains has 
increased overtime (from 31% to 39%). In both surveys whole grain-intake was 
lower in smokers than non-smokers, manual workers versus non-manual 
workers and older age groups consumed more whole grains than those in 
younger age groups.
There are many varieties of whole grains including, but not limited to, wheat, 
oats, rye, maize, rice and barley, although in the UK the most regularly 
consumed whole grains are wheat, rice and maize (Seal et al., 2006). Whilst all 
types of whole grain are comprised of the bran, germ and endosperm the actual 
nutrient content differs between grains, for example wheat grains are high in 
insoluble DF, whilst oats are high in soluble DF (Smith et al., 2003). In the work 
by Lang et al (2003), described above, it was found that wholegrain food choice 
also differs, in the younger group (adults aged 16 -64 years), the majority of 
whole grain-intake came from breads (48%) and then from breakfast cereals
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(29%); in older adults (aged 65 and over) most was from breakfast cereals 
(46%) and then wholemeal breads (42%).
Currently there is no dietary recommendation for whole grain consumption in the 
UK. However, higher amounts of DF rich foods are encouraged (Lang and Jebb,
2003), as well as whole grain varieties of starchy foods.
1.6.3. Health benefits of whole grains
Whole grains have been proposed to be beneficial in many chronic conditions 
including obesity, CVD, some cancers and T2DM (Seal et al., 2006, Slavin, 
2004, Smith et al., 2003). Although there are some intervention data, the 
majority of the evidence comes indirectly from epidemiological studies.
The health benefits of whole grains may come either from the individual 
components or from the different components working synergistically. Some 
whole grains contain high amounts of DF and in particular fermentable 
carbohydrates, RS (predominately RS1) and oligosaccharides (Smith et al., 
2003, Slavin, 2004). These fermentable carbohydrates have individually been 
shown to be beneficial, mostly likely due to fermentation and production of 
SCFA. Indeed it was stated in a review by Brown (2004) that “RS1 is likely to 
provide an important health contribution in whole grain foods”. Whole grains are 
also a good source of phytosterols (plant sterols and stanols), that lower blood 
cholesterol concentrations due to their similar structure to cholesterol (Slavin,
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2004), and are a good source of antioxidants (water and fat soluble), that are 
known to be important as a protective mechanism in many chronic diseases 
(Slavin, 2004).
Although evidence suggests high intakes of whole grains are beneficial, 
disentangling the effects of whole grains compared with DF alone is not always 
possible. It has been consistently found that individuals who consume higher 
amounts of whole grains also are likely to have other healthier lifestyle habits, 
such as not smoking, high activity levels, high consumption of fruits and 
vegetables and lower fat intakes (McKeown et al., 2002, Lang and Jebb, 2003). 
These factors serve as confounders to the interpretation of the whole grain data, 
although many of the studies do claim to adjust for these factors within their 
statistical analysis.
1.6.4. Effects of whole grains on weight and appetite
Whole grains have been proposed to be protective against the development of 
obesity (Koh-Banerjee and Rimm, 2003). However, there are limited studies, 
especially interventional, which have looked directly at the relationship between 
whole grains and body weight, with most of the existing evidence coming 
indirectly from epidemiology. Cohort studies do suggest an inverse association 
between body weight and higher levels of whole grain-intake (Koh-Banerjee and 
Rimm, 2003). However, some care needs to be taken when interpreting the data 
due to confounding factors, such as the often self-reported anthropometric
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measurements and whole grain-intake data obtained from questionnaires. Some 
of the evidence proposing a link between whole grains and weight comes from 
studies in which weight was not a primary outcome measure, but measured 
simply from routine.
The Nurses’ Health Study carried out over a period of 10 years found that 
women who had higher whole grain-intakes at baseline tended to weigh less 
than those with lower intakes, whereas for refined grain-intakes, high intakes 
were associated with higher body weights (Liu et al., 2003). They also found 
that, although BMI (calculated from self-reported weights) in the whole cohort 
increased over time, the increase was smaller in those who consumed whole 
grains rather than refined grains. Liu et al also reported that over a 10 year 
period whole grain-intake did increase slightly, by 0.13 servings per 1000 kcal. 
An inverse association has also reported between weight gain over 8 years and 
high levels of whole grain-intake from data from another prospective cohort 
study, the Health Professionals’ Follow-up Study (Koh-Banerjee et al., 2004).
In a study by McKeown et al (2002) it was found that after adjustment for 
confounding factors (such as age and gender) those who consumed high whole 
grain-intakes had lower BMI than those with low whole grain-intakes. The study 
also found that there was a significant inverse relationship between whole grain 
intake and waist to hip ratios, concentrations of fasting insulin, total cholesterol
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and LDL cholesterol. However, the relationship with insulin concentrations was 
lessened when corrections were made for DF and magnesium intakes.
Data from the Physicians’ Health Study examined the link between whole and 
refined grain breakfast cereal intake and weight change in men (Bazzano et al.,
2005). The study found that those who consumed breakfast cereals gained less 
weight than those who did not, although they did not find a significant difference 
between whole grain and refined grain cereals. The study also found that those 
who ate breakfast cereal also exhibited other healthier lifestyle choices (such as 
not smoking and having high physical activity levels). The authors attributed a 
lack of association between whole and refined grains to only assessing intake of 
breakfast cereals and not total daily grain intake.
A review by Seal (2006) discussed proposed mechanisms by which whole 
grains could lower CVD risk, including the beneficial effect of high whole grain 
intake on body weight. This review summarised several large studies (some of 
which were discussed above) that had investigated the effects of whole grains 
where weight and/or anthropometries had been outcome measures. It was 
concluded that there appeared to be a small inverse relationship between whole 
grain intake and body weight, but that further longer-term intervention studies 
were required.
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The exact mechanism, if any, by which whole grains may affect weight is not 
known, although various hypotheses have been proposed. These include effects 
of whole grains on the promotion of satiety, delayed digestion and absorption of 
nutrients and lower postprandial glucose and insulin concentrations (Slavin,
2004). The effects of whole grains on body weight regulation have been 
specifically postulated by Pereira (2002) and included the lower energy density 
of whole grain foods, the promotion of satiation (due to low palatability and 
effects of chewing) and prolonged satiety due to effects on gastrointestinal and 
pancreatic hormones. The presence of high amounts of DF and RS and their 
associated effects may also be a mechanism, as discussed above (Pereira, 
2 0 0 2 ), although as yet it has not been fully demonstrated that the effects of 
whole grains are fully independent from those of DF.
Although whole grains have been proposed to affect satiety (Slavin, 2004, 
Pereira, 2002), there is no direct evidence confirming this effect, although some 
indirect evidence exists.
In a study investigating the effects of whole grain intake on insulin sensitivity 
assessed using an euglycaemic-hyperinsulinaemic clamp (Pereira et al., 2002), 
all meals provided to the subjects for 6 weeks, were isoenergtic for energy 
requirements and weight maintenance. The subjects completed a daily 
questionnaire regarding ratings of hunger, which indicated a trend for less 
hunger between meals with whole grains compared with refined grains.
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Another study investigated the effect of particle size (a measure of grain 
processing) on satiety and glycaemic response (Holt and Miller, 1994). Four 
grades of wheat, whole grains, cracked grains, coarse wholemeal flour and fine 
wholemeal flour, were used. It was found that the satiety scores were higher in 
the less processed grains than with the refined grains. The glucose and insulin 
findings were inversed with the fine wholemeal flour producing higher responses 
than the less processed grains.
1.6.5. Effects of whole grains on insulin
In a review by Koh-Banerjee and Rimm (2003) improvement in insulin sensitivity 
was discussed as an indirect mechanism by which whole grains may be 
beneficial in weight regulation, due to the effects of high insulin concentrations 
on weight (as discussed above, section 1.3.3).
The relationship between whole grain intake and insulin sensitivity was 
discussed in a study by Steffen et al (2003). This study found that higher whole 
grain intake was associated with lower BMI and improved insulin sensitivity 
(measured by euglycaemic insulin clamp) in adolescents, and this association 
was strongest in adolescents with higher BMIs.
Data from a prospective cohort study showed an inverse association between 
whole grain-intake and several of the outcomes investigated, including BMI,
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inflammation, fasting insulin and insulin resistance (assessed by HOMA) (Lutsey 
et al., 2007).
The relationship between whole grain-intake and insulin sensitivity was also 
assessed in a study by Liese et al (2003). Data collected from the Insulin 
Resistance Atherosclerosis Study, combined insulin sensitivity, assessed by an 
insulin modified FSIVGTT, and whole grain-intake, assessed from food 
frequency questionnaires. The study found that on average the subjects 
consumed less than 1 serving of whole grain per day, but that high whole grain- 
intake was positively associated with insulin sensitivity and lower fasting insulin 
concentrations, when adjustments were made for lifestyle factors (such as 
smoking, energy intake and energy expenditure). When the authors adjusted for 
BMI and waist circumference the relationship remained, although at a lower 
significance level.
A study by Pereira et al (2002) investigated the effects of a 6 week whole grain 
intervention on insulin sensitivity in overweight adults. This was of a crossover 
design with all food on both legs (refined grain diet or whole grain diet) provided 
to the subjects and insulin sensitivity assessed by an euglycaemic- 
hyperinsulinaemic clamp. It was found that insulin sensitivity was increased 
following the whole grain compared with the refined grain intervention and 
fasting insulin concentrations were 10% lower with the whole grains compared 
with the refined grains.
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The effect of whole grains on insulin sensitivity, as measured by a euglycaemic- 
hyperinsulinaemic clamp, was also assessed in a recent study by Andersson et 
al (2007). This study found no improvement in insulin sensitivity in overweight 
subjects, from 6 week supplementation with either whole grain foods (112 g per 
day of whole grain ingredient) compared with refined grain foods, both supplied 
to be incorporated into habitual diets.
The combined effects of whole grains on insulin sensitivity were reviewed by 
McKeown (2004), in which potential mechanisms by which whole grains improve 
insulin sensitivity were proposed. These include (i) the high level of DF that 
would increase SCFA production and therefore improve insulin sensitivity, (ii) DF 
may reduce absorption of nutrients, leading to a reduced postprandial response 
of glucose and insulin, (iii) the high level of magnesium in whole grains could 
improve insulin signalling and regulate the action of insulin in peripheral tissues. 
Alternatively it is proposed that it may be the lower Gl of whole grain foods that 
could positively affect blood glucose and insulin concentrations, or the 
mechanism may be the effects of whole grains on body weight, as discussed 
above.
Whilst grains that have been processed are still considered to be whole grains, 
as per the definitions described above (section 1.6.1), the structure/form that the 
whole grain is in can have different effects on the metabolic response. Several 
studies have shown that when the whole grain is in the intact form there is a
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lower postprandial glycaemic and insulinaemic response than when the whole 
grain has been processed (Bjorck et al., 1994). For example a study by Holm 
and Bjorck (1992) investigated the effects of different breads (3 types of white 
wheat bread, 2 types of coarse breads and 3 high soluble DF rich breads) on 
glucose and insulin responses. The authors found that the coarse bread 
containing intact wheat kernels and the soluble DF rich bread (oat bran) 
produced the lowest metabolic response. An older study by Heaton et al (1988) 
investigated the effect of particle size (including whole grains, cracked grains 
and milled flours) of different whole grains (wheat, maize and oat) on glucose 
and insulin responses. This study found that for the wheat whole grains the 
glucose AUCs tended to be higher with the flours than with the less processed 
grains, although not significantly, whilst the insulin AUCs increased as the grains 
were more processed. The glucose AUCs were also not significantly different 
between the 3 types of maize or between the 3 types of oats. For the maize, 
insulin responses were higher with the flour than the other 2 types, whereas for 
the oats there was not a difference. Overall this suggests that particle sizes of 
wheat and maize may have different metabolic effects. However, whilst these 
studies show particle size to affect the metabolic response, a study by Behall et 
al (1999) comparing the effects of white bread, whole grain breads (one made 
with traditional whole grain wheat flour and the other with fine ground whole 
grain wheat flour) found no effect of the different particle sizes on the insulin or 
glucose AUC.
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The higher glucose and insulin responses observed with greater processed 
grains, compared with less processed grains, are most likely to be due to the 
change in structure which would increase accessibility of the carbohydrates to 
be digested and absorbed (Bjorck et al., 1994, Venn and Mann, 2004).
1.7. Aims of research
RS, a major DF component of whole grains, has been proposed to affect satiety, 
but there is little direct evidence in humans to confirm this. Whole grains have 
also been proposed to affect satiety and therefore may have a beneficial role in 
weight management; there is however, little direct evidence, with most coming 
from epidemiological studies.
This research was designed to test the hypothesis that the inclusion of RS into 
habitual diets, both acutely and chronically, would reduce appetite and food 
intake. It was also hypothesised that short and long-term consumption of whole 
grains, incorporated into bread rolls, would reduce appetite and food intake.
Therefore this research aimed to determine the effects of both RS and whole 
grains on appetite and food intake. In order to achieve these aims, a series of 
studies were conducted to investigate the role of both short and long term 
consumption of RS and whole grains on appetite and food intake. Some 
mechanisms by which these products exert their effects were also considered.
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General Methods
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This chapter describes the common methods used within the clinical studies and 
associated laboratory analysis; any deviations from these methods are 
described in each individual chapter in the study protocol section.
2.1. Participant Recruitment
All participants for the following clinical studies were recruited from the 
University staff and student population, by email and poster advertisements, and 
from the general population, using poster, email and, in some instances, 
newspaper advertisements. Individuals who had participated in previous studies 
and expressed interest in future studies were also contacted.
2.2. Screening
Prior to each study all participants were screened to ensure that they met the 
specific study inclusion criteria. The screening session always involved 
discussion of the study with the participants and completion of a health and 
lifestyle questionnaire. For the appetite studies, the Dutch Eating Behaviour 
Questionnaire (DEBQ) was completed. For the studies where blood was to be 
taken, haemoglobin and blood glucose concentrations were checked prior to 
inclusion. In all studies participants gave informed written consent. A favourable 
ethical opinion for each study was obtained from the University of Surrey’s 
ethics committee and, for the study described in Chapter 4, from Surrey 
Research Ethics Committee, as part of the study was conducted on NHS 
premises.
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2.2.1. Health and Lifestyle Questionnaire
These self-certificate medical questionnaires were tailored to each study, but in 
general included questions regarding the participants’ past and current medical 
history, any medications they were taking and questions specific to their lifestyle, 
including smoking, exercise and alcohol intake (see Appendix 1).
Specific exclusion or inclusion criteria for each study are detailed in the 
individual chapters; however general exclusion criteria for the studies included 
individuals with current or previous medical conditions, including cardiovascular 
disease (for example stroke and angina), diabetes, gastrointestinal diseases (for 
example Crohn’s disease, Coeliac disease, Irritable Bowel Syndrome), liver 
disease, endocrine diseases and clinical depression or other psychological 
disorders. Other exclusion criteria included individuals with anaemia, those 
following weight reducing diets and those not weight stable for at least the 
preceding three months. Participants were also excluded if they had participated 
in another clinical trial in the preceding three months, if they had a history of 
drug or alcohol abuse in the last two years, were pregnant or lactating females, 
or were taking certain prescription medications and supplements. There were no 
exclusions based on ethnicity for any of the studies.
2.2.2. The Dutch Eating Behaviour Questionnaire
Factors that can influence food intake need to be considered when changes to 
appetite are a primary outcome measure. Thus at screening participants for the
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appetite studies completed the DEBQ (see Appendix 2) to ensure they were not 
highly restrained, emotional or external eaters.
The DEBQ was developed in the 1980s and the 33 questions are based around 
the psychosomatic (emotional eating) theory, externality theory and the theory of 
restrained eating (van Strien et al., 1986). The psychosomatic theory 
concentrates on emotional eating, which is described as excessive eating in 
response to states of arousal (such as stress or fear) when normally these 
emotions would result in loss of appetite (van Strien et al., 1986). The externality 
theory is portrayed by excessive eating in response to food cues irrespective of 
feelings of hunger/fullness (van Strien et al., 1986). The theory of restrained 
eating suggests that an individual’s “natural weight” is set higher than others’ 
and therefore there is constant pressure to reduce weight, even in the presence 
of hunger, resulting in continuous control by dieting; once this control is lost, 
excessive eating results (van Strien et al., 1986).
The DEBQ questions require a response of never, seldom, sometimes, often, 
very often and not relevant. These are accorded a score of 1 -  5 with not 
relevant scoring 0. Each of the questions are separated into those relating to 
emotional, restrained and external eating (as indicated by the colours on the 
questionnaire, green for external, blue for emotional and red for restrained). The 
values for each category are averaged to provide a score. If a participant 
responds “not relevant” to a question the division for that category is reduced by
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one for each not relevant response. A high cut-off of 4.5 for all studies was used 
in order to exclude only those who were highly responsive in any one category.
2.2.3. Blood glucose and haemoglobin concentrations
Haemoglobin concentrations were checked on capillary blood and analysed on 
an haemoglobin HemoCue® 20T  (HemoCue, Sweden). Fasting blood glucose 
was checked on screening; this was also assessed on capillary blood and 
analysed on a HemoCue® glucose 201+ analyser (HemoCue, Sweden). Those 
with concentrations outside of standard normal ranges, >6 mmol/l for fasted 
blood glucose and <13 g/dl for men and <12 g/dl for women for haemoglobin 
concentrations (World Health Organisation (WHO), 1968), were excluded from 
study participation. In Chapter 6 screening blood samples were collected by 
venepuncture.
2.3. Anthropometric measurements
For each study anthropometric measurements were taken using the 
standardised procedures indicated below; all measurements were taken by the 
same investigator within a study in order to reduce inter-operator variation.
2.3.1. Height
Height was measured using a standard stadiometer. The participants removed 
their shoes and stood straight with their heels together and their back against 
the stadiometer. Height was recorded in centimetres to the nearest 0.1cm.
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2.3.2. Weight. Body Mass Index and % Body Fat
Weight, BMI and % body fat were taken on Tanita scales, which measure body 
fat by bioimpedance (Tanita TBF-300, Tanita, United Kingdom). Prior to the 
measurement all participants removed shoes and socks, they were asked not to 
wear moisturiser and to go to the toilet just before the measurement was taken 
in order to standardise water content on each visit. All measurements were 
taken to one decimal place.
2.3.3. Waist and Hip Circumferences
Waist and hip circumferences were taken with the participants in a relaxed 
position. In order to standardise the measurements, waist circumference was 
taken around the navel and hip circumference at the participants’ widest point 
around the hip bone. All measures were taken to the nearest 0.1 cm.
2.3.4. Blood Pressure
Blood pressure measurements were taken on each study visit using an 
automatic blood pressure cuff (Omron MX3 Plus, Omron Healthcare Europe, 
United Kingdom). Participants sat and relaxed for five minutes prior to the 
measurement. Three readings were taken on the relaxed non-dominant arm, 
whilst the participant remained silent. In Chapters 3 and 6 the three readings 
were averaged and in Chapters 4 and 5 the third reading was recorded.
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2.4. Subjective Appetite Ratings
Feelings of hunger and fullness vary between individuals and thus monitoring 
subjective feelings are important aspects of appetite research. Subjective 
appetite measures are most frequently taken using questionnaires, in particular 
visual analogue scales (VAS). initially VAS were used to assess pain and have 
evolved for use in other areas, such as appetite (Wewers and Lowe, 1990). The 
VAS used in the following studies have previously been validated by Flint, et al 
(2000). VAS are quick and easy to use and allow for simple measurement of 
subjective appetite; they also allow for differences in feelings to be calculated 
over time and between individuals (Flint et al., 2000, Stubbs et al., 2000). The 
reliability of VAS in appetite research has been evaluated; in some studies it has 
been suggested that the reproducibility is low (Raben et al., 1995), although the 
authors suggest this may be due to routine daily changes in biological 
processes. More recent studies and reviews have reported VAS to have good 
reproducibility for appetite research use (Flint et al., 2000, Stubbs et al., 2000).
VAS are a 100 mm horizontal line with extremes of feeling at each end (Figure
2.1). Participants place a mark on the line according to how they feel at the time, 
and are told to regard the statements at the ends of the line as the extremes of 
feeling that have ever been felt. The questions were given to participants in 
booklets (a new booklet each time) with each question on a separate page, to 
ensure that the marks could not be copied or compared with previous 
responses.
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I am not hungry 
at all
How hungry do you feel?
I have never
been more 
hungry
Figure 2.1. An example of one of the questions used in the visual analogue scales.
The measurement was taken from the left end of the line to the participants’ 
mark to obtain the appetite rating. The questions used in this research are 
shown in Appendix 3 and are standardised questions in appetite research.
In the studies two fasting VAS were completed (at least 15 minutes apart) and 
then further VAS were completed every 30 minutes during the postprandial 
study period.
2.5. Actual Food intake
Effects on food intake were assessed using two methods. The first investigated 
the effects on food intake at an ad libitum test meal and the second investigated 
differences in food intake over longer periods of time using diet diaries.
2.5.1. Ad libitum Test Meal
At the end of each postprandial study day participants were presented with a 
large pre-weighed ad libitum test meal. This was a homogenous meal designed 
to exceed normal portion sizes, and was comprised of 400 g dry weight fusilli 
pasta (Tesco, UK), 500 g Ragu® original tomato sauce (Unilever Foods, UK), 
100 g mild cheddar cheese (Tesco, UK) and 30 g vegetable oil (Tesco, UK). The 
nutritional composition of the meal is shown in Table 2.1. The meal provided
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27.2 % of energy from fat, 14.1 % of energy from protein and 58.7 % of energy 
from carbohydrate.
Table 2.1: Nutritional composition of the ad libitum test meal.
Energy Protein Carbohydrate Sugar Fat Saturates Fibre Sodium
KJ Kcal (g) (g) (g) (g) (g) (g) (mg)
9765 2315 81.5 339.1 44.7 70.0 25.3 15.9 3250
The reproducibility of homogenous test meals to assess ad libitum intake has 
been reported (Gregersen et al., 2008); it was found that the measurement of 
energy intake, from the ad libitum test meal used, was reproducible. Other test 
meals, such as a buffet meal, have been used in previous studies (Martins et al., 
2007b), which have been shown to be useful in not only obtaining energy intake 
at an ad libitum meal, but also at identifying macronutrient choice. The use of 
buffet meals for assessment of ad libitum intake has been evaluated and has 
been found to be highly reproducible for assessment of energy and 
macronutrient intake (Arvaniti et al., 2000). In the studies described in the 
following chapters the primary outcome from the ad libitum test meal was overall 
energy intake and therefore a homogenous meal was considered to be the most 
appropriate.
The ad libitum meal was weighed before and after consumption in order to 
calculate weight consumed. Participants consumed the meal in an isolated room 
with no distractions and were told to consume as much as they wanted until
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comfortably full; the participants were also informed that they could take home 
any of the meal that was not consumed to prevent over-consumption.
The total energy and macronutrient composition of the meal was identical on 
each visit; however as the pasta absorbed a slightly different amount of water 
each time during cooking the energy density per gram of food varied. An 
adjustment for this was made on each visit to allow calculation of the actual 
amount of energy consumed.
2.5.2. Diet Diaries
Diet diaries (Appendix 4) were used to assess energy and macronutrient intake 
either on one day or over a seven day period. Participants recorded all they 
consumed during this period in as much detail as possible. Standard portion 
sizes of some foods and photographs were included in the back of the diary to 
assist participants in providing more accurate details about the food they 
consumed.
The completed diaries were discussed with the participants immediately on 
return to ensure that they were legible and any further details were recorded. 
The diaries were analysed for average daily intakes of energy, protein, 
carbohydrate, sugar, total fat, saturated fat, total DF (TDF), alcohol and sodium. 
Analysis was performed using WinDiets Professional Version (Robert Gordon 
University, Aberdeen, UK) nutrition analysis programme. When the diaries were
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analysed, generic foods in the nutritional analysis programme were used and 
were standardised across all diaries, unless specific food brands had been 
provided by the participants. If specific food details were given the nutritional 
information for these products was obtained and added into the programme.
As dietary information was taken from the specific food packets wherever 
possible, the DF values obtained would have been measured by the AOAC 
measurement method. However, where generic foods within the program were 
used the AOAC cannot be guaranteed as the DF measurement method.
2.6. Resistant Starch and Placebo Supplements
The supplements used in the studies investigating the effects of RS were 
manufactured and supplied by the National Starch Company, LLC (NJ, USA). 
The RS supplement (Hi-Maize® 260), a high-amylose maize starch, is comprised 
of 60% RS2 and 40% RDS; the RS portion of the supplement was measured by 
the AOAC TDF method 991.43. The placebo (PL) supplement (Amioca®) is 
comprised of 100% RDS.
In the RS studies the amount of each supplement given was balanced to provide 
the same amount of RDS and therefore provided an identical amount of 
available carbohydrate between the two supplements, resulting in products 
which provided a similar glycaemic load. In these studies, no energy value for 
fermentation was assigned to the RS component of the supplement.
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2.7. Blood Collection and Analysis
Participants were requested to consume a similar evening meal on the day 
before each study visit and to fast for 10-12 hours. They were also asked to 
avoid alcohol, caffeine and strenuous exercise on the day before each study 
visit.
2.7.1. Blood collection
In the studies blood was collected from an intravenous cannula inserted into the 
antecubital vein. Blood was collected into sodium oxalate tubes for glucose 
analysis, potassium EDTA for insulin and lipid analysis, and potassium EDTA 
with 200 Kill aprotinin per ml of whole blood for C-peptide analysis to prevent 
enzymatic degradation. The samples were kept chilled until centrifuged at 3000 
RPM for 10 minutes using a Heraeus® centrifuge (Thermo Electron Corporation, 
Waltham, MA). Aliquots were taken and stored at -20°C until batch analysis at 
the end of each study, to minimise inter-assay variation.
2.7.2. Glucose
Glucose concentrations were analysed by one of two methods, although the 
method within each individual study was standardised.
(1) Plasma glucose concentrations were measured using an IL Test™ Glucose 
(oxidase) kit (Instrumentation Laboratory, UK) for the ILab650 (Instrumentation 
Laboratory, UK). This method measures glucose by the enzymatic colorimetric
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method, where the measured glucose concentration is proportional to the 
increase in absorbance generated by the red dye:
(3-D-Glucose + 02 + H20 Glucose °xldase ► Gluconic Acid + H202
2H202+ phenol + 4-aminoantipyrine p.er0Xldase ► red quinoneimine + 4H20
The sensitivity of the method was 0.1 mmol/l. Two quality controls (2.4 mmol/l 
and 5.1 mmol/l) were measured at the beginning and end of each run. The inter 
assay CVs were <2 %.
(2) Plasma or whole blood glucose concentrations were measured on a YSI 
2300 STAT Plus™ (YSI Life Sciences, UK). This method involves an 
immobilised enzyme biosensor. The glucose oxidase is immobilised between 
two membranes, as the glucose passes through the membrane it becomes 
oxidised and produces hydrogen peroxide which is in turn oxidised at the 
platinum electrode. The current that is then produced is proportional to the 
glucose concentration.
D-Glucose + 02 Glucose oxidase  ^D-glucono-5-lactone + H202
A standard glucose solution of 10 mmol/l was measured at the beginning and 
end of each run. The inter assay CVs were <1%.
2.7.3. Insulin
Plasma insulin concentrations were measured by radioimmunoassay (RIA) 
using a commercially available Human Specific Insulin kit (Millipore, UK). All
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samples were measured in duplicate. The assay uses a single labelled antigen 
that competes with the insulin in the blood sample for binding to the antibody. 
The assay had low cross-reactivity with Human Proinsulin, <0.2%.
The limit of detection of the assay was 2 pU/ml. Two quality controls (with an 
expected range of 5.9 -12.3 pU/ml and 20.4 -  42.4 pU/ml) were measured at the 
beginning and end of each assay run. The inter-assay variation across all the 
studies was <15% and the intra-assay variation was <10%.
2.7.4. C-peptide
Plasma C-peptide concentrations were measured by radioimmunoassay using a 
commercially available Human C-peptide RIA kit (Millipore, UK). All samples 
were measured in duplicate. The assay uses a single labelled antigen that 
competes with the C-peptide in the blood sample for binding to the antibody. 
The assay had a low cross-reactivity to Human Proinsulin, <4%.
The limit of detection of the assay was 0.1 ng/ml. Two quality controls (with an 
expected range of 0.28 -  0.58 ng/ml and 1.4 -  2.8 ng/ml) were measured at the 
start and end of each assay run. The inter-assay variation was <20% and the 
intra-assay variation was <10%.
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2.7.5. Triglyceride (TG)
Plasma TG concentrations were measured using an IL Test™ Triglyceride kit 
(Instrumentation Laboratory, UK) for the ILab650. This method measures TG by 
the enzymatic method, where the concentration of quinoneimine produced is 
proportional to the TG concentration:
Triglycerides lipoProte'n "pase  ^glycerol + fatty acids 
Glycerol + ATP g ^ 01 kinase ^glycerol-3-phosphate + ADP 
G!ycerol-3-phosphate + Q? glycerophosphate oxidase  ^dihydroxyacetone phosphate + H202
H202+ 4-chlorolphenol + 4-aminoantipyrine Peroxldase  ^quinoneimine dye + H202
The sensitivity of this method was 0.02 mmol/l. Two quality controls (1.5 mmol/l 
and 2.5 mmol/l) were measured, with inter-assay CVs of <2.5%.
2.7.6. Non-esterified Fatty Acids (NEFA)
NEFA concentrations were measured using a RANDOX NEFA kit (RANDOX 
Laboratories Ltd, UK) on the ILab650. This method measures NEFA by the 
colorimetric method:
NEFA + ATP + CoA Acyl CoA Synthetase ^Acy| qoA + AMp + ppj
Acyl CoA + 02 Acyl CoA oxidase  ^ 2,3,-trans-Enoyl-CoA + H202 
2H202+ TOOS + 4-aminoantipyrine peroxidase  ^ pUrp|e adduct + 4H20 
TOOS = N-ethyl-N-(2hydroxy-3-sulphopropyl)m-toluidine
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Two quality controls (0.11 mmol/l and 1.09 mmol/l) were measured. The inter­
assay variation was <4%.
2.7.7. Cholesterol
Total cholesterol concentrations were measured using an IL Test™ Cholesterol 
kit (Instrumentation Laboratory, UK) for the ILab650. This method measures 
total cholesterol by bichromatic analysis, where the concentration of 
quinoneimine produced is proportional to the total cholesterol concentration of 
the sample:
Cholesterol ester + H20 cholesterol esterase  ^ cholesterol + fatty acids 
Cholesterol + 02 cholesterol oxidase  ^cholest-4-en-3-one + H202 
2H202 + 4-aminoantipyrine + phenol Perox|dase  ^ quinoneimine + 4H20
The sensitivity of the method was 0.1 mmol/l. Two quality controls (2.4 mmol/l 
and 5.1 mmol/l) were measured. The inter-assay CV was <2.5%.
High-density lipoprotein (HDL) cholesterol concentrations were measured using 
RANDOX Direct HDL-Cholesterol kit (RANDOX Laboratories Ltd, UK) on the 
ILab650. This method measures HDL-cholesterol directly by the enzymatic 
clearance method. The measurement has two reaction steps; the first 
enzymatically removes chylomicrons, very-low-density lipoprotein (VLDL) 
cholesterol and low-density lipoproteins (LDL) cholesterol, and the second 
measures the HDL-cholesterol concentrations after it has been released by
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detergents. The concentration of the dye produced is then proportional to the 
HDL-cholesterol concentration:
Step 1: Cholesterol ester choiesteroiesterase  ^ cholesterol + fatty acid
Cholesterol + 02 cholestero' oxidase  ^cholestenone + H202
2HoO? Catalase » 2H20 + 02
Step 2: Cholesterol ester <+oiesteroiesterase  ^ cholesterol + fatty acid
Cholesterol + 02 cholesterol oxidase  ^Cholestenone + H202
2H202+ 4-aminoantipyrine + HDAOS Peroxidase  ^ Quinone pigment + 4H20 
HDAOS = N-(2-hydroxy-3-sulfopropyl)-3,5-dimethoxyaniline
Three quality controls (0.82, 1.32 and 1.88 mmol/l) were measured. Inter-assay 
CV was <6% for each quality control.
LDL-cholesterol concentrations were then calculated using the equation 
described by Friedewald et al (1972):
LDL-cholesterol = total cholesterol -  HDL-cholesterol -  (TG/5)
2.8. Insulin Sensitivity Calculations
On the study mornings when blood was collected, fasting insulin sensitivity and 
p-cell function (%S and %B respectively) were assessed using the homeostatic 
model assessment (HOMA) (Matthews et al., 1985) by the HOMA2 Calculator
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version 2.2 (University of Oxford, UK). The following equations are used by 
HOMA:
(3-cell function (%) = 20 x insulin / (glucose -  3.5)
Insulin sensitivity (%) = 100 / ((insulin x glucose) / 22.5)
Oral postprandial insulin sensitivity to the test meals was also calculated on the 
study mornings when blood was collected using the minimal model method 
described by Caumo et al (2000). The model provides an estimate of an 
individual’s insulin sensitivity (Si(0rai)) following carbohydrate consumption in a 
single meal. The method uses cumulative integrated AUC for glucose and 
insulin concentrations, and assumes that total glucose disposal from the system, 
at the end of the study period investigated or once basal values have been 
reached, equals the glucose entering the peripheral circulation and allows for 
first pass extraction by the liver. Insulin-independent mechanisms also 
contribute to glucose disposal and a constant rate of glucose effectiveness (GE) 
has been assumed for the whole time period. The equation below is used by the 
model (Caumo et al., 2000); f denotes the fraction of ingested carbohydrate 
reaching the peripheral circulation as glucose, a nominal value of 1 was used for 
all studies. Dorai is the amount of ingested carbohydrate per kg body weight 
(mg/kg), AUC is the area from baseline until the end of the test period 
investigated, GE was fixed at 0.024dl/kg min (the value given and used by 
Caumo et al (2000)).
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AUC[Ag(t)/g(t)] . ge x AUC[Ag(t)/g(t)]
AUC[Ag(t)] 
S|(oral) = f X Dora) -----
AUC[Ai(t)]
2.9. Statistical Analysis
AUC were always calculated using the trapezoid method. All statistical analyses 
were carried out using SPSS 15.0 and 16.0 for Windows (Chicago, USA). The 
data were checked for normality of distribution, using the Kolmogorov-Smirnov 
test and, where normally distributed, parametric tests were conducted; the 
corresponding non-parametric tests were used where data were not normally 
distributed or in some instances when the study participant numbers were small 
(£10). Statistical significance was taken as p<0.05. Specific statistical tests 
utilised in each study are detailed in the study chapter. Values given in the text 
are mean and standard error of mean (SEM), unless the test was non- 
parametric, in which case the median (Md) is stated.
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3.1. Introduction
RS, a fermentable carbohydrate, has been proposed to have properties similar 
to other types of DF (Champ, 2004) and therefore may affect satiety. As RS is 
non-viscous and is not thought to affect the absorption of nutrients or gastric 
emptying (Robertson et al., 2005), effects on satiety, if indeed there are any, are 
unclear. Few studies have investigated the effects of including RS in the diet 
and the subsequent effects on appetite. Whilst animal studies show consistent 
positive effects on appetite regulation, data in human studies are mixed 
(Higgins, 2004). In particular, there are no studies in humans that have explored 
the effects on appetite when RS is included as part of a meal, when compared 
with an energy and available carbohydrate matched placebo.
The postprandial effects of RS are also not known; however, as a non-viscous 
DF, it would not be predicted to affect glucose absorption. Nevertheless a recent 
study has shown that short-term consumption of RS2 improves postprandial 
glucose metabolism in healthy individuals (Robertson et al., 2005).
3.2. Aims and objectives
The study aimed to investigate the acute effects of 48 g RS2, on energy intake, 
subjective appetite measures and changes to postprandial metabolites, 
compared with a placebo. This was a randomised, single-blind balanced 
crossover study, in which the 48 g RS was consumed as part of mixed meals 
and was divided equally between breakfast and lunch (providing 24 g at each 
meal).
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3.3. Hypothesis
The inclusion of 48 g RS, over two meals, will prolong satiety and decrease 
intake at both the ad libitum test meal and over the 24 hour period.
3.4. Study Design
3.4.1. Participants
Twenty young healthy adult males participated in the study (Table 3.1). The 
participants included in the study had a mean score of 2.1 (SEM 0.22) on the 
restraint scale, 1.98 (SEM 0.13) on the emotional scale and 3.1 (SEM 0.11) on 
the external eating scale from the results of the DEBQ. At screening participants 
completed a food preferences questionnaire (Appendix 5).
Table 3.1: Participant measurements taken on the morning of the first study visit, n=20.
Measurement Mean ± SEM
Age (years) 25.8 ± 0.82
Height (cm) 181.2 ± 1.62
Weight (kg) 76.2 ± 2.48
BMI (kg/m2) 23.2 ± 0.65
Waist Circumference (cm) 85.5 ± 2.07
Hip Circumference (cm) 97.4 ± 1.42
Body Fat (%) 15.0 ± 1.17
Systolic Blood Pressure (mmHg) 120.8 ± 1.69
Diastolic Blood Pressure (mmHg) 74.4 ± 2.16
3.4.2. Protocol
Participants attended the investigation unit on two occasions, at least one week 
apart. During the visit participants consumed either the RS or PL within standard
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breakfast and lunch meals. The timeline for the study days is shown in Figure
3.1. The study received a favourable ethical opinion from the University of 
Surrey’s Ethics Committee (EC/2006/118/SBMS) and all participants gave 
informed written consent.
Body 
Measurements, 
fasting blood 
samples
Breakfast
test
meal
Lunch
test
meal
Blood samples 
and VAS 
"every 30mins"
Pre­
weighed 
large meal
Blood samples 
and VAS 
every 30mins
Diet
Diary
Arrival at Approx
CIU 9am
Approx
12pm
Approx
4pm
9am
Figure 3.1: Timeline of study day.
On each study day anthropometric measurements and blood pressure were 
taken. Participants remained in the unit for the entire postprandial period (seven 
hours), whilst minimising activity, and were able to drink water ad libitum.
Participants were cannulated and two fasting blood samples and VAS were 
taken, at -15 minutes and just before time zero. The test breakfast containing 
the RS or PL was given at time zero. The test lunch (containing a second dose 
of the test carbohydrate) was served at 180 minutes. VAS and blood samples 
were taken every 30 minutes during the seven hour postprandial study. All blood 
samples were analysed for glucose (using the I Lab method described in Chapter 
2), insulin and C-peptide concentrations.
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At the end of the seven hours and following the two meals containing the test 
starch, participants were provided with the ad libitum test meal (as described in 
Chapter 2). The participants were then free to leave the unit completing a diet 
diary for the remainder of the day to assess overall 24 hour intake. Bowel habit 
diaries (Appendix 6) were completed on the day of the study and the following 
day to assess gastrointestinal tolerance of the starches.
3.4.3. Starches
In this study 80 g of Hi-Maize® 260 (providing 48 g RS and 32 g RDS) and 32 g 
of Amioca® were used (starches described in detail in Chapter 2).
The starches were tested for incorporation prior to the start of the study to 
deliver two products with a similar taste and texture. When incorporated into 
milkshakes, the starches dissolved well but the RS tasted powdery and left a 
greater aftertaste, compared with the corresponding PL drink. In jelly, as used in 
Robertson et al (2003), the starches worked well at low amounts but higher 
amounts resulted in unpleasant tasting products that resembled the texture of 
mousse rather than jelly. Various amounts of Hi-Maize® 260 were mixed with 
mousse (Angel Delight®, Premier Foods, UK). The best amount, in an individual 
portion, was 40 g of the Hi-Maize® 260, which resulted in a good consistency, 
less aftertaste, was an acceptable portion size and differed very little in taste 
and texture from the corresponding PL mousse. Mousse was therefore chosen 
as the delivery vehicle for this study.
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Two portions of the mousse were used to provide a total of 48 g RS (24 g at 
each meal), a level similar to that which has been used in previous studies 
without accompanying adverse gastrointestinal effects and at a level high 
enough to potentially elicit an effect on appetite. The participants were offered a 
choice of three flavours of mousse (chocolate, butterscotch and raspberry), but 
consumed the same flavour for both meals and on each visit. The nutritional 
composition of one portion of each flavour of mousse and starch are shown in 
Table 3.2. The mousses provided an identical glycaemic carbohydrate load and 
differed, between starch type, only in weight and DF content.
Table 3.2: Nutritional composition of one portion of mousse with each starch.
Chocolate Butterscotch Raspberry
RS PL RS PL RS PL
Weight (g) 162.0 138.0 162.0 138.0 160.0 136.0
Energy (kJ) 907 907 911 911 884 884
Energy (kcal) 216 216 217 217 211 211
Protein (g) 4.3 4.3 4.1 4.1 4.1 4.1
Carbohydrate (g) 36.9 36.9 36.9 36.9 35.1 35.1
Fat (g) 5.7 5.7 5.9 5.9 6.0 6.0
Fibre (g) 24.5 0.5 24.1 0.1 24.0 0.0
3.4.4. Meals
The breakfast and lunch meals were standardised between visits with each 
participant consuming identical food (except for the starch) on both visits. The 
food given to the participants was of typical portion sizes for an adult male and
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overall the two meals combined were low in DF (mean DF intake 5.5 g ± 0.21), 
excluding the RS portion.
All food was weighed before each meal. The test breakfast consisted of 30 g 
Rice Krispies® (Kellogg’s, UK) with 100 g semi-skimmed milk (Tesco, UK) and 
one portion of the mousse with the starch. The test lunch was sandwiches 
(Kingsmill® white bread (Allied Bakeries, UK) with Flora Light®, (Unilever Foods, 
UK)) containing either Tesco Healthy Living Honey Cured Roast Ham (Tesco, 
UK) or mild cheddar cheese (Tesco, UK), with the same filling being consumed 
on each study day by a participant. Participants were also given ready salted 
crisps (Walkers®, Walkers Snack Foods Ltd, UK), a sugar-free orange drink 
(Tesco No Added Sugar Orange Squash, Tesco, UK) and one portion of the 
mousse with the starch.
At lunch on the first visit participants were able to regulate their intake from the 
offered food (except for the mousse which they were required to fully consume 
on all visits). Whatever was not consumed was weighed and the participants 
were then required to consume an identical amount on the subsequent visit to 
ensure the energy and macronutrient intake were matched with only the 
presence of the RS differing. A similar study design has been used successfully 
in previous studies (Weststrate and van Amelsvoort, 1993). The mean values for 
the amounts consumed at the meals are shown in Table 3.3.
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Table 3.3: Mean intake at breakfast and lunch on both study days, n=20.
Breakfast Lunch
Energy (kJ) 1584 ± 2.5 3865 ± 152.8
Energy (kcal) 379 ± 0.6 924 ± 36.5
Protein (g) 9.6 ± 0.03 35.6 ± 1.54
Carbohydrate (g) 67.2 ± 0.20 111.9 ± 3.36
Fat (g) 7.9 ± 0.03 36.8 ± 2.87
Fibre (g) 0.5 (24*) ± 0.05 5.0(24*) ± 0.20
* = resistant starch meals only
3.4.5 Calculations and Statistical Analysis
The ratio of C-peptide to insulin was calculated using the AUC for both 
measures up to two hours after each meal ( 0 - 1 2 0  minutes and 180 -  300 
minutes) and overall until two hours after the test lunch (0 -  300 minutes) and 
this was used as a surrogate marker of hepatic insulin clearance.
The data were normally distributed and therefore paired samples t tests were 
used to compare between the groups. All time course data were analysed by 
repeated measures ANOVA, with starch and time as independent variables and 
the measurements themselves as the continuous dependent variable.
3.5. Results
Both starches were well tolerated by the participants with no adverse 
gastrointestinal effects reported on either the study day or the following day.
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The fasting insulin sensitivity (95.9 ± 7.5 % vs 97.0 ± 8.9 %, RS and PL legs 
respectively) and (3-cell function (105.3 ± 5.9 % vs 111.4 ± 9.8 %, RS and PL 
legs respectively) as assessed by HOMA (described in Chapter 2), were not 
significantly different at the start of each study day, which confirms that the 
participants were in a similar metabolic state. Values for each variable were 
close to 100 % as the participants used for the study were young and healthy.
3.5.1. Test meal
Intake of 48 g RS split over breakfast and lunch caused a reduced energy intake 
at the ad libitum test meal at the end of the 7 hour postprandial period (Figure
3.2) compared with the PL (5241 ± 313 kJ vs 5606 ± 345 kJ, p=0.033). The 
weight consumed was not significantly different between the starches, although 
there was a trend that participants consumed less weight of food on the RS leg 
than the PL leg (775.4 ± 46.2 g vs 821.9 ± 48 g, p=0.061).
*6000 n
Figure 3.2: Energy intake at the ad libitum test meal for each intervention. Mean ± SEM, 
n=20. Paired samples f-test showed significant difference between interventions (* p=0.033).
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3.5.2. Subjective appetite ratings
Despite the lower intake at the ad libitum test meal there were no significant 
differences between the two starches for the subjective appetite ratings, 
measured by VAS. This was true for ratings of hunger (Figure 3.3), fullness and 
prospective food consumption. There also were no significant differences 
between the starches for ratings of thirst, or desire for different foods (sweet, 
salty, savoury or fatty foods).
Baseline -nme
Figure 3.3: Subjective appetite ratings in response to the question “how hungry do you 
feel?" Mean ± SEM, n=20. Supplements were consumed at the test meals represented by 
the dashed lines. Repeated measures ANOVA showed no significant difference between the 
supplements for any of the subjective appetite ratings.
3.5.3. 24 hour intake
Over the entire 24 hour period there was a significantly lower energy intake 
following the 48 g RS compared with the PL; from 12603 ± 519 kJ compared 
with 13949 ± 755 kJ (p=0.044) respectively (Table 3.4). Following RS, the mean 
energy intake was 104% of calculated habitual energy requirements (calculated
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with the Schofield Equation (Schofield et al., 1985) and applying a moderate 
activity level of 1.6 for all participants) compared with 116% for the PL leg.
Table 3.4. 24 hour intake following supplementation with 48 g RS or PL, measured from 24 hour 
diet diaries, n=20. Comparisons were made with paired samples t test.
RS
Mean SEM
PL
Mean SEM
P
Value
Energy (kJ) 12603 519 13949 755 0.044
Energy (kcal) 2994 123 3312 180 0.048
Protein (g) 104.9 5.63 115.3 6.87 0.060
Carbohydrate (g) 424.4 18.40 452.6 23.00 NS
Sugar (g) 97.2 6.1 104.7 8.8 NS
Fat (g) 96.7 4.56 110.0 4.79 0.017
Saturated Fat (g) 39.2 2.18 45.2 2.37 0.014
Dietary Fibre (g) 65.1 0.95 16.7 0.84 <0.001
Sodium (mg) 4375 195 4757 243 0.048
The lower energy intake can be primarily attributed to a significantly lower fat 
intake, following the RS (13.3 g lower) compared with the PL (Table 3.4). There 
was also a trend towards a lower protein intake with RS compared with PL, 
whilst the carbohydrate intake was not significantly changed. There was also a 
significantly lower sodium intake with RS than with PL.
As expected, there was a significant difference in DF during this 24 hour period 
(difference of 48.4 g) attributed directly to the supplementation with 48 g RS.
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3.5.4. Metabolite analysis
The postprandial plasma glucose concentrations were not significantly different 
between the RS and the PL (Figure 3.4). The total AUC (for the seven hour 
postprandial period) was not significantly different between starches; however, 
when the response to each meal was compared, 0 - 1 2 0  minutes and 180 -  300 
minutes, (as used in an OGTT), no significant difference was found for the test 
lunch, but the AUC for the RS leg was significantly lower than for the PL leg at 
the test breakfast (677.7 ± 22 mmol/l.min vs 710.5 ± 21 mmol/l.min, p=0.025).
There was a significantly lower postprandial insulin response following the RS 
compared with the PL over the whole acute study period (p=0.029) (Figure
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3.5A). However, the corresponding C-peptide concentrations were not 
significantly different between the two starches (figure 3.5B).
Baseline Time(mins)
Baseline
Time (mins)
Figure 3.5: Postprandial plasma insulin (pmol/l) (A.) and C-peptide (nmol/l) (B.) 
concentrations after consumption of 48 g RS compared with PL. Mean ± SEM, n= 20. 
Starches were consumed at test meals represented by the dashed lines. Repeated 
measures ANOVA showed the plasma insulin response was significantly lower (p=0.029) 
following RS and no significant differences between the starches for the C-peptide 
concentrations.
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The AUC for two hours after each meal were also compared for insulin and C- 
peptide. For insulin they were significantly lower with the RS than the PL for both 
meals (breakfast = 30456.5 ± 3933.3 pmol/l.min vs 39655.8 ± 6655.2 pmol/l.min, 
p=0.02, lunch = 34605.5 ± 4176.2 pmol/l.min vs 41607.6 ± 6752.5 pmol/l.min, 
p=0.039). There were no significant differences at either meal for C-peptide 
AUC.
Consequently there was a trend towards significance for a higher molar ratio of 
C-peptide:insulin for the RS leg compared with the PL leg for 0 - 1 2 0  minutes 
and for 0 to 300 minutes and no significant difference for 180 -  300 minutes, 
which is a surrogate marker to indicate an increase in hepatic insulin clearance 
(Table 3.5). There was, however, no significant difference in postprandial oral 
insulin sensitivity between the two starches at either test meal (Table 3.5).
Table 3.5. C-peptide to insulin AUC ratio and postprandial oral insulin sensitivity following 
consumption of 48 g RS or PL, n=20. Comparisons made with a paired samples t test.
RS
Mean SEM Mean
PL
SEM
P
Value
C-peptide:lnsulin AUC 
0-120 minutes 6.52 0.39 5.74 0.43 0.065
C-peptide:lnsulin AUC 
180-300 minutes 6.45 0.49 6.08 0.46 NS
C-peptide:lnsulin AUC 
0-300 minutes
Oral S|1 Breakfast 
(dl/kg-min/pU-mi)
Oral S|1 Lunch 
(d!/kgmin/pU-ml)
6.69 
3.36 x 10'3 
5.65 x 10'3
0.37 
0.44 x 10'3 
1.11 x 10"3
6.13 
8.50 x 10‘3 
4.43 x 10'3
0.42 
5.58x1 O’3 
0.63 x 10'3
0.059
NS
NS
1 S| = oral insulin sensitivity for each meal, calculated by minimal model (described in Chapter 2)
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3.6. Discussion
This study found that after consumption of 48 g RS (split equally over the test 
breakfast and lunch meals) there was a lower energy intake at both the ad 
libitum test meal and over the whole 24 hour period, without an associated effect 
on subjective appetite ratings. The study also found a significant novel effect of 
the RS on lowering the postprandial insulin response. To our knowledge this is 
the first study where RS has been provided to participants as part of a mixed 
meal and compared with a placebo, where available carbohydrate and energy 
load have been matched, and so provides novel information on the role of DF as 
a bioactive compound in appetite regulation.
Previous studies investigating the effects of RS on appetite have replaced 
proportions of digestible carbohydrate with RS and therefore the amount of 
glycaemic carbohydrate provided has varied between the supplements which 
would confound the interpretation of the results. Indeed in one study 
consumption of RS appeared to cause a reduction in subjective feelings of 
satiety (Raben et al., 1994). However, a limitation of the study was that there 
were differences in texture between the supplements, one liquid and the other 
semi-solid, with liquids being known to be less satiating than solid foods 
(Mourao et al., 2007). The study by Raben et al (1994) also matched the 
supplements by weight of starch and therefore the supplements differed in 
energy and available carbohydrate content. A recent study found greater satiety 
(measured by VAS) following consumption of muffins containing 8 g RS
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compared with other fibres (Willis et al., 2009); however this study provided no 
information on actual food intake. In studies where the effects of different ratios 
of amylose to amylopectin ratio on appetite were investigated, it was found that 
the high amylose meals (least digestible) were the most satisfying but also the 
least palatable (van Amelsvoort and Weststrate, 1992). Another study, that also 
varied amylose and amylopectin ratios, found no significant effect between their 
treatments on VAS ratings (Weststrate and van Amelsvoort, 1993).
In our study, none of the participants would have been classified as under­
reporters based on the Goldberg cut-off values for under-reporting (Goldberg et 
al., 1991); indeed, on both study days, the participants consumed more than 
their estimated requirements (104% for RS leg and 116% for the PL leg) and 
therefore there was likely to be an element of over-consumption. This over­
consumption may have arisen because the participants were given food and did 
not need to prepare/cook it themselves; nevertheless the over-consumption was 
less on the RS leg than PL leg. The over-consumption may explain why no 
effects were found on any of the subjective appetite ratings.
The breakfast and lunch meals provided to the participants were based on 
standard portion sizes rather than set to basal metabolic rate (BMR), as only 
part of the daily intake was provided to the participants and an outcome of the 
study was to investigate any effects on the metabolic response, which may have 
been masked if intakes were set to BMR. The only difference between the two
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legs, apart from the 48 g of RS, could have been a slight difference in the 
energy density of the meals due to the presence of the RS; however, the 
difference in energy density was minor (for breakfast and lunch combined the 
density per g for meals was 7.2 kJ/g for the RS leg and 7.7 kJ/g for the PL leg) 
and the GL of the two legs was identical.
The lower energy intake over 24 hours appeared to be primarily explained by a 
significantly lower fat intake following the RS. However the reason for this lower 
fat intake is unclear, as the participants did not report a difference in desire for 
fatty foods on the subjective appetite ratings during the postprandial study. This 
difference in macronutrient choice following RS consumption would require 
further investigation to determine whether it was an incidental finding or a true 
effect. There also did not appear to be an influence of the high RS intake on DF 
intake later in the day; however there may have been an effect on the following 
day’s DF intake that was not monitored in this study.
Although in the present study a reduced energy intake was found following the 
RS, it is not possible from the design of this study to determine the mechanisms 
for this effect. However, as the main effect on food intake appeared to occur at 
the ad libitum test meal at the end of the postprandial study and later in the 
evening, a possible mechanism could be the fermentation of the RS in the colon, 
by colonic microflora and the subsequent effects of the production and action of
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SCFA, which has been hypothesized as a mechanism for the effects of DF on 
appetite (Pereira and Ludwig, 2001).
Whilst the metabolism of SCFA may result in potential additional energy being 
provided to the body, this was not accounted for in this study and no value was 
assigned for the fermentation of the RS. There was no way of assessing SCFA 
absorption in the participants and an amount cannot be assumed as this is 
highly variable. This variability depends on factors including, but not limited to, 
extent of fermentation and metabolism within the colon (Wolever et al., 2002), 
variations in colonic gut transit time (Macfarlane and Macfarlane, 2003), the 
colonic microbiota and the SCFA produced but lost to the faeces (although it has 
been estimated that less than 5% of produced SCFA are lost to the faeces 
(Topping and Clifton, 2001)). Published works have attributed an energy value 
of 8 kJ/g for Hi-Maize® 260 (Behall and Howe, 1996, Livesey, 1994) assuming 
100% fermentation and 100% absorption of resulting SCFA, compared with the 
16 kJ/g for the PL. In this study we matched the starches by GL as this was the 
largest confounder to the glycaemic response. When taking into consideration 
the amounts of each starch given it would have resulted in energy doses of 640 
kJ for the RS and 512 kJ for the PL, with a maximal difference of only 128 kJ. 
This therefore does not account for the full difference in 24 hour energy intake 
observed.
94
Chapter 3
It is possible that the increase in production of SCFA may consequently increase 
production of satiety hormones from the colon, such as PYY (Cuche et al., 2000, 
Cherbut, 2003). However, so far the only evidence of an effect of RS on these 
hormones, particularly PYY and GLP-1, has been shown in rodent studies 
(Keenan et al., 2006, Zhou et al., 2006, Zhou et al., 2008). Rodents are, in terms 
of the gastrointestinal tract, anatomically different; indeed the large bowel of a 
human has been said to comprise 17% of the gastrointestinal tract, whereas in a 
rodent it makes up 61% (Topping and Clifton, 2001) and thus rodents are a poor 
model for the human colon. In addition, some studies in humans that have 
measured changes to GLP-1 after consumption of RS have not found the 
concentrations to be elevated (Raben et al., 1994, Robertson et al., 2005), either 
acutely or following chronic intake.
As insulin and C-peptide are co-secreted, the lower postprandial insulin 
concentration detected was likely to be due to increased hepatic insulin 
clearance, as there was a trend towards significance between the two starches 
for the molar ratio of C-peptide to insulin. An increase in hepatic insulin 
clearance has previously been reported following RS intake over 24 hours 
(Robertson et al., 2003). It has been proposed that the increase in production of 
SCFA and their exposure to the liver may ultimately be responsible for the 
increase in insulin clearance, although this remains to be fully clarified. 
However, it is difficult from this study to determine exactly what the mechanism 
is for an effect of RS on lower postprandial insulin responses and further
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investigations, specifically tailored to determine the mechanisms would be 
required.
The lower energy intake observed in this study following RS consumption as 
part of a mixed meal could have beneficial implications in weight management 
and, potentially, weight loss; however further studies are required to confirm 
whether a similar finding is shown in other population groups such as the 
overweight or obese, and to determine the actual mechanisms for the effect. 
Although the dose in this study was well tolerated for a single day, and a lower 
energy intake was observed, further investigations are needed to establish 
whether lower doses would also produce a clinically relevant finding. A lower 
postprandial insulin response was also observed, was entirely novel, and could 
change our understanding of the acute effects of non-viscous DF. Increased 
intakes of RS in the diet may therefore have beneficial implications in weight 
management and metabolic control.
This work has recently been accepted for publication in the British Journal of 
Nutrition. Please see published work and abstracts on page 226.
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Effects of Chronic 
Consumption of 
Resistant Starch 
on Appetite and 
Insulin Clearance
Chapter 4
4.1. Introduction
As the findings from the acute RS and appetite study indicated a reduced 
energy intake over 24 hours (Chapter 3), and there are few chronic studies 
investigating the effects of RS consumption on appetite, this follow-on study was 
designed to determine the effects of longer-term RS ingestion on appetite and 
food intake. In contrast to Chapter 3, obese or overweight individuals were the 
target group, as weight loss, rather than maintenance, is often a primary goal. A 
novel finding from Chapter 3 was a significantly lower postprandial insulin 
response with RS. As such, this study was also designed to determine whether 
the lower postprandial insulin response would be observed following chronic 
consumption and elucidate possible mechanisms.
4.2. Aims and objectives
The aim was to investigate the effects on appetite, food intake and the insulin 
response following consumption of 40 g RS daily for four weeks, compared with 
a placebo, in a randomised, single-blind crossover study, combining both a 
postprandial feeding study and an insulin-modified FSIVGTT.
The main objectives were to investigate the effects of RS on appetite, including 
effects on actual food intake (using ad libitum test meals and a seven day diet 
diary) and subjective measures of appetite (using VAS). The effects of RS on 
the insulin response and insulin sensitivity were also assessed using an insulin- 
modified FSIVGTT.
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4.3. Hypothesis
The inclusion of 40 g RS per day for four weeks will cause a decrease in 
participants’ intake both in their habitual diets and at a pre-weighed ad libitum 
meal at the end of the intervention. The RS will cause an increase in insulin 
clearance and an improvement in insulin sensitivity.
4.4. Study Design
4.4.1. Participants
In addition to the general inclusion criteria (described in Chapter 2) participants 
required for the study were adult males (aged between 20 and 60 years) with a 
waist circumference greater than 94 cm (37 inches) and adult females (aged 
between 20 and 60 years) with a waist circumference greater than 80 cm (31.5 
inches) and, for both males and females, a BMI of 26 -  35 kg/m2.
Due to time constraints for recruitment, seven healthy adult males and females 
(5 M, 2 F) completed this pilot study (Table 4.1). The participants included had 
mean scores of 2.07 (± 0.22), 3.54 (± 0.10) and 2.81 (± 0.31) on the emotional, 
external and restrained scales of the DEBQ, respectively.
Eight participants started the study, with one drop-out who did not tolerate 
taking the placebo in their diet (due to gastrointestinal upset). The other seven 
participants completed the study.
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Table 4.1: Baseline anthropometric measurements and fasting blood values, n=7.
Measurement Mean ± SEM
Age (years) 32.6 ± 5.4
Height (cm) 176.1 ± 4.1
Weight (kg) 91.2 ± 4.2
BMI (kg/m2) 29.3 ± 0.7
Waist Circumference (cm) 98.9 ± 2.6
Hip Circumference (cm) 108.1 ± 1.5
Body Fat (%)1 30.1 ± 3.6
Systolic Blood Pressure (mmHg) 120.6 ± 1.5
Diastolic Blood Pressure (mmHg) 72.6 ± 4.4
Fasting glucose (mmol/I) 4.75 ± 0.2
Fasting insulin (pmol/l) 75.98 ± 10.4
Fasting TG (mmol/l) 0.88 ± 0.2
Fasting Non-esterified fatty acids (mmol/l) 0.50 ± 0.1
Total cholesterol (mmol/l) 3.35 ± 0.2
HDL-cholesterol (mmol/l) 1.13 ± 0.1
LDL-cholesterol (mmol/l) 2.04 ± 0.2
HOMA % S2 72.2 ± 12.0
HOMA % B3 147.4 ± 17.9
2 HOMA %S = fasted oral insulin sensitivity, assessed by homeostatic model assessment
3 HOMA %B = (3-cell function, assessed by homeostatic model assessment
4.4.2. Starches
In this study 67 g of Hi-Maize® 260 (providing 40 g RS and 27 g RDS) and 27 g 
of Amioca® were used (starches described in Chapter 2). The starches were 
provided in pre-weighed sachets and participants consumed two sachets daily 
for four weeks. Participants were free to include the starches into their habitual
100
Chapter 4
diets in a method and time of day of their own choice, although mixing with a 
cold liquid (especially milk) was advised as the best method of incorporation.
4.4.3. Protocol
A favourable ethical opinion was given for this study by the University of 
Surrey’s Ethics Committee (EC/2008/80/FHMS -  fast track) and from Surrey 
Research Ethics Committee (08/H1109/112) as the FSIVGTT was conducted on 
NHS premises, and all participants gave informed, written consent.
Following recruitment, a fasting baseline blood sample was collected to 
characterise the participants. Participants attended for a “practice” morning, 
which was identical to study morning 1 , to allow them to become familiarised 
with the procedures and environment. At the end of each four weeks 
intervention, participants attended for two study mornings. The two intervention 
periods were separated by a four week washout period (Figure 4.1).
4 week intervention with RS or Placebo 4 week intervention with RS or Placebo
7 day diet and bowel | diaries
4 week wash­out
7 day diet and bowel I diaries
Practicemorning
Study
morning1
Study morninc 1
Studymorning
Studymorning2
Figure 4.1: Timeline for the study
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Study morning 1 -  Appetite Assessment. Anthropometric measurements and 
blood pressure were taken on arrival. Participants were cannulated and two 
fasting blood samples and VAS were taken. At time zero a standard 
commercially available fibre-free milkshake (Nurishment®, ENCO Products Ltd, 
UK) breakfast (Table 4.2) was consumed, from a choice of three flavours (each 
participant had the same flavour on each visit). VAS and blood samples were 
taken every 30 minutes for three hours, with two additional blood samples 
collected at 15 and 45 minutes postprandially for insulin and glucose 
measurement. An ad libitum test meal was provided at the end of the three 
hours to quantify food intake.
Table 4.2: Nutritional composition of the fibre-free breakfast (Nurishment® Drinks), per 420 g.
Energy Protein Carbohydrate Sugar Fat Saturates FibreFlavour
(KJ) (kcal) (g) (g) (g) (g) (g) (g)
Strawberry 1940 462 21.0 67.6 67.6 11.8 7.1 Nil
Chocolate 1726 412 21.0 55.9 55.9 11.3 7.1 Nil
Vanilla 1804 428 21.0 60.0 60.0 12.6 7.1 Nil
Study morning 2 -  Insulin sensitivity, secretion and metabolic clearance were 
assessed by an insulin-modified FSIVGTT. Participants arrived fasted and a 
cannula was placed into each arm in the anticubital vein, one for sampling and 
the other for infusions. At time zero glucose (50% dextrose, Baxter Fleaithcare 
Ltd, UK) (0.3 g/kg body weight, with a maximum dose of 25 g) was infused for 5 
minutes using an infusion pump (lVAC 560 volumetric pump). After 20 minutes
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the insulin (Actrapid®, Novo Nordisk, UK) (0.03 U/kg body weight) infusion 
commenced and was infused (Graseby 3100 syringe pump) for 5 minutes. Blood 
samples for glucose, C-peptide and insulin concentrations were taken at 1, 3, 5, 
7, 10, 15, 19, 22, 24, 26, 28, 30, 32, 34, 36, 38, 40, 42, 44, 46, 48, 50, 60, 90, 
120 , 150 and 180 minutes (protocol modified from those previously described by 
Bingley et al (1992), Vicini et al (1999) and Trout et al (2007)). Blood glucose 
concentrations were measured immediately by the YSI method (described in 
Chapter 2). Insulin and C-peptide concentrations were measured by RIA on all 
the plasma samples by batch analysis at the end of the study.
Seven day diet diaries (to assess dietary intake) and bowel diaries (to assess 
gastrointestinal tolerance), were completed for the last week of each 
intervention.
4.4.4. Calculations and Statistical Analysis
All postprandial data from the appetite study morning were analysed using 
repeated measures ANOVA with starch and time as independent variables and 
the measurements themselves as the continuous dependent variable. The 
AUCs for the time course data were also calculated and then compared using 
paired samples f-tests. All other data were compared using paired samples t- 
tests. Non-parametric tests were also run due to small participant numbers and 
the consequent difficulty in assessing normality accurately. However, as 
statistical significance did not differ between tests, parametric tests are reported 
as the more powerful statistical test.
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The raw glucose, insulin and C-peptide data from the FSIVGTT data were 
analysed using repeated measures ANOVA with starch and time as independent 
variables and the measurements themselves as the continuous dependent 
variable.
The data from the FSIVGTT were also modelled using Bergman’s minimal 
model (Bergman et al., 1981). The program used was the MINMOD Millennium 
version, which has been described by Boston et al (2003). This version of the 
minimal model uses two equations, one of which is the glucose minimal model, 
which attempts to determine the glucose dynamics and the other the insulin 
minimal model, which attempts to determine the insulin dynamics (Bergman, 
2005). Four key indices are reported from the modelling of IVGTT data. These 
are: (i) insulin sensitivity (Si) which measures the ability of insulin to promote 
glucose clearance; (ii) the first-phase insulin response (AIRg) that assesses the 
initial insulin secretion; (iii) glucose effectiveness (Sg) which measures the ability 
of glucose to cause its own disposal separately to the effect of increased insulin 
(an insulin-independent glucose disposal); (iv) the disposition index (DI) (which 
is equal to the AIRg*S|) which provides a measure of (3-cell function as it 
proposes that there is an increase in (3-cell secretion due to increased insulin 
resistance to avoid impaired glucose responses (Bergman, 2005).
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4.5. Results
The starches were equally well tolerated by participants, with a weekly bowel 
movement frequency of 7.3 ± 0.8 on the RS leg and 8.9 ± 1.3 on the PL leg, 
which were not significantly different. A similar number of gastrointestinal 
complaints (flatulence and looser stools) were recorded for both starches.
4.5.1. Anthropometries
There were no significant differences between the RS and PL for any of the 
anthropometric measurements taken or for resting blood pressure (Table 4.3). 
There was also no significant difference between the RS and PL when 
percentage changes from baseline were calculated and compared.
Table 4.3: Anthropom etric m easurem ents taken at baseline and end of each intervention, n=7.
Measurement
Baseline 
Mean ± SEM
End of RS Leg 
Mean ± SEM
End of PL Leg 
Mean ± SEM
Weight (kg) 91.2 ± 4.2 90.9 ± 4.4 90.6 ± 4.2
BMI (kg/m2) 29.3 ± 0.7 29.2 ± 1.1 29.2 ± 0.9
Waist Circumference (cm) 98.9 ± 2.6 99.6 ± 2.5 99.6 ± 2.5
Hip Circumference (cm) 108.1 ± 1.5 107.5 ± 1.4 108.7 ± 1.4
Body Fat (%)1 30.1 ± 3.6 27.7 ± 2.9 28.0 ± 3.0
Systolic Blood Pressure (mmHg) 120.6 ± 1.5 121.4 ± 2.9 120.7 ± 2.2
Diastolic Blood Pressure (mmHg) 72.6 ± 4.4 74.9 ± 2.1 72.3 ± 3.0
V a lu e  for five participants for baseline m easurem ent
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4.5.2. Subjective appetite ratings
There was no significant difference between the starches for subjective ratings
of prospective food consumption following the fibre-free breakfast; however the
responses differed significantly over time for each starch (p=0.003) (Figure 4.2).
There were no significant differences between the starches for subjective ratings
of hunger or fullness following consumption of the fibre-free breakfast. There
was a significantly greater desire for fatty foods on the RS leg compared with the
PL leg (p=0.008) (Figure 4.3), but there were no significant differences between
the starches in desire for salty, sweet or savoury foods; however, the
postprandial responses for each starch differed over time for sweet (p=0.044)
and savoury (p=0.014). There were also no significant differences between the
starches for AUC for any of the questions, except in relation to the question
regarding desire for fatty foods (p=0 .0 1 1 ).
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Figure 4.2: Subjective appetite ratings in response to the question “how much do you 
think you can eat?” Following the fibre-free breakfast at the end of the RS and PL 
interventions. Mean ± SEM, n=7. Repeated measures ANOVA showed no significant 
difference between starches, but a significant starch*time interaction (p=0.003).
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Figure 4.3: Subjective appetite ratings in response to the question “Would you like to eat 
something fatty?” Following the fibre-free breakfast at the end of the RS and PL 
interventions. Mean ± SEM, n=7. Repeated measures ANOVA showed a significant 
difference between starches (p=0.008).
4.5.3. Test meal
There was no significant difference in either weight or energy intake between the 
two starches at the ad libitum test meal (Figure 4.4). However, there appeared 
to be a slightly lower energy intake with the RS than with the PL, which was not 
significant most likely due to the small sample size.
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Figure 4.4: Energy intake (kJ) at the ad libitum test meal consumed at the end of the 
postprandial period following the fibre-free breakfast at the end of each intervention. Mean 
± SEM, n=7. Paired samples f-test showed no significant difference between the starches.
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4.5.4. Cholesterol
There were no significant differences between the RS and PL legs for total 
plasma cholesterol, HDL-cholesterol or LDL-cholesterol (Table 4.4).
Table 4.4: Cholesterol concentrations prior to and following consumption of 40 g RS or the PL 
per day for 4 weeks, n=7.
Measurement
Baseline 
Mean ± SEM
End of RS Leg 
Mean ± SEM
End of PL Leg 
Mean ± SEM
Total cholesterol (mmo/l) 3.35 ±0.2 3.44 ± 0.2 3.36 ± 0.2
HDL-cholesterol (mmo/l) 1.13 ± 0.1 1.13 ± 0.1 1.23 ±0.1
LDL-cholesterol (mmo/l) 2.04 ± 0.2 2.05 ±0.2 1.91 ± 0.2
4.5.5. Postprandial metabolite analysis
There were no significant differences between the starches for fasting glucose
(plasma samples measured by YSI method described in Chapter 2), insulin or
NEFA concentrations (Table 4.5), or for the postprandial glucose, insulin or
NEFA concentrations (Figure 4.5) following the standard fibre-free breakfast.
Table 4.5: Fasting metabolite concentrations prior to and following consumption of 40 g RS or
the PL per day for 4 weeks, n=7.
Measurement
Baseline 
Mean ± SEM
End of RS Leg 
Mean ± SEM
End of PL Leg 
Mean ± SEM
Fasting glucose (mmol/l) 4.75 ± 0.2 4.93 ±0.1 5.02 ±0.1
Fasting insulin (pmol/l) 75.98 ± 10.4 77.91 ± 12.6 78.07 ± 7.4
Fasting TG (mmol/l) 0.88 ± 0.2 1.27 ±0.4 1.10 ± 0.3
Fasting NEFA (mmol/l) 0.50 + 0.1 0.56 ± 0.2 0.62 ±0.1
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Figure 4.5: Postprandial glucose (A), insulin (B) and NEFA (C) concentrations for the two 
supplements following the fibre-free breakfast at the end of each intervention. Mean ± 
SEM, n=7. Repeated measures ANOVA revealed no significant differences between 
supplements for any of the measurements.
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There were also no significant differences between the starches for fasting 
(Table 4.5) or postprandial TG concentrations (Figure 4.6).
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Figure 4.6: Postprandial TG concentrations for RS and PL, following the fibre-free 
breakfasts at the end of the interventions. Mean ± SEM, n=7. Repeated measures ANOVA 
revealed no significant differences between the starches.
There were no significant differences between the two starches in fasting insulin 
sensitivity (HOMA %S) or (3-cell function (HOMA %B) as calculated by the 
HOMA model (described in Chapter 2) (Table 4.6).
There was also no significant difference between the starches in postprandial 
oral insulin sensitivity (method described in Chapter 2) (Table 4.6) following the 
fibre-free breakfasts at the end of the interventions.
110
Chapter 4
Table 4.6. Indices of insulin sensitivity following consumption of 40 g RS or the PL per day for 4 
weeks, n=7. Comparisons were made with a paired samples t test.
RS
Mean SEM
PL
Mean SEM
P
value
HOMA % S1 73.3 12.1 65.6 6.8 NS
HOMA % B2 136.4 14.4 133.9 10.1 NS
Oral Si3 Breakfast
1.10 x 10*3 0.23 x 10'3 1.97 x 10'3 0.76 x 10’3 NS
(dl/kg-min/pU-ml)
HOMA %S = fasted oral insulin sensitivity, assessed by homeostatic model assessment.2 HOMA %B = (3-cell function, assessed by homeostatic mode! assessment.3 Si = oral insulin sensitivity to breakfast meal, calculated by minimal model.
4.5.6. Diet diaries
There were no significant differences between the RS and PL for mean daily 
energy or macronutrient intake as measured from the seven day diet diaries 
completed during the final week of each intervention (Table 4.7). However, total 
DF intake was significantly higher following the RS compared with the PL (56.5 
± 2.3 g vs 18.2 ± 2.7 g, p=<0.001), attributable to the RS supplement.
Table 4.7: Average daily energy and macronutrient intake following supplementation with 40 g 
RS or the PL, measured from seven day diet diaries, n=7. Comparisons were made with a 
paired samples ftest.
Mean
RS
SEM
PL
Mean SEM
P
Value
Energy (kJ) 8913 792 8941 399 NS
Energy (kcal) 2122 189 2129 95 NS
Protein (g) 89.6 8.0 89.8 8.8 NS
Carbohydrate (g) 254.8 27.3 244.1 15.6 NS
Fat (g) 79.0 9.7 78.2 5.7 NS
Dietary Fibre (g) 56.5 2.3 18.2 2.7 <0.001
111
Chapter 4
4.5.7. FSIVGTT
The data presented for the FSIVGTT are for six participants, due to cannulation 
problems for one subject. Wilcoxon Signed-Rank tests were used, to compare 
AUC and values from the model, due to the smaller participant numbers.
The FSIVGTT glucose concentrations following consumption of 40 g RS per day 
for 4 weeks were significantly higher (p=0.045) than the concentrations following 
the PL (Figure 4.7A). There was also a significantly higher insulin response 
following consumption of the RS for 4 weeks compared with the PL (p=0.003) 
which was accompanied by a significant treatment*time interaction (p=0.012) 
(Figure 4.7B). The C-peptide concentrations were also significantly higher 
following 4 weeks consumption of RS compared with the PL (p=0.039), which 
also had a significant treatment*time interaction (p=<0.001) (Figure 4.7C).
The AUC were significantly higher with the RS than with the PL for the glucose 
(Md 949.7 mmol/l.min vs Md 922.0 mmol/l.min, p=0.028) and insulin responses 
{Md 47485.0 pmol/l.min vs Md 33709.5 pmol/l.min, p=0.028), whilst there was a 
trend for a higher C-peptide response with the RS compared with the PL {Md
233.5 nmol/l.min vs Md 196.7 nmol/l.min, p= 0.075).
Examples of the output graphs from the MINMOD Millennium program are 
shown in Figure 4.8. These graphs are for the mean glucose and insulin 
concentrations from the FSIVGTT for both the RS (Figure 4.8A) and PL legs 
(Figure 4.8B).
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Figure 4.7: FSIVGTT glucose (A), insulin (B) and C-peptide (C) concentrations for the RS 
and PL legs at the end of 4 weeks supplementation. Glucose infused at time zero and 
insulin at time 20 minutes. Mean ± SEM, n=6. Repeated measures ANOVA showed 
significant difference between starches for glucose (p=0.045), insulin (p=0.003) and C- 
peptide (p=0.039).
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Figure 4.8: Output graphs from the MINMOD Millennium program for mean glucose (mg/dl) 
and insulin (mU/l) responses from the FSIVGTT for the RS (A) and PL (B) legs. Blue 
lines/circles indicate glucose observations, white circles indicate unweighted glucose 
observations, green circles/lines indicate insulin observations, red lines indicate the fit of the 
model to the glucose observations and the black lines indicate the IAGD, which is the insulin 
attributable glucose disposal (instantaneous % of glucose disposal due to the action of 
insulin).
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Results from the modelling of the glucose and insulin data indicated no
significant difference between the two supplements for insulin sensitivity (S|),
first-phase insulin responses (AlRg) glucose effectiveness (Sg) or the disposition
index (Dl) Table 4.8.
Table 4.8. Indices from the MINMOD Millennium program for modelling of the FSIVGTT data
following consumption of 40 g RS or the PL, n=6. Comparisons were made with Wilcoxon
Signed-Rank tests.
RS PL P
Median
Inter-quartile
Median
range
Inter-quartile
value
range
S| ((mu/l)-1.min-1) 2.53 1.52-4.35 3.32 1.85-5.72 °-116
AlRg (mu.1-1.min) 543.5 369.1 -1441.4 392.5 312.6-1123.7 °-116
Sg (min-1) 0.024 0.019-0.029 0.026 0.016-0.031 °-917
Dl 1304.9 913.9-3848.0 1343.6
1_ - * rtirtn j  -rntn _ _ ah
807.7-4763.1 °-783
Inter-quartile range 25,n and 75tn percentiles.
4.6. Discussion
This study was the first to our knowledge that investigated the effects of longer- 
term (4 week) consumption of RS on appetite and food intake when compared 
with an energy and carbohydrate matched placebo. However, unlike in the acute 
RS and appetite study (Chapter 3), no significant difference was found in food 
intake following consumption of 40 g RS for four weeks, compared with the PL. 
The data from the FSIVGTT indicated a significant difference between the RS 
and PL for concentrations of glucose, insulin and C-peptide; however, there was
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no significant difference between the supplements when the data were 
modelled.
A major limitation of the study and an important reason as to why no significant 
differences were found, and why no conclusion can be completely drawn from 
the study, is the very small participant numbers (n=7) due to time constraints. 
However, ethics were obtained for 20 participants based on findings from 
previous studies, where changes to appetite and insulin responses were 
observed, and it is hoped more individuals will be recruited in the future to 
confirm or refute the current findings. The original power calculations for the 
study were based on changes to appetite ratings, where there was a calculated 
80% probability of detecting a 20% increase in subjective hunger scores with a 
SD (standard deviation) of 17% based on the work by Martins et al (2007a), and 
changes to postprandial insulin responses, where there was a calculated 89% 
probability of detecting a 5035 pU/ml.min difference in postprandial insulin AUC 
between the two treatments based on a SD of 6693 pU/ml.min taken from the 
work described in Chapter 3. Based on the data obtained so far, power 
calculations (on the ad libitum test meal data and the parameters obtained from 
the modelling of the FSIVGTT data) were performed to determine the number of 
participants required to elicit a significant difference. These showed that, to 
determine significant differences between the treatments at 5%, with an 80% 
probability, 10 individuals would be needed based on the ad libitum test meal 
data and 14 individuals based on the FSIVGTT data.
116
Chapter 4
In this study, effects on food intake were assessed by diet diaries recorded 
during the final week of each intervention and from food intake at the ad libitum 
test meal after consumption of a standard fibre-free breakfast. No significant 
effect was observed on food intake from either measurement. From the seven 
day diaries there was only an average 28 kJ per day difference in mean intake 
between the two supplements. At the ad libitum test meal there was a lower 
energy intake (394 kJ) following the RS (4521 ± 541 kJ) compared with the PL 
(4915 ± 533 kJ). A possible hypothesis as to why there was such a small 
difference in intake from the diet diaries compared with that measured with the 
ad libitum test meal, could be the nature of how the intakes were assessed. At 
the ad libitum meal (single-meal) the participants were isolated, with any 
distractions removed, and were asked to consume as much as they wanted until 
comfortably full; therefore enabling them to focus more clearly on the meal and 
being more aware of when they were actually full. When the diet diaries were 
completed, participants were free to consume according to their normal dietary 
patterns and would have been subjected to influences of everyday life, including 
external cues and habits. External influences (such as the availability and 
olfactory properties of foods and the presence/absence of other individuals), 
which are removed in the ad libitum setting, could have influenced the amount of 
food consumed. Alternatively, satiety signals may have been ignored in the free- 
living situation and therefore food may have been consumed according to 
normal patterns, rather than in relation to hunger, which is important when 
translating single-meal findings to weight management. This hypothesis is
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corroborated in a review of biomarkers of satiation and satiety by de Graaf et al 
(2004) where it was reported that many factors (cognitive and external) can 
affect food intake, but when food intake is measured under controlled conditions 
this can act as a measure of appetite. This suggests that the ad libitum intake in 
our study could have provided a more accurate marker of intake than the 
reported diet diaries, although not perhaps an accurate marker of free-living 
conditions.
Our study also found no significant difference between the two starches on 
subjective appetite ratings (hunger, fullness or prospective food consumption), 
but again this may have been because of habitual overriding of internal cues, 
and therefore the participants may have been unable to distinguish between the 
two supplements. A study by Barkeiing et al (2007) investigated the relationship 
between eating patterns and feelings of fullness and hunger in obese subjects (a 
control group of lean individuals was also studied). Subjective appetite ratings 
were taken before and after fixed energy breakfast and lunch meals in a 
laboratory setting. The obese subjects were divided into two groups at 
screening, one group who experienced appetite sensations related to eating and 
the other whose eating was not related to appetite sensations (allocated in 
response to screening questions). The authors reported that all groups showed 
changes to appetite ratings in response to the meals, which they suggest shows 
that those in the group where eating was not related to appetite sensations 
could in fact note changes under certain conditions; and that the laboratory
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setting used is different to reai-life settings where other effects can influence 
appetite. This could support the hypothesis from our study discussed above, that 
the lower energy intake observed with the ad libitum test meal (compared with 
the dietary records) could have been due to the participants being more aware 
of their appetite sensations.
A significant difference was found between the RS and PL for ratings of desire 
for fatty foods, with participants- appearing to have a greater desire for fatty 
foods after the RS compared with the PL. The reason for this greater desire for 
fatty foods is unclear, especially as there was no significant difference between 
the supplements in consumption of fatty foods from the seven day diet diaries, 
and the result contradicts our own earlier findings (Chapter 3), where 
participants consumed less fat over the 24 hour period with the RS compared 
with the PL. This greater desire for fatty foods may therefore be a coincidental 
finding especially as the subject numbers were small.
There are few long-term human interventions investigating the effects of RS on 
appetite and food intake. In a study by de Roos et al (1995), where two types of 
30 g RS (Type 2 and Type 3) or glucose were consumed, each for one week, it 
was found that there was little effect on appetite (although subjects were more 
satiated following RS2) or energy and macronutrient intakes from either type of 
RS. However, whilst the supplements were matched for total carbohydrate 
content, the proportion of available carbohydrate was lower in both of the RS
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supplements. One possible reason for the lack of effect on appetite and food 
intake could also be the short duration of the intervention. One week, when 
supplements are consumed in participants’ habitual diets with possible 
influences from external factors (as discussed above), may be insufficient time 
for effects on appetite to become evident, especially if the primary mechanism is 
due to the products of fermentation, which may increase over time. Similarly the 
dose of RS used in de Roos’ study may have been too low to elicit an effect on 
appetite. In a study where the effects on appetite and ad libitum energy intake of 
consumption of fermentable (pectin and (3-glucan) and non-fermentable 
(methylcellulose) DF for 3 weeks were assessed, it was found that satiety was 
higher following the non-fermentable DF, whilst there were no effects on 
reported energy intake (Howarth et al., 2003). However, again the 3 week 
intervention may have been insufficient time for the body to adapt to the 
fermentable DF and therefore the intervention did not affect appetite and food 
intake.
In our study, when using the Goldberg cut-off values to estimate under­
reporting, two participants on the RS leg and three on the PL leg (of which two 
were the same as the ones on the RS leg) would have been classified as under­
reporters. These participants were included in the analysis for the 7 day diet 
diaries due to the small participant numbers. However, when the analysis was 
re-run with the three under-reporters excluded from both legs of the study, there 
were no changes to the results for energy or macronutrient intake.
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As has been demonstrated in previous studies with RS (discussed in Chapter 1), 
our study found no effect of RS intake on body weight, when the starches were 
consumed within habitual diets. This has aiso been found in two other recent 
studies conducted by our group (Johnston et al and Robertson et al, 
unpublished). The lack of effect of RS on body weight has been demonstrated in 
both normal weight (de Roos et al., 1995, Heijnen et al., 1996) and overweight 
individuals (Park et al., 2004). In contrast to the lack of effect of RS on body 
weight in humans, rodent studies have reported effects of high RS consumption 
on lower epididymal fat pad weight compared with low RS diets (de Deckere et 
al., 1993) and rats fed a high amylose-resistant cornstarch diet had decreased 
abdominal fat compared with those on a control diet (Keenan et al., 2006).
Our study found no significant differences between the RS and PL legs for any 
of the blood lipids measured (total, HDL and LDL cholesterol or postprandial 
NEFA and TG concentrations). Whilst there is evidence in rodent studies for a 
lipid lowering effect of RS (de Deckere et al., 1993) the evidence in humans is 
less clear; indeed in a review by Nugent (2005) it was stated that overall RS 
consumption may be lipid neutral. A study by Robertson et al (2005) found no 
effect of 4 week supplementation with RS compared with a placebo on fasting 
TG or NEFA concentrations, although postprandial NEFA concentrations were 
significantly lower with RS. A study by Heijnen et al (1996) where 30 g RS2, 30 
g RS3 or glucose were consumed for 3 weeks each within habitual diets of 
normolipidaemic individuals, also found no effect on total, HDL or LDL
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cholesterol or TG. Higgins et al (2004) also found no significant difference with 4 
different amounts of RS on fasting and postprandial TG concentrations. 
However, in contrast to this evidence, a parallel study conducted in overweight 
and obese subjects, where subjects consumed either 24 g per day RS or regular 
corn starch for 3 weeks, the RS resulted in a decrease in total and LDL 
cholesterol whilst no effect was demonstrated with the regular corn starch (Park 
et al., 2004). A study by Behall and Howe (1995) found that after 14 week 
consumption of a high amylose cornstarch diet (70% amylose and 30% 
amylopectin) the TG concentrations were significantly lower during the study 
than after a high amylopectin diet (standard cornstarch 30% amylose and 70% 
amylopectin). In the light of the mixed findings from the published work further 
investigation would be required to determine what effect, if any, consumption of 
RS has on lipid concentrations in humans.
The postprandial glucose and insulin concentrations in response to the standard 
fibre-free breakfast given in our study did not differ between the RS and PL. 
However, in a study by Behall and Howe (1995) following 14 week consumption 
of high or low amylose cornstarch, glucose responses were similar between the 
two diets, but the insulin responses were significantly lower with the high 
amylose diet compared with the low amylose diet. This suggests that the 
participant numbers may indeed have been too small in our study to detect 
significant differences; alternatively 4 weeks may have been insufficient time for
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effects on metabolites to occur, as demonstrated by an effect being observed 
after 14 weeks in the Behall and Howe (1995) study.
In our study, when the glycaemic and insulinaemic responses were investigated 
using the FSIVGTT, there was a significant difference between the RS and PL 
for glucose, insulin and C-peptide concentrations. In all instances the metabolite 
responses were significantly higher with the RS than with the PL. However, 
when the data were modelled there were no significant differences between the 
starches for the parameters obtained. The raw data indicates that there is an 
improved first-phase insulin response with the RS compared with the PL whilst 
the AIRg values obtained from the model were not significantly different; these 
apparent contradictory findings are likely to be due to a lack of study power for 
the modelling of the data to determine differences between the treatments. 
Improvements in the first-phase insulin response due to consumption of RS, 
could have beneficial implications in diabetes, as the reduction of first-phase 
insulin is a primary defect of (3-cell functioning in the development of diabetes 
(Gerich, 2002). This finding would need further investigation with more 
participants to determine whether it is a true physiological effect.
Both the oral insulin sensitivity (in response to the standard fibre-free meal) and 
the insulin sensitivity values obtained by the FSIVGTT were not significantly 
different between the RS and the PL, but both measures produced insulin 
sensitivity values that were higher with the PL than with the RS. These findings
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contradict those of previous studies where consumption of RS has been seen to 
improve insulin sensitivity compared with a placebo, measured by oral insulin 
sensitivity in one study and by an euglycaemic-hyperinsulinaemic clamp in 
another study (Robertson et al., 2003, Robertson et al., 2005). It is therefore 
likely that the lack of finding of an effect of consumption of RS on insulin 
sensitivity in our study compared with the PL is due to the very small participant 
numbers and thus more participants would need to be added to this body of 
work before a final conclusion can be drawn.
Overall it would appear from this study that longer-term (4 week) consumption of 
RS by overweight individuals does not impact on appetite or food intake. The 
study also found that there appears to be a treatment effect of the RS on the 
insulin response, although further investigation is required to confirm this finding. 
All of the results from the study are probably affected by the small participant 
numbers and therefore it is difficult to draw any concrete conclusions from the 
study. Further investigation with more participants (as is planned) would be 
required to confirm or disprove the preliminary findings.
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This chapter describes three studies, using specially developed whole grain 
bread rolls, to determine glycaemic index, acceptability to participants and short­
term effects on appetite and food intake. This was important preliminary data, 
necessary before commencing a longer-term intervention using these rolls.
5.1. Introduction
There is epidemiological evidence suggesting whole grains have a beneficial 
role in several chronic diseases (Seal et al., 2006) and that they may regulate 
body weight and thus could be beneficial in obesity prevention. However, there 
are few intervention studies that directly examine this (Koh-Banerjee and Rimm, 
2003).
As the majority of evidence for the effect of whole grains on weight comes from 
cohort studies, it is unclear if the benefits reported are due to the whole grains 
themselves or because those who consume high intakes of whole grains also 
tend to have other healthier lifestyle habits. These studies alone are therefore 
too weak to provide evidence of a causal relationship.
For use in a controlled intervention study bread rolls were specially 
manufactured by Premier Foods. These rolls delivered a high level of whole 
grains to individuals in order to determine if this dietary factor does possess 
health benefiting properties. The studies in this chapter provide necessary 
information in terms of taste and Gl of the bread roll products, which could
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confound the interpretation of the data in the intervention study, with reference 
to the beneficial effects of the whole grains themselves. An initial small 
crossover study using the rolls is also outlined in this chapter, which was 
conducted to provide initial data on the effect of whole grains on appetite, as 
there is no current evidence for this effect in the literature.
5.2. Aim
The overall aim of the studies described in this chapter was to acquire 
information regarding the glycaemic index, taste and short-term appetite effects 
of the developed whole grain roll products to complement data obtained from a 
chronic study.
5.3. The Products
The bread rolls were developed, manufactured and supplied by Premier Foods.
5.3.1. Description
When the products were developed there were no UK recommendations for the 
level of whole grains to include in the diet; however, it was recommended that 
levels of intake should be increased. The 2005 Dietary Guidelines for Americans 
recommend that individuals consume three or more servings of whole grains per 
day. A serving is considered to equate to 16 g of the whole grain ingredient 
(Whole Grains Council, USA) and therefore 48 g of whole grains would be the 
recommended intake per day.
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Based on these recommendations the experimental products developed for the 
following studies provided 48 g whole grain (wheat grains), in a two roll serving. 
Premier Foods developed the bread rolls as a controlled and reproducible 
vehicle to provide the specified whole grain. Two types of whole grain rolls were 
developed, one where the grains were in the intact form and the other where the 
product contained exactly the same ingredients and level of whole grain, but 
where the grains had been milled. This would allow for the influence of whole 
grain structure to also be investigated, as both the intact and milled whole grain 
products fulfil the definition of whole grains. A refined grain roll, baked from 
identical dough, containing no whole grains was also produced and used as a 
control. The bread rolls used in the study are shown in Figure 5.1.
Whole Grain
Bread Rolls -  Whole Grain
“Milled” a------- Bread Rolls
v _ - “Intact”
\
\  Refined Grain 
v w  Bread Rolls -
“Control”
■ ' ' 3':' \
Figure 5.1: Bread rolls used within the studies.
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5.3.2. Nutritional information
The nutritional information for each roll (per 100 g of product and per average 
roll) is shown in Table 5.1. The basic bread dough was identical for all three 
rolls, the only differences arising from the addition of whole grains in different 
structures.
Table 5.1: Nutritional composition of the developed bread rolls, per 100 g and per average roll.
Intact whole grain Milled whole grain Refined grain rolls -
rolls rolls Control
Per100g P e r  8 0 . Og Per 100g P e r  9 7 . Og Per 10Og P e r  1 0 6 .9g
Energy (KJ) 1243 9 9 4 1200 11 6 4 1093 1 1 6 8
Energy (kcal) 293 2 3 4 283 2 7 5 258 2 7 6
Protein (g) 10.0 8.00 9.7 9.41 7.6 8.12
Carbohydrate (g) 59.5 4 7 .6 0 57.4 5 5 .6 8 54.1 5 7 .8 3
Sugar (g) 1.5 1.20 1.5 1 .46 1.1 1 .18
Fat (g) 1.7 1 .36 1.6 1 .55 1.2 1 .28
Saturates (g) 0.22 0 .1 8 0.22 0.21 0.16 0.17
Fibre (g)1 5.6 4 .4 8 5.4 5 .2 4 2.7 2 .8 9
Sodium (g) 0.29 0 .2 3 0.28 0.27 0.51 0 .5 4
Moisture (g) 21.8 17.44 24.5 2 3 .7 7 30.4 3 2 .5 0
1 Fibre measured by the AOAC method
5.4. Study 1 -  Taste test
It is important when developing products for use in intervention studies that they 
are acceptable to the consumer, which ultimately would enhance study 
compliance. Differences in taste and acceptability could result in differing 
postprandial responses, irrespective of nutritional properties. Therefore a taste 
test on the developed experimental rolls was carried out to gather data on the 
acceptability and organoleptic properties of the products. Commercially available
Study 1 contains the products of joint research between Laura Tripkovic and myself. Whilst the planning and data 
collection were conducted in collaboration, all analysis was conducted by myself.
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products were chosen to which the three developed bread rolls could be 
compared. These were matched as closely to the developed breads as possible, 
but as there are no commercially available products that are the same as the 
developed products these were predominately visually matched.
5.4.1. Aim
To investigate the similarities and differences between the developed bread rolls 
(intact and milled whole grain roils and control rolls) and compare them to 
visually similar commercially available bread products.
5.4.2. Hypothesis
The three developed products will not differ significantly from each other, which 
might impact on appetite and food intake in the intervention study.
5.4.3. Study Design
5.4.3.1. Participants
Thirty adult males and females (15 M, 15 F) participated in the study. Individuals 
suitable for inclusion for the taste test met similar criteria to those who would be 
participating in the intervention. The main inclusion criteria for the taste test were 
individuals without food allergies or intolerances, those without bowel 
complaints, such as irritable bowel syndrome, those who did not have other 
problems associated with foods high in DF (such as poor dentition) and those 
who did not regularly consume high intakes of whole grains.
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5.4.3.2. Protocol
The study was a blinded, comparison sensory evaluation, using a Difference 
Test, Hedonic Scale and Visual Analysis. Participants attended for a maximum 
of 45 minutes to complete questionnaires regarding the breads. The University 
of Surrey’s Ethics Committee gave a favourable ethical opinion for this study 
(EC/2007/02/SBMS) and all participants gave informed, written consent.
There were six samples, three experimental rolls and three commercial products 
(Figure 5.2). The six breads were randomly assigned a number for the test.
Figure 5.2: Commercially available bread products for taste test comparison. A = milled 
whole grain roll equivalent, B = refined grain roll equivalent, C = intact whole grain roll 
equivalent.
The taste test was guided by the methodology in the British Standards in 
Sensory Analysis (BS ISO 6658:2005, Standards Policy and Strategy 
Committee). As per these Standards, the test was performed mid-afternoon, one
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to two hours after the participants had consumed lunch, to eliminate possible 
influences of appetite. The test was conducted in controlled conditions. All 
participants were placed in individual areas and all surroundings and equipment 
were kept as neutral as possible to reduce external influences. The participants 
remained silent throughout the test and were unable to communicate either with 
each other or the investigators. All six samples were provided to the participants 
as 1 inch squares and were on a covered plate. Each sample was identified by a 
randomly assigned number. A glass of water was provided.
Three tests were used to determine information on the breads, a difference test, 
a visual analysis and a hedonic scale. The difference tests involved participants 
rating, on a scale of 1 to 9 (one being the most negative and nine the most 
positive), properties of each of the breads (Figure 5.3). The properties rated 
were aftertaste, saltiness, moistness, roughness, chewiness and hardness.
1) Moistness
Very dry Just right Very moist
1 2 3 4 5 6 7 8 9
Figure 5.3: An example of one of the questions asked in the difference tests. Participants 
were asked to circle the answer they felt most appropriate for each of the breads and 
questions.
The visual analysis gauged the visual acceptability of each of the samples from 
photographs and participants were asked to rank them from 1st choice to 6th. 
The hedonic scale involved the participants rating how much they liked or 
disliked each bread (Figure 5.4).
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Sample 1 Sample 2
Like extremely
Like very much
Like moderately
Like slightly
Neither like nor dislike
Dislike slightly
Dislike moderately
Dislike very much
Dislike extremely
Figure 5.4: An example of the question asked in the hedonic scale test. Participants were 
asked to tick the statement that best described their feeling about each sample.
5.4.3.3. Statistical Analysis
The data were analysed using non-parametric statistics. Each grain type was 
compared with their corresponding commercial product using Wilcoxon Signed- 
Rank. The three test breads were compared using the Friedman test and when 
significant differences were found, Post Hoc Wilcoxon Signed-Rank tests, with a 
Bonferonni adjustment. Data are presented in the text as the median and on 
graphs as the median and inter-quartile range. On all graphs and tables intact 
whole grain rolls are referred to as “WG”, milled whole grain rolls as “MWG” and 
control rolls as “C”.
5.4.4. Results
5.4.4.1. Difference Test
There were no significant differences in aftertaste between the experimental and 
commercial rolls of the same grain, or between the three experimental rolls. The 
experimental and commercial intact whole grain rolls and control rolls did not 
differ significantly in ratings of saltiness. The experimental milled whole grain
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rolls were perceived as significantly less salty than the matching commercial 
rolls (Md 6 vs 5 Md, p=0.044). The ratings of saltiness were not significantly 
different between the experimental rolls (Figure 5.5).
Bland g- 
8- 
7-
•)</> c_<D 6“c 
1co5_ 
o
t  4- 
-I
H 
2-
Salty 1-
Figure 5.5: Results from difference test for saltiness, n=30 for all groups. E = experimental,
Co = commercial. Numbers on graph represent outliers at each point. Wilcoxon Signed Rank 
test showed no significant difference between E and Co WG and C rolls and a significant 
difference between MWG E and Co rolls (* p=0.044). Friedman test showed no significant 
difference between the E rolls.
All three experimental rolls (intact, milled and control) were significantly drier and 
more bitty than their commercial counterparts (Md 3 vs Md 3, p=0.009, Md 1 vs 
Md 5, p=<0.001 and Md 2 vs Md 3, p=0.014, respectively for moistness; Md 3 vs 
Md 6, p=<0.001, Md 5 vs Md 7, p=<0.001 and Md 6 vs Md 7, p=0.024, 
respectively for roughness). There was a significant difference between the 
three experimental breads when compared for moistness (p=0.007). Post Hoc 
tests revealed that the intact whole grain rolls were significantly less dry than the 
milled whole grain rolls (p=0.008) (Figure 5.6). The three experimental rolls 
were also significantly different (p<0.001) for roughness, with Post Hoc tests
n i
WG E WG Co MWG E MWG Co
Bread Type
C E C Co
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revealing the difference lay between all three products, intact vs milled 
(p=0.001), intact vs control (p=<0.001) and milled vs control (p=<0.001) (Figure 
5.6).
A  Moist 9- 
8-
7-
*>■2 6-
o 1
> 4-
2-
Dry 1'
g  Smooth
c 6
3-
Bitty
II
WG E WG Co MWG E MWG Co 
Bread Type
C E C Co
I
WG E
II
• 1
WG Co MWG E MWG Co C E C Co
Bread Type
Figure 5.6: Results from difference test for moistness (A) and roughness (B), n=30 for all 
groups. E = experimental, Co = commercial. Numbers on graph represent outliers at each 
point. All three E rolls were significantly drier than Co pair and the three E rolls were 
significantly different to each other (p=0.007). All three E rolls were significantly were more 
bitty than Co pair and the three E rolls were significantly different to each other (p<0.001).
All three experimental rolls (intact, milled and control) were significantly more 
chewy and hard than their commercial pair (Md 2 vs Md 4, p=<0.001, Md 3 vs
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Md 5, p=<0.001 and Md 3 vs Md 5.5, p=<0.001, respectively for chewiness; and 
Md 4 vs Md 5 p=<0.001, /Wc/ 3 vs Md 7 p=<0.001 and Md 4 vs Md 6.5 p=<0.001, 
respectively for hardness). There was no significant difference between the 
three experimental rolls for chewiness or hardness (Figure 5.7).
Soft 9-
7-
o 1
o 2
SB­
'S
• 2
Chewy
g  Soft
3-
2-
1-
II
WG E WG Co MWG E MWG Co C E 
Bread Typo
C Co
WG E WG Co MWG E MWG Co C E C Co 
Bread Type
Figure 5.7: Results from difference tests for chew iness (A) and hardness (B), n=30 for all 
groups, except W G  E for hardness n=29. E = experimental, C o  = commercial. Num bers on 
graph represent outliers at each point. All three E rolls significantly more chew y and harder 
than their C o  pair. There  w ere no significant differences between the three E rolls for 
chew iness or hardness.
136
C hapter 5
5.4.4.2. Visual Analysis
The visual ranking of the breads from the photographs, revealed the order of 
acceptability to be:
s^t Intact whole grain commercial
2nd Milled whole grain commercial
3rd Milled whole grain experimental
4th Intact whole grain experimental
5th Control experimental
6th Control commercial
5.4.4.3. Hedonic Scale
Figure 5.8 shows the frequency of response for each of the breads on the 
hedonic scale. The density of the colour on the charts signifies the degree of 
liking/disliking, with the orange shades indicating liking, blue/green shades 
disliking and white indicates neither like nor dislike.
From all of the breads it appears that the control rolls were the most disliked with 
the commercial roll being the least acceptable of the two rolls. From the two 
types of whole grain rolls the commercial intact and milled rolls appeared to be 
more acceptable than the corresponding experimental rolls.
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□ Like extremely
□ Like very rruch
□ Like moderately
□ Likesligrtly
□ Neither like/dislike
□ Dislike slighdy
□ Dislike moderately
■ Dislike very much
■ Dislike extremely
Figure 5.8: Frequency of response on the hedonic scale for each bread, n=30. A = intact 
whole grain experimental, B = intact whole grain commercial, C = milled whole grain 
experimental, D = milled whole grain commercial, E = control experimental, F = control 
commercial. Orange colours represent liking, blue/green colours represent disliking and 
white represents neither like nor dislike.
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Comparison of the experimental breads against commercial breads showed the 
experimental milled whole grain rolls were significantly more disliked than the 
corresponding commercial roll (Md = 6 vs Md = 3, p=0.001), there was a trend 
towards the experimental intact whole grain roll being more disliked than the 
corresponding commercial product (Md = 4 vs Md =3, p=0.097) and there was 
no significant difference between the two types of control roll (Figure 5.9). When 
the three experimental rolls were compared there was a significant difference 
(p=0.042) and Post Hoc analysis revealed the difference lay between the intact 
whole grain rolls and control rolls (Md = 4 vs Md = 7, p=0.013) (Figure 5.9), with 
the intact whole grain rolls being more preferred than the control rolls.
Figure 5.9: Hedonic rating for each bread, n=30. E = experimental, Co = commercial. 
Wilcoxon Signed-Rank tests showed a significant difference between MWG E and MWG 
Co (* p=0.001). The Friedman Test showed a significant difference between the three E 
groups (t p=0.042).
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5.5. Study 2 -  Glycaemic Index
This section of the chapter will outline the study undertaken to determine the Gl 
of the three developed bread rolls. The methodology for this study followed the 
guidelines outlined in the paper by Brouns et al “Glycaemic index methodology” 
(2005), which is the accepted protocol for Gl measurement.
5.5.1. Aim
To determine the Gl and insulin response of the developed whole grain bread 
rolls (intact and milled) and the control roll (refined grain).
5.5.2. Hypothesis
The refined grain bread roll will have a Gl similar to that of published GIs for 
commercially available white bread. The whole grain rolls will have lower GIs 
than the refined grain roll, with the roll containing grains in the intact form having 
a lower Gl than the milled grain roll.
5.5.3. Study Design
5.5.3.1. Participants
Twelve young, healthy participants were recruited and nine (5 M, 4 F), 
completed the study. The participant characteristics are shown in Table 5.2. Of 
the participants who dropped out of the study, one stopped due to sleep 
deprivation, which could have impacted on blood glucose responses and the 
other two due to problems with time commitments due to personal work load.
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Table 5.2: Baseline characteristics of the participants, n=9.
Measurement Mean ± SEM
Age (years) 26.9 ± 1.86
Height (cm) 74.4 ± 3.90
Weight (kg) 74.2 ± 4.47
BMI (kg/m2) 24.3 ± 1.00
Waist Circumference (cm) 87.1 ±2.60
Hip Circumference (cm) 102.6 ±2.37
Body Fat (%) 23.5 ± 1.91
Systolic Blood Pressure (mmHg) 118.7 ±4.98
Diastolic Blood Pressure (mmHg) 71.0 ±3.26
5.5.3.2. Protocol
The study was a randomised crossover study investigating the glycaemic index 
of the three manufactured test bread rolls. Participants attended for six study 
mornings, when they consumed one of the three bread rolls (intact, milled or 
control rolls) and, on three occasions, the reference food (glucose). Each study 
morning was separated by at least one day for washout. The University of 
Surrey’s Ethics Committee gave a favourable ethical opinion for this study 
(EC/2008/66/FHMS) and all participants gave informed, written consent.
Participants were given a weighed amount of bread (weighed to 0.1 g) that 
provided 50 g of available carbohydrate (Table 5.3). The reference food used 
was 50 g of glucose powder (Thornton and Ross Ltd, UK) in 250 ml water. All
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participants started with a glucose drink as their first test product. The bread 
rolls and two other glucose drinks were randomised for the subsequent visits for 
each participant using a web-based randomisation program.
Table 5.3: Amounts of product given to provide 50 g available carbohydrate
Available Carbohydrate
(g)
Amount of product
(g)
Whole grain “intact” roll 50 84.0
Whole grain “milled" roll 50 87.1
Refined grain “control" roll 50 92.4
On the day before each study day participants were requested to refrain from 
strenuous exercise and alcohol, and were asked to consume the same evening 
meal the evening before each study morning and then fast for 12 hours. On the 
first study morning anthropometric measurements and blood pressure were 
taken.
On each study morning a fasting capillary blood sample was taken by finger 
prick. After this the participants consumed either the test roll with 250 ml of 
water or the glucose drink. Participants consumed the products within 10 
minutes. Further capillary blood samples were taken at 15, 30, 45, 60, 90 and 
120 minutes after the first mouthful of the test product. Participants returned for 
the next study morning after at least one day to allow for washout.
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After consumption of the breads roils, the participants completed a questionnaire 
regarding the taste, texture, smell, palatability and aftertaste of each of the 
tested products. These questionnaires required the participant to rate the 
products on a scale of 1 to 5, with 1 being unpleasant and 5 very acceptable.
On each occasion approximately 300 pi of blood was collected into heparinized 
tubes. All samples were centrifuged and the plasma was immediately analysed 
for plasma glucose concentrations, using the YSl method (described in Chapter 
2). All plasma samples were then frozen at -20oC prior to analysis of insulin 
concentrations by RIA (as described in Chapter 2).
5.5.3.3. Calculations and Statistical Analysis
The iAUC for each participant’s glucose response to each product was 
calculated using the trapezoid method, ignoring all points that went below 
baseline, according to Brouns et al (2005). A mean glucose response was then 
used to compare the bread samples. The glycaemic index of each product for 
each participant was then calculated by dividing the iAUC of the test food by the 
iAUC of the mean glucose scores (reference food), times 100. The overall GI of 
each product was then calculated as the mean value from the 9 participants.
iAUC of the test food
---------------------------------------------  X100
IAUC of the reference food
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The glucose and insulin data were also analysed using repeated measures 
ANOVA with bread type and time as independent variables and the 
measurements themselves as the continuous dependent variable. AUC were 
also calculated for the insulin and glucose responses to each bread, using the 
trapezoid method, and compared using one-way repeated measures ANOVA. 
The questionnaire data regarding the breads’ properties were analysed using 
the Friedman test and when significant differences were found, Post Hoc 
Wilcoxon Signed-Rank tests, with a Bonferonni adjustment. On all graphs and 
tables intact whole grain rolls are referred to as “WG”, milled whole grain rolls as 
“MWG” and control rolls as “C”.
5.5.4. Results
5.5.4.1. Glycaemic Index
The Gl of the bread rolls are shown in Table 5.4. The results suggest that the 
milled grain roll and the control roll have similar a Gl whilst the intact grain roll 
has a lower Gl. However, the difference between the Gl of the breads was not 
significantly different.
Table 5.4: Glycaemic Index of the three test bread rolls.
Gl SEM
Whole grain “intact” roll 60.7 5.6
Whole grain "milled” roll 81.3 8.1
Refined grain “control” roll 78.3 10.6
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These values would be classified as high GI for the milled whole grain and 
control rolls (high GI >70) and medium GI for the intact grain rolls (medium GI 
55-70). The control roll GI is similar to that of commercially available white wheat 
bread, which has previously been assigned an average GI of 75 ± 2 (Atkinson et 
al., 2008).
5.5.4.2. Glucose and insulin Responses
The fasting insulin sensitivity and (3-cell function (assessed by the homeostatic 
model assessment, described in Chapter 2) were not significantly different at the 
start of the study days, which confirms that the participants were in a similar 
metabolic state at the start of each study day, Table 5.5.
Table 5.5: Fasted insulin sensitivity and (3-cell function on each study day, n=9. Comparisons 
were made with one-way repeated measures ANOVA.
Average
Glucose
Mean SEM
WG 
Mean SEM
MWG 
Mean SEM
C
Mean SEM
P
Value
HOMA % S1 147.3 13.1 141.6 17.3 146.8 16.8 139.1 17.9 NS
HOMA % B2
1 ■ TX* .  A n, rx
85.3 8.1 92.7 8.8 88.4 7.9 91.4 8.2 NS
1 HOMA %S = fasted oral insulin sensitivity, assessed by homeostatic model assessment.
2 HOMA %B = (3-cell function, assessed by homeostatic model assessment.
Figure 5.10 shows the mean plasma glucose response to all four products. 
There was a greater response to the glucose drink and a similar response for 
the three test rolls. There was no significant difference between the three rolls 
when the glucose responses were compared using repeated measures ANOVA.
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However, there was a treatment*time interaction, indicating that the responses 
differed over time between the breads. Post Hoc analysis indicated that the 
significant difference arose between the intact grain rolls and the control rolls. 
This difference over time could be explained by the lower drop in plasma 
glucose concentrations noted with the intact grain roll, whilst the control roll 
plasma glucose concentrations remained fairly constant.
0 15 30 45 60 75 90 105 120
Time (mins)
Figure 5.10: Postprandial plasma glucose response to the four products. Mean ± SEM; n=9. 
Repeated measures ANOVA showed no significant differences between the plasma glucose 
responses for three bread rolls.
The mean insulin responses to the four products are shown in Figure 5.11. As 
with the plasma glucose concentration there is a greater insulin response to the 
glucose drink than the three test rolls. The insulin response of the three rolls is 
comparable, with a slightly lower response for the milled grain rolls than for the 
other two, although these differences were not significant.
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Figure 5.11: Postprandial plasma insulin response to the four products. Mean ± SEM; 
n=9. Repeated measures ANOVA showed no significant differences between the plasma 
insulin responses for the three bread rolls.
There was also no significant difference between the three test breads for the 
glucose or insulin responses measured by AUC (Figure 5.12).
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Figure 5.12: AUC for the three bread rolls for:
A = Plasma glucose response.
B = Plasma insulin response
Mean ± SEM; n=9. One-way repeated measures ANOVA showed no significant differences 
between breads for either the plasma glucose or insulin responses.
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5.5.4.3. Product Evaluation
Figure 5.13 shows the total score for each bread. Each question was marked on 
a scale of 1 to 5, where 5 was considered very acceptable, so a maximum score 
of 25 could have been achieved. As can be seen, overall the milled whole grain 
roll appeared to be most acceptable to the participants with a median score of 
17, whilst the control rolls were least acceptable with a median score of 13. 
There was a significant difference between the breads (p=0.014), with the Post 
Hoc test indicating the significant difference was between the milled whole grain 
and control rolls, p=0.017.
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Figure 5.13: Total score from the evaluation questionnaire for each of the three bread 
rolls. Median and inter-quartile range; n=9. Friedman test showed a significant difference 
between the three breads (p=0.014).
Figure 5.14 shows the results for each bread in response to each of the 
evaluation questions. There was no significant difference between the breads for 
smell or taste.
i t
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Payability Tast# Smell Texture After Taste
Figure 5.14: Average score for each roll in response to the questions on the evaluation 
questionnaire. Median and inter-quartile range; n=9. No significant difference between rolls 
for taste or smell. Significant difference between rolls for palatability (p=0.039), texture 
(p=0.004) and aftertaste (p=0.0011). Comparisons made with the Friedman test.
There were significant differences between the breads for palatability (p=0.039), 
with the milled whole grain rolls being more preferable than the control rolls 
(p=0.014); and for ratings of texture (p=0.004), where the intact whole grain rolls 
were much less acceptable than the milled whole grain rolls (p=0.009).
A significant difference was also found between the breads for ratings of 
aftertaste (p=0.011), where the aftertaste of the control rolls was least 
acceptable to the participants and these rolls were significantly different to the 
intact whole grain rolls (p=0.011). There was also a trend towards significance 
with the milled whole grain and control rolls (p=0.034).
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5.6. Study 3 -  Short-term effects of whole grains on appetite
This section of the chapter describes a short-term appetite study using the 
developed bread rolls. Results from studies 1 and 2 indicated the milled whole 
grain and control rolls had comparable GIs and the milled whole grain rolls 
appeared to be the more acceptable of the two whole grain rolls. Therefore this 
pilot appetite study used the milled whole grain rolls compared with the control 
rolls to determine the effect of whole grains on appetite and food intake.
5.6.1. Aim
The aim was to investigate the effects on appetite and satiety of three weeks’ 
consumption of milled whole grain bread rolls (providing 48 g whole grain per 
day) compared with the refined grain bread rolls. This was measured 
subjectively using VAS and quantitatively using actual food intake (at a test meal 
and over one week using diet diaries). The effects of the milled rolls on 
anthropometric measurements were also assessed.
5.6.2. Hypothesis
The inclusion of 48 g of milled whole grains per day for three weeks will promote 
satiety and decrease participants’ intake compared with refined grain at an ad 
libitum test meal and their habitual food intake measured by a seven day diet 
diary.
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5.6.3. Study Design
5.6.3.1. Participants
Fourteen young healthy adults (5 M, 9 F) participated in the study (Table 5.6). 
The participants included in the study had mean scores of 2.27 (± 0.23), 2.88 (± 
0.10) and 1.91 (± 0.16) on the emotional, external and restrained scales of the 
DEBQ, respectively.
Table 5.6: Baseline anthropometric measurements taken on the first study morning, n=14.
Measurement Mean ± SEM
Age (years) 26 ± 1.43
Height (cm) 170.9 ± 2.36
Weight (kg) 64.0 ± 2.89
BMI (kg/m2) 21.8 ± 0.76
Waist Circumference (cm) 77.8 ± 2.45
Hip Circumference (cm) 92.7 ± 2.78
Body Fat (%)1 22.3 ± 2.83
Systolic Blood Pressure (mmHg) 114.2 ± 2.75
Diastolic Blood Pressure (mmHg)
1 w  t.  . r
70.4 ± 1.61
= Value for 13 participants
5.6.3.2. Protocol
The study was a randomised balanced crossover study investigating the effects 
of 48 g milled whole grain on measures of appetite and satiety compared with 
refined grain. Participants consumed two of the milled whole grain bread rolls or 
two of the refined grain bread rolls (control) daily for three weeks, separated by 
a three week wash-out period (Figure 5.15). A favourable ethical opinion was
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given for this study by the University of Surrey’s Ethics Committee 
(EC/2007/65/FHMS) and all participants gave informed, written consent. 
Participants could consume the rolls at any time of day and with any fillings of 
their choice.
3 week intervention with milled grain or 3 week intervention with milled grain or
refined grain bread roll refined 8raln roll
Morning Morning Morning Morning
Figure 5.15: Study timeline
A diet diary was completed for a week before the start of the study to obtain 
baseline dietary intake. Participants attended for a study morning at the 
beginning and end of each intervention. On each study morning anthropometric 
measurements and blood pressure were taken. The participants completed two 
fasting VAS and were given a standard commercially available milkshake 
breakfast (Nurishment®, ENCO Products Ltd, UK), as described in Chapter 4, 
section 4.4.3 and Table 4.2. Each participant consumed the same flavour on all 
visits. Following breakfast, VAS were completed every 30 minutes for three 
hours, after which participants were given the ad libitum test meal.
152
C hapter 5
Participants began consuming the bread rolls on the day after the study day and 
completed a seven day diet diary during the last week of each intervention.
At the end of each intervention an evaluation questionnaire regarding the taste, 
texture, smell, aftertaste, palatability and ease of incorporation of the bread rolls 
into their normal diets was completed. The participants were asked to rate these 
factors from 1 to 5 where 1 was considered unpleasant and 5 pleasant.
5.6.3.3. Calculations and Statistical Analysis
The VAS data were analysed using repeated measures ANOVA with bread type 
and time as independent variables and the measurements themselves as the 
continuous dependent variable. The AUC for each VAS question was also 
calculated and then compared using paired samples f-tests. Comparisons were 
made between treatments (using percentage change from the beginning to end 
of each treatment) and between the ends of each treatment after the three week 
intervention, using paired samples f-tests. Responses to the evaluation 
questionnaires were analysed using the Wilcoxon Signed-Rank tests. On all 
graphs and tables milled whole grain rolls are referred to as “MWG” and control 
rolls as “C”.
5.6.4. Results
5.6.4.1. Anthropometries
Anthropometric measurements taken at baseline and end of each intervention 
are shown in Table 5.7.
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Table 5.7: Anthropometric measurements taken at baseline and end of each intervention, n=14.
Measurement
WG Baseline 
Mean ± SEM
WG End 
Mean ± SEM
C Baseline 
Mean ± SEM
CEnd 
Mean± SEM
Weight (kg) 64.2 ± 2.9 64.0 ±2.9 63.9 ± 3.0 64.2 ± 2.9
BMI (kg/m2) 21.9 ±0.8 21.8 ±0.8 21.8 ±0.8 21.9 ±0.7
Waist Circumference (cm) 78.0 ±2.5 79.5 ± 2.4 78.3 ±2.1 79.0 ±2.8
Hip Circumference (cm) 92.6 ±2.7 92.8 ±2.6 92.1 ±2.6 91.9 + 2.8
Body Fat (%)1 22.5 + 2.8 22.5 ±2.8 23.0 ± 2.9 22.6 ±2.8
Systolic Blood Pressure (mmHg) 114.3 ±2.7 112.4 ±2.6 112.8 ±2.2 117.1 ± 1.7
Diastolic Blood Pressure (mmHg) 72.3 ± 1.5 71.5 ± 1.7 70.9 ± 1.6 72.7 ± 1.9
-  Value for 13 participants
There was no effect of whole grain intake on % body fat, waist or hip 
circumference or diastolic blood pressure. However, there was a significant 
difference between breads for systolic blood pressure (p=0.016) which 
decreased during the milled whole grain intervention and increased during the 
control intervention, as shown in Figure 5.16, There was also a significant 
difference between the ends of the milled whole grain and control interventions 
for systolic blood pressure, 112.4 ± 2.56 mmHg versus 117.1 ± 1.71 mmHg 
(p=0.038).
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Figure 5.16: Percentage change for systolic blood pressure from beginning to end of the 
MWG and C interventions. Mean ± SEM; n=14. Paired samples t test showed a significant 
difference between the interventions, p=0.016.
There was also a trend towards significance for body weight and therefore BMI. 
The percentage change for body weight on the milled whole grain intervention 
reduced by an average of 0.38 ± 0.27%, whilst increased by an average of 0.49 
± 0.44% on the control intervention (p=0.07). This translated as an average 
decrease in BMI of 0.09 kg/m2 on the milled whole grain intervention and an 
average increase of 0.09 kg/m2 on the control intervention.
5.6.4.2. Subjective appetite ratings
There were no significant differences in VAS ratings for hunger (Figure 5.17), 
prospective food consumption, fullness or desire for different foods (sweet, salty, 
savoury or fatty) either within each intervention or between interventions when 
the responses were compared. It should be noted that the subjective appetite 
ratings were in response to the fibre-free meal on the test mornings and not to 
the products themselves.
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Figure 5.17: Subjective appetite ratings in response to the question “how hungry do you feel?”
A) Pre and post MWG intervention.
B) Pre and post C intervention.
C) Post each intervention.
Mean ± SEM, n=14. No significant differences observed when comparisons were made with 
repeated measures ANOVA.
There was also no significant difference between the AUC, for the VAS ratings 
relating to hunger, fullness, prospective food consumption, or desire for different 
foods, when the ends of both interventions were compared and when the 
difference between beginning and end of each intervention were compared.
5.6.4.3. Test Meal
There was no significant difference in either weight consumed or in energy 
intake at the ad libitum test meal within interventions or between interventions 
(absolute difference between beginning and end of each intervention was 
calculated) (Figure 5.18). However, following the control intervention there was
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an increase in intake (mean increase of 367 kJ ± 270 kJ) at the ad libitum test 
meal which was not observed with the milled whole grain intervention (mean 
decrease of 0.7 kJ ± 300 kJ).
4000
MWG
Figure 5.18: Energy intake at the ad libitum test meal, pre and post each intervention. 
Mean ± SEM, n=14. Comparisons made with a paired samples t test showed no 
sianificant differences within or between interventions.
5.6.4.4. Diet Diaries
There was no significant difference in average daily energy intake between the 
seven day diaries completed at the end of milled whole grain intervention 
compared with the control intervention (Figure 5.19). However, participants 
consumed on average 495 ± 370 kJ more during consumption of the control rolls 
compared with the period during which the milled whole grain rolls were 
consumed.
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Figure 5.19: Average daily energy intake from the 7 day diet diaries completed at the end of 
the MWG and C interventions. Mean ± SEM, n=14. Comparisons with a paired samples t test 
showed no significant difference between the interventions..
There was no significant difference in protein or fat intake between the 
interventions (Figure 5.20). Carbohydrate intake tended to be higher during the 
control compared with the milled whole grain intervention (369.3 ± 21.2 g versus 
344.5 ± 19.8 g, p=0.054) (Figure 5.20), sugar intake also tended to be higher 
following the control compared with the milled whole grain (126.3 ± 15.5 g 
versus 115.3 ± 15.4 g, p=0.072), although neither difference was significant. 
When the diaries were analysed the bread rolls were included within the 
analysis and this resulted in a significantly higher total DF intake with the milled 
whole grain rolls compared with the control rolls (30.1 ± 1.7 g versus 25.5 ±1.8 
g, p=<0.001) (Figure 5.20). Sodium intake was significantly lower with the milled 
whole grain compared with the control (3192 ± 204 mg versus 3674 ± 199 mg, 
p=0.027).
*
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Figure 5.20: Mean daily macronutrient and total DF (TDF) intake from the 7 day diet diaries 
completed at the end of the interventions. Mean ± SEM, n=14. Paired samples f-tests showed 
no significant difference between the interventions for protein or fat. Carbohydrate (CHO) 
intake was higher following the C compared with the MWG (p=0.054). TDF was significantly 
higher following the MWG compared with the C (* p<0.001).
Percentage change for each intervention was calculated from the pre study diary 
and the diary completed during the final week of each intervention. There were 
no significant differences between the two interventions for percentage change 
for energy or macronutrients. There was a significant difference between the 
percentage changes for total DF intake, which increased by 40.1 ± 6.9% for the 
milled whole grain intervention compared with 17.3 ± 6.8% for the control 
intervention (p=<0.001).
5.6.4.5. Evaluation Questionnaires
The scores from each of the questions, where the breads were rated 1 to 5 (with 
5 being the highest score in each category), showed the two breads to be 
closely matched in ease of incorporation into diets, palatability, taste, texture,
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smell and aftertaste (Figure 5.21). There were no significant differences 
between the breads for any of the questions.
1 - j x  i i i i  i *
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Incorporation
Figure 5.21: Mean response to each question on the evaluation questionnaire for the MWG 
rolls and C rolls. Median and inter-quartile range, n=14. No significant differences between 
the breads for any of the questions. Comparisons made with Wilcoxon Signed-Rank Tests.
5.7. Discussion
These three studies were conducted to obtain preliminary information on the 
properties of the developed bread rolls prior to a long-term intervention. 
Information gathered included data on the taste and organoleptic properties, Gl 
and effects on appetite of short-term consumption of the experimental whole 
grain (intact and milled) and control rolls.
Assessing the palatability of test products is important as differences between 
products could affect both the postprandial response and appetite, and foods
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that are found to be highly unpalatable could negatively impact compliance in a 
study. The cephalic phase (which occurs before and during the start of a meal 
and plays a role in nutrient absorption) is affected by the organoleptic properties 
of food and is stimulated by the smell, sight, taste and thought of foods 
(Robertson, 2006). The sensory properties of foods have important implications 
on food intake, in particular the amount which is consumed. The effects of 
sensory perception on food intake and subjective appetite have been reviewed 
by Sorensen et al (2003). It was stated that studies have shown highly palatable 
foods positively influence food intake, but that effects on subjective appetite are 
more mixed, with some palatable foods increasing hunger, some decreasing 
hunger and some having no effect at all (Sorensen et al., 2003). The palatability 
of the three experimental grain rolls was assessed in the taste test and as a 
secondary outcome of the other studies in this chapter.
Results from the difference test in Study 1 revealed that, for the majority of the 
factors explored, the experimental rolls were rated lower than the corresponding 
commercially matched rolls. This finding was not too surprising as the rolls 
provided a much higher amount of whole grain per serving than the commercial 
products, which would have influenced the sensory properties of the rolls. 
However, the experimental and commercial rolls were not significantly different 
between the same types of grain for ratings of aftertaste, which is one factor that 
could affect appetite ratings to a greater extent. If the experimental rolls were to 
be provided on a commercial basis, then further investigation into the
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organoleptic properties would be necessary to improve the products. For all but 
two of the factors explored there were no significant differences between the 
three experimental rolls. The two factors where the ratings were significantly 
different were for roughness of the rolls, where the experimental intact whole 
grain rolls were perceived as more bitty, and for ratings of moistness, with the 
milled grain rolls being significantly drier than the intact grain rolls. These 
findings were not surprising due to the presence of the whole grains in the rolls. 
Overall, the three experimental rolls appeared to be comparably rated and 
therefore effects on appetite due to the organoleptic properties are likely to be 
similar for all three rolls.
The hedonic properties of the breads were also assessed in Study 1 and again 
the commercial rolls appeared to be preferred over their experimental 
counterparts. The experimental control rolls were disliked more than either of the 
two whole grain rolls. Similarly the visual analysis revealed that the control rolls 
were the least visually acceptable. These differences may impact on the findings 
from a chronic appetite study. The data from the evaluation questionnaires 
completed in Study 2 confirmed that the control rolls were the least acceptable 
of the experimental rolls. The control rolls were rated as least acceptable for 
palatability and aftertaste, whilst the intact whole grain rolls were rated as having 
the worst texture, which again agrees with the findings of Study 1. The results 
from the evaluation questionnaire completed in Study 3, following 3 week 
consumption of either the milled whole grain or control rolls showed no
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significant differences between the two breads for the factors assessed. This 
finding indicates that when the breads are consumed over a longer time period 
there is less perceived difference in organoleptic properties as the participants 
were able to incorporate the rolls into their habitual diets, with fillings of their 
choice rather than consuming them in isolation as in studies 1 and 2.
Bakke and Vickers (2007) recently conducted a taste test to determine 
consumer liking of whole wheat and refined breads. They compared "laboratory- 
produced” refined and whole wheat breads and commercially available whole 
wheat and refined breads. In contrast to our study, their study reported that, 
when the results were investigated as a whole, the refined grain products were 
preferred compared with the whole wheat products. However, the commercial 
refined and whole wheat samples were equally well liked, which is similar to our 
findings regarding our experimental control and milled whole grain rolls in Study 
3. Overall it would suggest that liking of the products based on their organoleptic 
properties is very subject specific and may depend on the habits of the 
participants, which was not investigated in our study. The evaluation data 
obtained from Study 3 (short-term crossover study) may provide more valuable 
information on the liking of the products and their effect on food intake, 
compared with the taste test (Study 1), as the amount ingested was greater 
compared with the small square given at the taste test. Indeed in the review by 
Sorensen et al (2003) it is stated that pleasantness ratings from taste tests are 
not a good indicator of the actual amounts that different individuals would
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consume, but can provide information on differences between intakes of 
different foods for an individual.
For the Gl study it was hypothesised that the control rolls would have the 
highest Gl, followed by the milled whole grain rolls and then the intact whole 
grain rolls. In fact the results indicated that despite the presence of the whole 
grains in the milled rolls, the Gl of these rolls was not significantly different to 
that of the control rolls (both in the high Gl category), whilst the intact whole 
grain rolls had a Gl in the “medium” category. This finding of a similar Gl 
between the milled whole grain rolls and control rolls in our study was 
unexpected, especially in view of studies that have demonstrated that the more 
processed and the smaller the particle size of cereal foods the higher the Gl 
(Englyst et al., 2003). Our data suggest that, although both of the whole grain 
roll types used in the study met the definition of a whole grain (all three 
components were present in amounts found naturally) the processing of the 
grain resulted in contrasting GIs. This may suggest that in order to beneficially 
affect the glycaemic response, consumption of intact whole grains would be 
preferable to milled whole grains. In a review by Venn and Mann (2004) it was 
found that, from the studies examined, grains that had an intact cellular structure 
resulted in lower postprandial responses than those where the grains had been 
milled, which would agree with the lower Gl finding of the intact whole grains in 
our study, even though there was no significant difference in the glycaemic or 
insulinaemic responses.
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Our GI values are slightly higher than for the published GI of similar breads. For 
example Atkinson et al (2008) published values of 75 ± 2 for “white wheat 
breads”, 74 ± 2 for “whole wheat/whole meal bread” and 53 ± 2 for “speciality 
grain bread”. This difference may be due to our smaller sample size (one 
participant less than the recommend number of participants in the GI 
methodology paper (Brouns et al., 2005)) and the fact that the published values 
in this table are an amalgamation of various studies. The number of participants 
included was one less than in the recommend paper due to difficulties with 
retention of the participants. However, the inclusion of 9 participants rather than 
10 is unlikely to have notably changed the results of the study.
The glycaemic and insulinaemic responses were not significantly different 
between the three rolls, although the insulin AUC increased in a stepwise order 
of grain processing. This increase in insulin AUC is similar to the finding 
observed in the study by Heaton et al (1988) where the more processed the 
wheat whole grain, the higher the insulin response (whole<cracked<coarsely 
milled flour <finely milled flour); they also found the glucose AUCs to be higher 
with the flours than with the whole and cracked grains, but not significantly. 
Holm and Bjorck (1992) also found that a whole grain wheat bread which 
contained intact wheat kernels resulted in a greater reduction in the glucose and 
insulin responses compared with the other breads investigated.
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A recent study by Najjar et al (2009) investigated the effects of four different 
breads (white, whole wheat (made with ground whole wheat and whole grain 
flours), sourdough and whole wheat barley (made with ground whole wheat and 
barley flours)) on postprandial glucose and insulin responses. They found .that 
the whole wheat barley bread glucose response was significantly lower than the 
whole wheat bread, and the whole wheat bread had the highest glucose 
response; whilst overall the sourdough bread had the lowest response. As in our 
study, there was no significant difference between the breads for the 
postprandial insulin responses. Contrary to our findings and the findings in the 
study by Najjar et al, an older study by Holt and Miller (1994) found that the level 
of processing of wheat grains was a determinant in glycaemic and insulinaemeic 
responses, with the greater processing resulting in higher postprandial glucose 
and insulin responses. The difference between the findings of these studies 
could be explained by a difference in the amounts of test products given, with 
our study and the study by Najjar et al giving portions of bread to provide 50 g 
available carbohydrate, whilst Holt and Miller gave equal portions of 
carbohydrate for each test bread but based this on body weight (0.75 g / kg 
body weight) therefore delivering a mean of 62.7 g. A study by Behall et al 
(1999) which investigated the effects of different particle sizes of whole-grain 
(white bread, whole wheat bread or ultra-fine whole wheat bread) on glucose 
and insulin responses, also gave equal carbohydrate based on body weight (1 g 
/ kg body weight). They found that the particle size did not significantly affect the 
glycaemic or insulinaemic responses. These studies contribute conflicting
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evidence as to the glycaemic or insulinaemic effects of different grain types and, 
as the protocols varied between the studies, comparison is difficult.
The insulin responses in our study may have also been affected by measuring 
the insulin concentrations on capillary blood samples. The capillary samples 
were small due to problems with some participants being unable to collect a full 
sample at all time points. Consequently, all samples were analysed at 50 pi, as 
opposed to 100 pi samples, (values obtained were therefore doubled as per the 
instructions given with the assay kit) and some were only analysed as singletons 
rather than duplicates, which therefore could mean the values were less 
accurate.
Despite some data in acute studies showing that Gl may affect appetite and 
food intake, the data from long-term studies shows less conclusive evidence (as 
discussed in Chapter 1). If a difference in glucose and insulin responses was 
observed in a follow-on chronic intervention study using these rolls, the 
difference in Gl could be considered as a possible explanation; although this is 
unlikely as no significant difference was found between the rolls for their Gl 
values or in either their glucose or insulin responses and thus differences in an 
intervention study may indeed reflect direct effects of chronic whole grain 
consumption.
The short-term intervention study indicated no effect on appetite or food intake 
following 3 week consumption of the milled whole grain rolls compared with the
167
C hapter 5
control rolls. However, there was a significant difference between the 
interventions for systolic blood pressure, which increased during the control 
intervention and decreased following consumption of the milled whole grain.
To our knowledge this is the first study that has directly compared whole grain 
intake to refined grain intake and measured effects of short-term consumption 
on actual food intake. None of the 14 participants in this study would have been 
classified as under-reporters for either the milled whole grain or control 
intervention diaries according to the Goldberg cut-off values (Goldberg et al., 
1991) and therefore all were included in the dietary analysis. Whist there was no 
significant difference in energy intake between the control and milled whole 
grain interventions at the ad libitum test meal or from the 7 day dietary records, 
participants consumed less with the milled grain than with the control. At the ad 
libitum test meal there was an average increase in energy intake of 367 kJ on 
the control intervention compared with an average decrease of 0.7 kJ 
(effectively no change) on the milled whole grain intervention. This could 
potentially demonstrate a protective role of whole grains in food intake 
regulation. The energy intake assessed from the 7 day diet diaries was also 495 
kJ per day lower with the milled whole grain intervention than with the control. 
The energy intakes were calculated as a percentage of estimated energy 
requirements (using the Schofield Equation (Schofield et al., 1985) and an 
activity factor of 1.6) and were lower with the milled whole grain (99.4%) than 
with the control (104.8%) intervention. This again could suggest a potential
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protective role of high whole grain intake in food intake regulation compared with 
high refined grain intake, although further investigation would be required as 
these findings were not significantly different and therefore do not provide actual 
evidence for this hypothesis. The lack of findings could be due to the 
participants being healthy, normal weight adults and therefore able to regulate 
their intake closely. The participants habitual DF intakes (22.3 ±1 .9  g), were 
higher than the UK average intake of 13 g per day (Buttriss and Stokes, 2008) 
and this may have been a contributing factor as to why there was little effect on 
energy intake in this study. Further investigation with other population groups, 
such as the overweight or obese, or those with lower habitual DF intakes, would 
therefore be beneficial.
A recently published intervention study by Isaksson et al (2008) investigated the 
effects of whole grains compared with refined grains on food intake over 24 
hours. Their study involved three test days where participants consumed whole 
grain rye porridge (2 occasions) or refined wheat bread (1 occasion) for 
breakfast and then, at lunch consumed, whole grain wheat pasta (after one rye 
porridge breakfast) or refined wheat pasta (after the other rye porridge breakfast 
and the bread breakfast), energy intake was then assessed at an ad libitum test 
meal and for the whole day from self-reported intake later in the evening and the 
following mornings breakfast. There was no effect of treatment on energy intake 
at the ad libitum test meal, during the evening or on breakfast the following 
morning. The participants in the study by Isaksson et al were older (mean age
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40.7 years) than those included in our study (mean age 26 years), but also had 
a mean BMI in the healthy range (23.3 kg/m2) which was similar to ours (21.8 
kg/m2), which again could explain the lack of an effect on food intake, or could 
reflect that longer-term consumption of these products is required to allow for 
affects on appetite to be observed.
Our study also found no effect of either the control or milled whole grain 
interventions on subjective appetite ratings. There are few other intervention 
studies that have investigated the effects of whole grain intake on appetite and 
satiety using subjective appetite ratings. The study by Isaksson et al (2008) 
found that consumption of whole grain rye porridge at breakfast resulted in 
reports of greater satiety. Other studies where appetite ratings were measured 
have found consumption of whole grains (80% wheat and the remainder from 
other whole grain sources) indicated a trend towards less hunger between 
meals compared with refined grain consumption (Pereira et al., 2002). In a study 
by Holt and Miller (1994) satiety scores where found to be higher following the 
least processed grains compared with the refined grains. These studies, 
contrary to ours, suggest that whole grains may have a role in appetite 
regulation and therefore this would be an interesting area to further explore in a 
population where positive effects on appetite would be most desirable, such as 
in the overweight.
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Our investigation found a trend towards a significant difference in weight change 
(and therefore BMI) between the two interventions. This finding is in line with the 
epidemiological evidence (as discussed in Chapter 1) that suggests a beneficial 
role of whole grains on weight regulation. In our study the participants were of 
normal weight and so only a minor effect on body weight would have been 
expected. Our finding does not agree with very recent epidemiological evidence 
from a study based in the UK (Thane et al., 2009). This study investigated the 
relationship between whole grain intake and adiposity or BMI, from data 
collected from two dietary surveys, the Dietary and Nutritional Survey of British 
Adults (aged 16-64 years) in 1986-87 and the National Diet and Nutrition Survey 
(in adults aged 19-64) in 2000-01. They found little association between whole 
grain-intake and body weight or BMI in either survey or with waist circumference 
in the later survey (Thane et al., 2009). However, our data do agree with that 
obtained from another recent study, conducted in an American female 
population, which found that individuals with higher whole grain intakes had a 
lower BMI (Good et al., 2008). The finding in the study by Good et al (2008) is 
similar to that seen in a recent cross-sectional investigation, conducted in the 
Netherlands, where it was found that whole grain-intake was lower in those with 
a higher BMI (van de Vijver et al., 2009). The relationship between whole grain 
intake and adiposity from observational studies was recently systematically 
reviewed by Harland and Garton (2008). This review found that overall a lower 
BMI and central adiposity were associated with a higher whole grain-intake. 
Therefore our intervention data showing a trend towards a decrease in weight
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following milled whole grain consumption for 3 weeks adds valuable information 
to the effects of whole grains on weight regulation, although further investigation, 
over longer time periods and in other population groups (particularly the 
overweight), is required to confirm or refute the finding.
An interesting incidental finding from the study was an effect on systolic blood 
pressure, which decreased during the milled whole grain intervention and 
increased during the control intervention, with a significant difference of 4.7 
mmHg between the ends of each intervention. This lower systolic blood 
pressure occurred in individuals who were normotensive and therefore this 
difference would be considered clinically significant. Other studies have 
demonstrated an effect of whole grain-intake on hypertension. In a prospective 
study high whole grain-intake at baseline resulted in less hypertension at 10 
years follow-up (Wang et al., 2007). An inverse relationship between whole grain 
intake and hypertension in males was also reported in a recent prospective 
cohort study (Flint et ai., 2009). In a crossover intervention study different types 
of whole grains (barley, whole wheat/brown rice and a half and half mix of the 
two) consumed for 5 weeks each, resulted in significantly lower systolic and 
diastolic blood pressures (Behall et al., 2006).
The lower blood pressure observed in our study following the milled whole 
grains could be explained by the lower sodium intake (482 mg/day lower) 
compared with the control intervention. However, this was assessed from self­
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reported diet diaries and therefore the accuracy of these needs to be considered 
before concluding that this was a contributing factor.
Overall, the three studies in this chapter have shown that the three breads were 
equally as acceptable to the participants, the Gl values were not significantly 
different (although the two whole grain rolls had a Gl in different categories) and 
there could be a moderate effect of the milled whole grains on food intake. 
These findings suggest whole grains may affect appetite and that the rolls could 
be a useful means of delivering a controlled amount of whole grains for use in 
an intervention study and findings from an intervention study may not be 
affected by differences in taste or Gl.
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6.1. Introduction
As there is little previous interventional evidence for a role of whole grains on 
appetite, satiety or food intake, and having determined that RS, a main DF 
constituent of whole grains, has some affects on food intake (Chapter 3), a long­
term intervention was conducted, using the developed bread rolls. Due to the 
lack of findings on food intake in normal-weight individuals (Chapter 5) the 
participants in this study were overweight/obese individuals, who would be the 
target group for weight loss. The effects of the whole grain rolls, in both forms, 
were investigated and compared with each other and the control roll.
6.2. Aims
The aim of the study was to investigate the acute (single meal) and chronic 
(eight weeks) effects of whole grain (both intact and milled) consumption on 
appetite, food intake and postprandial metabolites, compared with refined 
grains. Effects on appetite and food intake were assessed subjectively using 
VAS and quantitatively using ad libitum test meals and diet diaries. Effects of the 
different breads on anthropometries and blood pressure were also assessed.
6.3. Hypothesis
The inclusion in the diet of whole grains (intact or milled) will cause a reduction 
in food intake and beneficially affect the metabolic response, after eight weeks 
consumption, compared with refined grain. Whole grains included in a single
meal will also have beneficial effects on food intake and metabolic responses._
This Chapter contains the products of joint research between Laura Tripkovic, Nicola Muirhead and myself. Some data 
were shared, but each of us had our own particular outcome measures. Whilst the planning and data collection were 
conducted in collaboration, glucose and lipid concentrations measured by Nicola Muirhead and insulin concentrations by 
Laura Tripkovic and myself, all statistical analysis and discussion included in the Chapter are my own work.
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6.4. Study Design
6.4.1. Design
The study was a randomised, parallel dietary intervention. Participants were 
randomly assigned to consume two bread rolls, containing 48 g of intact whole 
grains, 48 g milled whole grains or control rolls (containing refined grain only), 
daily for eight weeks. A favourable ethical opinion was given for this study by the 
University of Surrey’s Ethics Committee (EC/2006/89/SBMS) and all participants 
gave informed, written consent.
6.4.2. Participants
Twenty-one individuals participated in this pilot study. In addition to the general 
criteria (described in Chapter 2) participants required for this study were adult 
males (aged 30 to 55 years) with a waist circumference greater than 94 cm (37 
inches) and postmenopausal females with a waist circumference greater than 80 
cm (31.5 inches). Other criteria included, a BMI of 25 -  35 kg/m2, fasting insulin 
greater than 60 pmol/l (EGIR criteria for Insulin Resistance) and exclusion of 
those who regularly consumed high whole grain-intakes (three or more servings 
per day) (assessed by a questionnaire, Appendix 7).
Twenty-two participants started the study, with one drop-out due to 
gastrointestinal intolerance of the whole grains. All other 21 participants 
completed the study.
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The 21 participants had mean scores of 2.12 (± 0.18), 3.07 (± 0.14) and 2.39 (± 
0.12) on the emotional, external and restrained scales of the DEBQ, 
respectively. The participants’ baseline anthropometries are shown in Table 6.1.
Table 6.1: Baseline anthropometric measurements, n=21.
Measurement Mean ± SEM
Age (years) 47.6 ± 2.6
Height (cm) 175.5 ± 1.9
Weight (kg) 89.8 ±3.8
BMI (kg/m2) 28.9 ±0.7
Waist Circumference (cm) 102.5 ±2.2
Hip Circumference (cm) 108.7 ± 1.5
Body Fat (%) 31.2 ±1.4
Systolic Blood Pressure (mmHg) 127.2 ±2.3
Diastolic Blood Pressure (mmHg) 77.1 ± 1.7
The 21 participants were randomly (by a web-based randomisation program) 
assigned to one of the three groups with seven participants (5 M, 2 F) in each 
group.
6.4.3. Protocol
Before starting the study participants completed a seven day diet diary to obtain 
baseline dietary intakes. Participants were requested to consume a low-fibre 
evening meal prior to each study morning, before fasting for 10-12 hours.
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Participants attended for three study mornings during the eight week 
intervention, shown in the study timeline (Figure 6.1). The study investigated 
both acute (single meal) and chronic (eight week) effects of whole grain intake.
8 week intervention with intact whole grain rolls, 
milled whole grain rolls or control rolls
morning
-2
Figure 6.1: Timeline for the 8 week intervention study.
Study mornings 1 and 3, at the beginning and end of the intervention, were 
identical. On each occasion anthropometries and blood pressure were taken. 
Participants were cannulated and two fasting samples and VAS were taken. At 
time zero participants consumed a nutritionally balanced low-fibre preload (hot 
chocolate) (Table 6.2).
Table 6.2: Nutritional composition of the preload (hot chocolate), per 250 ml.
Energy Protein Carbohydrate Sugar Fat Saturates Fibre
(KJ) (kcal) (g) (g) (g) (g) (g) (g)
2130 510 19.5 59.4 58.8 21.8 3.8 0.8
The hot chocolate was made to a standard recipe, comprised of 18 g Cadbury’s 
drinking chocolate (Cadbury® UK Ltd, UK), 20 g glucose powder (Thornton and
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Ross Ltd, UK), 31 g skimmed milk powder (Marvel®, Premier Foods, UK), 200 g 
skimmed milk (Tesco, UK) and 20 g mild olive oil (Tesco, UK).
VAS and blood samples were taken every 30 minutes for three hours. At the end 
of the three hour period participants were given the ad libitum test meal.
Study morning 2 occurred 24 hours after study morning 1. On this occasion 
breakfast was two of the test bread rolls (to which the participants had been 
randomly assigned), with a standard amount of margarine (20 g Flora®, Unilever 
Foods, UK), to determine any acute effects of the whole grains. VAS and blood 
samples were collected as in study mornings 1 and 3 and participants were 
provided with the ad libitum test meal to quantify food intake.
A seven day diet diary was completed for the final week of the eight week 
intervention period to determine changes to habitual intake.
6.4.4. Calculations and Statistical analysis
Normal distribution was tested with the Kolmogorov-Smirnov test. Data were 
analysed both parametrically and non-parametrically due to the small participant 
numbers in each group and the inability therefore to assess normality 
accurately. Results from the parametric tests (as the more powerful statistic) are 
shown, as there were few differences between the parametric and non- 
parametric tests in terms of significance and the majority of the data were 
normally distributed.
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Time course data from the acute postprandial morning (study morning 2) were 
analysed using mixed between-within subjects ANOVA, with roll type as the 
independent between-subjects variable, time as the independent within-subjects 
variable and the measurements as the continuous dependent variables. AUC for 
postprandial data and data from the ad libitum test meal were compared using a 
one-way between groups ANOVA with Post Hoc tests (Tukey).
Data collected pre and post intervention (study mornings 1 and 3) were 
compared within and between groups, to determine whether an individual 
treatment elicited a response and whether there were treatment effects. Within 
group analysis involved repeated measures ANOVA for postprandial data and 
paired samples f-test comparisons of AUC and other pre/post data.
Differences between fasting blood concentrations were compared using one­
way between groups ANOVA. Differences between treatments for postprandial 
data were compared using mixed between-within subjects ANOVA, with roll type 
and visit as independent between-subjects variables, time as the independent 
within-subjects variable and the measurement as the continuous dependent 
variable. The difference (either percentage change or absolute difference) 
between pre and post data (and postprandial AUC) were compared using one­
way between groups ANOVA with Post Hoc tests (Tukey).
On all graphs and tables intact whole grain rolls are referred to as “WG”, milled 
whole grain rolls as “MWG” and control rolls as “C”.
180
Chapter 6
6.5. Results
There were no significant differences between the three groups (Table 6.3) for 
any of the baseline anthropometric measurements or for systolic blood pressure. 
However, there was a significant difference between the groups for diastolic 
blood pressure, p=0.029. Post Hoc tests revealed the difference lay between the 
milled grain group and the intact whole grain (82.4 ± 3.6 mmHg vs 71.9 ± 2.1 
mmHg, p=0.023).
Table 6.3: Baseline measurements, n=7 (5 M and 2 F) in each group.
Measurement
WG Group 
Mean ± SEM
MWG Group 
Mean ± SEM
C Group 
Mean ± SEM
Age (years) 45.9 ± 4.6 51.4 ± 1.8 45.4 ± 0.76
Height (cm) 174.6 ±2.8 176.1 ±3.8 175.9 ±3.9
Weight (kg) 86.5 ±5.2 90.9 ± 8.4 92.1 ±6.4
BMI (kg/m2) 28.3 ± 1.2 28.9 ± 1.5 29.5 ± 1.0
Waist Circumference (cm) 101.7 ±3.2 103.6 ±5.0 102.1 ±3.8
Hip Circumference (cm) 108.5 ±2.9 108.0 ±2.8 109.7 ±2.6
Body Fat (%) 29.6 ±3.1 32.4 ±2.1 31.6 ±2.4
Systolic Blood Pressure (mmHg) 120.9 ±4.0 132.1 ±3.0 128.7 ±3.9
Diastolic Blood Pressure (mmHg) 71.9 ±2.1 82.4 ± 3.6 77.0 ± 1.4
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6.5.1. Acute postprandial results
This section of the results shows the acute single meal response (study morning 
2) to each of the three test breads. Due to cannulation problems for some 
participants the metabolite data are not complete, but sample size for each 
variable is indicated in figures and tables.
6.5.1.1. Subjective appetite ratings
There were no significant differences between the three test rolls for the 
subjective ratings of hunger, fullness or prospective food consumption (Figure
6.2), when analysed either by repeated measures ANOVA or comparison of 
AUC. There also were no significant differences between the rolls for ratings of 
thirst, or desire for different foods (sweet, salty, savoury or fatty foods).
182
C hapter 6
8000
7000
EEE.
^ 6 0 0 0<
5000 I
MWG
B
1  8000
I
WG MWG
WG
Figure 6.2: AUC for the three breads in response to subjective appetite ratings for A = 
hunger, B = prospective food consumption, C = fullness. Mean ± SEM; n=7 in each group. 
One-way between groups ANOVA showed no significant differences between the rolls.
6.5.1.2. Test meal
There were no significant differences in either weight or energy intake (Figure
6.3) between the three groups at the ad libitum test meal. Despite
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those in the intact whole grain group indicating they felt they could eat the least 
on the subjective appetite ratings, they consumed the most at the test meal.
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Figure 6.3: Energy intake (kJ) at the ad libitum test meal at study morning 2. Mean ± SEM, 
n=7 in each group. One-way between groups ANOVA showed no significant differences 
between the three rolls.
6.5.1.3. Metabolite analysis
There was no significant difference between the fasting concentrations of the 
three groups for glucose (measured by the ILab method described in Chapter 2), 
NEFA or TG (Table 6.4).
Table 6.4: Fasting concentrations of metabolites measured on the acute day, n=7 (5 M and 2 F) 
in WG and C groups, n=6 (4 M and 2 F) in MWG group.
Measurement
WG Group 
Mean ± SEM
MWG Group 
Mean ± SEM
C Group 
Mean ± SEM
Fasting glucose (mmol/l) 5.11 ±0.2 5.00 ±0.1 5.22 ±0.2
Fasting TG (mmol/l) 1.22 ± 0.2 1.26 ± 0.2 1.72 ±0.3
Fasting NEFA (mmol/l) 0.47 ± 0.05 0.48 ± 0.10 0.44 ± 0.03
Metabolites measured by Nicola Muirhead
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There were no significant differences between the three groups for postprandial 
plasma glucose or NEFA concentrations. The postprandial TG concentrations 
(Figure 6.4) were not significantly different between the groups; however, the 
TG concentrations for each bread type exhibited different patterns over time 
(p=0.078).
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Figure 6.4: Acute postprandial TG concentrations for each of the breads. Mean ± SEM, n=7 in 
WG and C groups and n=6 in MWG group. Mixed between-within subjects ANOVA showed no 
significant differences between the three breads, but a trend towards different responses over 
time (p = 0.078).
6.5.2. Chronic whole grain intervention results
This section of the results shows the pre and post (study mornings 1 and 3) 
eight week intervention comparisons for the three rolls, where the postprandial 
data is in response to a nutritionally balanced low-fibre preload (hot chocolate). 
Again due to cannulation problems, some of the data are incomplete (data for 
six participants only in the intact whole grain group).
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6.5.2.1. Anthropometries
Anthropometric measurements taken at baseline and end of each intervention 
are shown in Table 6.5.
Table 6.5: Anthropometric measurements taken at baseline and post each intervention, n=7 (5
M and 2 F) in each group. Mean± SEM.
WG Group MWG Group C Group
Measurement Baseline Post Baseline Post Baseline Post
Weight (kg)
86.5± 5.2 86.8± 5.1 90.9± 8.4 90.8± 8.4 92.1+6.4 93.7± 6.1
BMI (kg/m2)
28.3± 1.2 28.5± 1.2 28.9+ 1.5 28.9± 1.5 29.5± 1.0 30.0± 1.0
Waist
Circumference (cm)
101.7+ 3.2 101.4± 2.9 103.6± 5.0 101.8± 4.8 102.1 ± 3.8 102.8± 3.4
Hip Circumference 
(cm)
108.5± 2.9 108.5± 2.9 108.0± 2.8 107.7± 4.1 109.7± 2.6 111.5± 2.9
Body Fat (%)
29.6± 3.1 29.6± 3.1 32.4± 2.1 32.7± 2.3 31.6± 2.4 31.0+2.7
Systolic Blood 
Pressure (mmHg)
120.9± 4.0 123.6± 5.0 132.1± 3.0 125.4± 3.9 128.7± 3.9 129.1+4.6
Diastolic Blood 
Pressure (mmHg)
71.9± 2.1 79.6± 2.5 82.4± 3.6 78.4+ 2.4 77.0± 1.4 72.0± 2.4
There were no significant differences between the start and end of the control 
intervention for any of the anthropometric or blood pressure measurements. For 
the milled grain group there was a significant decrease from beginning to end of 
the intervention only for waist circumference (103.6 ± 5.0 cm vs 101.8 ± 4.8 cm, 
p=0.045). With the intact whole grain group there was a significant difference 
only in diastolic blood pressure, where it increased from the start of the 
intervention to the end (71.9 ± 2.1 mmHg vs 79.6 ± 2.4 mmHg, p=0.007).
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When the differences between the start and end of interventions were calculated 
as percentage change and then compared between groups, there were no 
significant differences for any of the anthropometric measurements. However, 
there was a significant difference between the breads for diastolic blood 
pressure (p=0.008) (Figure 6.5). The Post Hoc test revealed the difference lay 
between the intact whole grain and the milled whole grain groups (10.9 ± 2.9 
mmHg vs -4.1 ± 3.9 mmHg, p=0.025) and the intact whole grain group and the 
control group (10.9 ± 2.9 mmHg vs -6.2 ± 4.1, p=0.011).
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Figure 6.5: Percentage change for diastolic blood pressure from beginning to the end of 
each intervention. Mean ± SEM, n=7 in each group. Significant difference between the three 
breads (p=0.008), Post Hoc tests revealed the difference to be between WG and MWG rolls 
(* p=0.025) and WG and C rolls (t p=0.011).
6 .5.2.2. Subjective appetite ratings
There were no significant differences within each intervention for any of the 
subjective appetite ratings. However, there was a trend for higher ratings of 
fullness at the end of the milled whole grain intervention (p=0.071) (Figure 6 .6).
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Figure 6.6: Subjective appetite ratings in response to the question "how full do you feel?” 
pre and post MWG. Mean ± SEM, n=7. Repeated measures ANOVA showed a trend for 
participants to feel fuller at the end of the intervention compared with the start.
When the VAS AUC pre and post interventions were compared for the intact 
whole grain group there were no significant differences. For the milled whole 
grain intervention AUC, there was just a trend for a higher rating post 
intervention compared with pre in relation to fullness (7937.1 ± 1013.3 mm.min 
vs 6079.0 ± 841.5 mm.min, p=0.062). With the control intervention AUC desire 
for fatty foods was significantly lower pre intervention compared with post 
(6182.1 ± 2467.3 mm.min vs 7538.6 ± 2711.0 mm.min, p=0.044) (Figure 6.7).
There were no significant differences between the three breads for any of the 
subjective appetite ratings when the differences in AUC between the start and 
end of each intervention were compared.
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Figure 6.7: AUC for the C intervention in response to the question “Would you like to eat 
something fatty?” Mean ± SEM; n=7. Paired samples f-test showed AUC significantly higher 
post intervention compared with pre (* p=0.044).
6 .5.2.3. Test meal
There were no significant differences at the ad libitum test meal, in weight or 
energy intake, either within each intervention or between interventions when 
absolute differences in intake were compared (Figure 6 .8).
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Figure 6.8: Energy intake at the ad libitum test meal, pre and post each intervention. Mean 
± SEM, n=7 in each group. No significant differences either pre and post each intervention 
or between interventions.
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6 .5.2.4. Diet diaries
Due to two final diet diaries not being returned by the participants, the 7 day 
dietary data for the milled whole grain group is for 5 participants only. The study 
rolls were included in the dietary analysis as stated by the participants.
Within treatment effects showed that in the intact whole grain group there was a 
significant increase in energy intake during the intervention (p=0.019), and a 
significant increase in protein (p=0.011), carbohydrate (p=0.002) and DF intake 
(p=0.006) (Table 6 .6). With the milled grain group there was a trend towards a 
decrease in fat (p=0.076) and saturated fat (p=0.058) intake during the 
intervention (Table 6.7). During the control intervention there was a trend 
towards an increase in energy (p=0.055) and fat intake (p=0.081) and a 
significant increase in saturated fat (p=0.019) intake (Table 6.8).
Table 6.6. Average daily intakes calculated pre and post the WG intervention, n=7. Comparisons 
made with a paired samples t test.
Pre
Mean SEM
Post
Mean SEM
P
Value
Energy (kJ) 8082 587 9352 616 0.017
Energy (kcal) 1927 142 2226 147 0.019
Protein (g) 75.3 5.1 88.9 3.2 0.011
Carbohydrate (g) 233.3 14.9 299.7 19.4 0.002
Sugar (g) 95.4 9.9 85.7 10.3 NS
Fat (g) 71.9 9.7 67.5 6.8 NS
Saturated Fat (g) 23.8 3 22.9 2.1 NS
Dietary Fibre (g) 19.5 1.9 27.2 2.6 0.006
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Table 6.7. Average daily intakes calculated pre and post the MWG intervention, n=5. 
Comparisons made with a paired samples ftest.
Mean
Pre
SEM
Post
Mean SEM
P
Value
Energy (kJ) 9613 893 9922 471 NS
Energy (kcal) 2291 213 2371 107 NS
Protein (g) 88.5 11.4 86.7 5.5 NS
Carbohydrate (g) 268.6 23.3 304.9 16.2 NS
Sugar (g) 120.2 12.8 107.3 13.6 NS
Fat (g) 89.4 8.9 77.2 7.3 0.076
Saturated Fat (g) 34.3 4.2 27.6 3.7 0.058
Dietary Fibre (g) 21.4 3.4 23.4 1.5 NS
Table 6.8. Average daily intakes calculated pre and post the C intervention, n=7. Comparisons 
made with a paired samples t test.
Mean
Pre
SEM
Post
Mean SEM
P
Value
Energy (kJ) 8605 624 9707 724 0.054
Energy (kcal) 2049 149 2308 172 0.055
Protein (g) 82.3 11.9 85.9 9.7 NS
Carbohydrate (g) 246.0 15.1 276.5 20.7 NS
Sugar (g) 103.9 22.7 98.4 21.3 NS
Fat (g) 63.5 6.8 75.1 7.1 0.081
Saturated Fat (g) 21.2 2.5 29.3 3.9 0.019
Dietary Fibre (g) 15.3 2.0 16.3 2.0 NS
Actual differences in intake between pre and post interventions were calculated 
and then compared between groups for treatment effects. There were no 
significant differences between the three breads in differences in average daily 
energy intake (Figure 6.9). There were also no significant differences between 
groups for protein, carbohydrate or sugar intake.
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Figure 6.9: Absolute difference in average daily energy intake (kJ) between the pre and 
post diaries. Mean ± SEM, n=7 in the WG and C groups and n=5 in the MWG group. No 
significant differences between the interventions.
However, there was a significant difference between the three groups for fat 
(p=0.029) and saturated fat intake (p=0.005) (Figure 6.10). Post hoc tests 
revealed the difference for fat intake lay between the milled whole grain group 
(decreased during the intervention) and control group (increased during the 
intervention) (p=0.030) and, for saturated fat intake, lay between the milled 
whole grain group and control group (p=0.004) and between the intact whole 
grain group and the control group (p=0.057), where intakes increased in the 
control group and decreased in the two whole grain groups.
There was also a treatment effect for total DF intake which increased in all 
groups (Figure 6.11), and was significantly different between the three rolls 
(p=0.032). Post Hoc analysis revealed the difference lay between the intact 
whole grain and the control groups (p=0.035).
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Figure 6.10: Absolute difference in average daily fat and saturated fat (SFA) intake between 
the start and end of the interventions calculated from the diet diaries. Mean ± SEM, n=7 in 
WG and C groups and n=5 in MWG group. Significant difference between the three breads for 
fat (p=0.029) and SFA (p=0.005) intake. Post Hoc tests showed difference for fat intake was 
between MWG and C (* p=0.030) and for SFA was between the MWG and C (t p=0.004) and 
WG and C (t p=0.057).
MWG
Figure 6.11: Difference in average daily total DF intake calculated from the seven day diet 
diaries completed pre and post the interventions. Mean ± SEM, n=7 in WG and C groups and 
n=5 in MWG group. Significant difference between the three groups (p=0.032) with Post Hoc 
analysis revealing the difference was between the WG and C groups (* p=0.035).
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6.5.2.5. Cholesterol
There were no significant differences between the three groups for plasma total 
cholesterol, HDL-cholesterol or LDL-cholesterol concentrations at the start of the 
study or after the intervention. There were also no significant differences 
between the beginning and end of the milled whole grain and control 
interventions for total plasma cholesterol, HDL-cholesterol or LDL-cholesterol. 
However, for the intact whole grain intervention total plasma cholesterol 
significantly increased during the intervention (3.9 ± 0.4 mmol/l vs 4.3 ± 0.4 
mmol/l, p=0.046) and there were trends towards significant increases for both 
HDL-cholesterol (1.0 ±0.1 mmol/l vs 1.1 ± 0.1 mmol/l, p=0.095) and LDL- 
cholesterol (2.7 ± 0.3 mmol/l vs 2.9 ± 0.3 mmol/l, p=0.071).
When the absolute difference between pre and post was calculated and the 
three interventions compared for treatment effects, there was no significant 
difference between the breads for HDL-cholesterol and LDL-cholesterol; 
however, there was trend towards a significant difference between the breads 
for total plasma cholesterol (p=0.069), with Post Hoc analysis determining the 
difference lay between the intact whole grain and the milled whole grain 
interventions (0.39 ± 0.1 mmol/l vs -0.18 ± 0.2 mmol/l, p=0.058) (Figure 6.12).
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Figure 6.12: Absolute differences in blood cholesterol concentrations calculated from values 
obtained pre and post each intervention. Mean ± SEM, n=7 in MWG and C groups and n=6 
in WG group. No significant differences between interventions for HDL or LDL cholesterol 
but a trend towards significance for total cholesterol (p=0.069).
6 .5.2.6 . Metabolite analysis
Fasting insulin sensitivity and (3-cell function (HOMA %S and %B, respectively) 
were calculated by the HOMA model (described in Chapter 2) for each 
participant for study mornings 1 and 3. There were no significant differences for 
either HOMA %S or %B between the three groups at the start or end of the 
study (Table 6.9), within each intervention from study morning 1 to 3 or between 
groups when the absolute differences were compared.
Blood lipids and glucose measured by Nicola Muirhead, insulin measured by Laura Tripkovic and myself
195
Chapter 6
Table 6.9: Fasting concentrations of metabolites and fasting insulin sensitivity and (3-cell function 
pre and post each intervention, n=7 (5 M and 2 F) MWG and C groups, n=6 (4M and 2F) WG 
group. Mean± SEM.
Measurement
WG Group 
Pre Post
MWG Group 
Pre Post
C Group 
Pre Post
Fasting glucose 
(mmoi/l)
5.06± 0.2 5.08+ 0.2 4.99± 0.2 5.06± 0.1 5.11± 0.2 5.03± 0.2
Fasting insulin 
(pmol/I)
88.2± 22.6 92,5+ 26.0 107.7± 19.1 123.8± 23.2 107.4+ 33.3 106.2± 20.9
Fasting TG 
(mmol/l) 1.19± 0.1
1.35± 0.2 1.15± 0.2 1.40± 0.2 1.77± 0.3 1.96± 0.3
Fasting NEFA 
(mmol/l)
0.50± 0.05 0.44± 0.06 0.54± 0.06 0.47± 0.07 0.51± 0.05 0.47± 0.06
HOMA % S1 66.8± 10.9 65.8± 1.7 54.2± 9.9 50.6± 11.2 60.0± 9.6 52.4± 7.7
HOMA % B2
---------- 11 i+ L
143.9± 27.5 143.8± 26.6 170.9± 23.3 175.0± 26.7 147.6± 17.9 159.2± 12.2
HOMA %B = (3-celt function, assessed by homeostatic model assessment.
There were no significant differences in fasting glucose concentrations between 
the three groups at the start or end of the study (Table 6.9). There were also no 
significant differences either within or between the three groups for 
measurements of postprandial glucose concentrations (Figure 6.13).
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Figure 6.13: Postprandial glucose response (mmol/l) for each of the three grains. A = WG,
B = MWG, C = C Mean ± SEM, n=6 in WG group and n=7 in MWG and C groups. Repeated 
measures ANOVA showed no significant differences for any of the groups.
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There were no significant differences in fasting insulin concentrations between 
the three groups at the start or end of the study (Table 6.9). When postprandial 
insulin concentrations were analysed by the mixed between-within subjects 
ANOVA there was no significant difference between the three breads. However, 
the test did reveal differences between visit (pre/post) and grain type (p=0.058), 
visit (pre/post) and time (postprandial period) (p=0.026) and visit (pre/post) grain 
type and time (p=0.059). Therefore repeated measures ANOVA (comparing the 
postprandial data for pre to post) were conducted for each bread type to 
determine where the differences were. There was no significant difference 
between pre and post for the control intervention and the values were not 
different over time for each visit. For the intact whole grain intervention the 
postprandial response was not significantly different between visits, but there 
was a trend for the responses to differ over time for each visit (p=0.068). For the 
milled whole grain intervention there was also no significant difference for the 
response between visits, but again the postprandial responses were different 
over time for each visit (p=0.035) (Figure 6.14).
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Figure 6.14: Postprandial insulin response (pmol/l) for each of the three grains. A = WG, B 
= MWG, C = C. Mean ± SEM, n=6 in WG group and n=7 in MWG and C groups. Repeated 
measures ANOVA showed no significant differences for the C group and whilst the WG and 
MWG groups did not differ between visits, the postprandial responses were different over 
time (WG p=0.068, MWG p=0.035).
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The AUC for the postprandial insulin concentrations were calculated for each 
bread and each visit, and compared. There were no significant differences within 
each treatment group. When the absolute differences between pre intervention 
and post were compared there was a trend towards a significant difference 
between the three breads (p=0.057). The Post Hoc analysis revealed the 
difference lay between the intact whole grain and control groups (p=0.046) 
(Figure 6.15).
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Figure 6.15: Absolute difference in postprandial insulin AUC between the values obtained pre 
and post each intervention. Mean ± SEM, n=6 in the WG group and n=7 in the MWG and C 
groups. One-way between groups ANOVA showed a trend towards a significant difference 
between the three grain groups (p=0.057).
The postprandial oral insulin sensitivity for each study visit was calculated (by 
the minimal model method, described in Chapter 2). When compared within 
interventions there was a significant increase in oral insulin sensitivity from the 
start to the end of the intact whole grain intervention (p=0.014), but no difference
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between the other interventions (Figure 6.16). When the absolute differences 
were compared the three interventions were not significantly different.
Pre
Post
WG MWG
Figure 6.16: Postprandial oral insulin sensitivity (Si) pre and post each intervention. Mean 
± SEM, n=6 in the WG group and n=7 in the MWG and C groups. Significant difference 
between pre and post WG intervention (* p=0.014) and no significant differences for the 
MWG and C groups or between the interventions when absolute differences were 
compared.
There were no significant differences in fasting NEFA concentrations between 
the three groups at the start or end of the study (Table 6.9). There were also no 
significant differences either within or between the three groups for postprandial 
NEFA concentrations. However, there was a trend towards a lower NEFA AUC 
post milled whole grain intervention compared with pre (55.5 ± 6.9 mmol/l.min vs 
47.8 ± 5.2 mmol/l.min, p=0.06).
There were no significant differences in fasting TG concentrations between the 
three groups at the start or end of the study (Table 6.9). For all three 
interventions the postprandial TG concentrations were higher post intervention 
compared with pre. When the postprandial TG responses were analysed with
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the mixed between-within subjects ANOVA there was not a significant difference 
between the three groups. However, the test did reveal a significant difference 
between visit (pre/post) (p=0.022). Follow-up repeated measures ANOVA for 
each bread type were therefore conducted to determine where the difference 
lay. There was no significant difference between pre and post intervention for 
either the milled whole grain or control groups, whilst for the intact whole grain 
group there was a visit (pre/post) time interaction (p=0.008), but there was not a 
significant difference between visits. The AUC for the three interventions, 
despite all being higher post interventions compared with pre (Figure 6.17), 
were not significantly different either within each intervention or between 
interventions when the absolute differences were compared.
WG MWG
Figure 6.17: AUC for postprandial TG concentrations pre and post each intervention. Mean 
± SEM, n=6 in the WG group and n=7 in the MWG and C groups. No significant difference 
either within interventions or between interventions when absolute differences compared.
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6 .6 . Discussion
The results from the acute postprandial study day and the chronic intervention 
will initially be discussed separately and then overall conclusions will be drawn.
6.6.1 Acute postprandial results
It was hypothesised that when whole grains (intact or milled) were consumed at 
a single meal there would be a reduction in food intake, at an ad libitum test 
meal, compared with refined grains (control). It was also hypothesised that the 
consumption of the whole grains, of either form, would beneficially affect the 
metabolic response.
In fact we found no significant difference between the three breads for energy 
intake at the ad libitum test meal. Indeed intakes were the reverse to that 
hypothesised, with more consumed with the intact whole grain rolls and least 
with the control rolls. No significant difference was also found between the three 
breads for any of the subjective appetite ratings, but there were conflicting 
findings within the same grain type (those who consumed the intact whole grain 
rolls felt most hungry, but rated that they could eat the least, whilst those who 
consumed the control rolls were least hungry and full, but felt they could eat the 
most). There were also no significant differences between the three breads for 
postprandial glucose, NEFA orTG concentrations following each bread type.
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An initial power calculation was conducted based on a metabolically significant 
fall (20%) in postprandial insulin AUC and gave an estimate of 17 participants 
per group. As there was no similar previously conducted study, we aimed to 
recruit 20 participants per group, with an interim power calculation to be 
conducted on the data obtained from 12  participants per group to confirm the 
correct number of subjects required. Therefore 36 participants were aimed to be 
recruited. Due to difficulties with recruitment a total of 7 participants per group 
were all that could be recruited in the time frame. The parallel study design 
combined with the eventual small sample size resulted in a major limitation for 
determining significant differences between groups. This was especially difficult 
for the subjective appetite ratings, which by their very nature are particular to an 
individual and feelings of hunger for one person may not be the same feelings 
experienced by another, therefore making it difficult to compare between groups, 
which may account for the lack of findings. Indeed in a review of biomarkers of 
satiation and satiety by de Graaf et al (2004) it was stated that as individuals 
differ in their responses VAS are "preferably used in within-subject s tu d ie s One 
study that has investigated the reproducibility, power and validity of VAS in 
single meal studies (Flint et al., 2000), reported that when using unpaired 
designed studies more participants would be required to determine differences 
in VAS ratings, with a minimum of 32 to ascertain a 10 mm difference in hunger 
and fullness ratings. VAS may therefore have provided valuable data in our 
study had we been able to recruit the original number of participants.
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The low participant numbers and parallel nature of the study could also explain 
the lack of significant findings between the breads at the ad libitum test meal 
and for the metabolic postprandial responses. The use of a single dish ad libitum 
test meal has been evaluated and was found, in a study by Gergersen et al 
(2008), to be reproducible. However, as with the findings regarding VAS, 
Gregersen et al found that ad libitum test meals are better in studies using 
paired designs where smaller participant numbers can be used compared with 
unpaired designed studies.
The TG concentrations, even though not significantly different at fasting or for 
the postprandial concentrations, did differ over time, and were highest following 
the control rolls. The different concentrations could be explained by the different 
fasting TG concentration or may differ between the groups simply due to there 
being different participants in each group, or may in fact be due to a blood lipid 
lowering effect of consumption of whole grains. Further investigation, using a 
paired designed study, would be necessary, as it is not possible to draw 
conclusions from the findings of this study.
Three hours post consumption of whole grains may be insufficient time for the 
whole grains to influence either food intake or postprandial metabolite 
responses. Indeed, as was observed in our acute RS and appetite study 
(Chapter 3) effects on food intake occurred after 7 hours suggesting that 
fermentation, by colonic microflora, of the RS could be a mechanism by which it
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exerted its effects on food intake. As RS is a major DF component of whole 
grains, fermentation may be an important means by which whole grains could 
affect appetite and therefore 3 hours would not have been sufficient time for this 
to occur.
6 .6.2 Chronic whole grain intervention results
We hypothesised that the inclusion of whole grains of either structure (intact or 
milled) in habitual diets for 8 weeks would result in a reduction of food intake 
and beneficial effects on the metabolic response, compared with refined grain.
Contrary to the hypothesis there were no significant differences either between 
interventions or within each intervention for weight or energy consumed at the 
ad libitum test meal. There was also no effect of any of the three interventions 
on the subjective appetite ratings for hunger or prospective food consumption. 
Similarly, for the intact whole grain and control rolls there was no effect of 
consumption over 8 weeks on ratings of fullness; however for the milled whole 
grain rolls there was a trend towards significance for the participants to feel fuller 
at the end of the intervention than before the start. This could indicate a role of 
whole grains in the milled form on satiety and may not have reached 
significance due to the small participant numbers. There were no differences 
between the three interventions for any of the subjective appetite ratings, but 
again potential effects may have been masked due to the small participant 
numbers and the parallel design of the study, as discussed in section 6 .6 .1 .
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Data from the diet diaries were compared within interventions and between 
interventions. The degree of under-reporting was assessed in all diaries using 
the Goldberg cut-off limits (Goldberg et al., 1991). In each group there was at 
least one participant classified as an under-reporter. When these were excluded 
from the analysis it did not alter the findings from the between groups 
comparison and therefore as exclusion of these individuals would have lead to 
even smaller participant numbers they were included in the full dietary analysis. 
When effects within interventions were investigated it was found that in all 
groups average daily energy intake increased from the start to the end of the 
interventions. This was significantly so for the intact whole grain rolls (1270 kJ 
per day increase), explained by a significant increase in both protein and 
carbohydrate intake. There was a trend towards a significant increase during the 
control intervention (1102 kJ per day increase), explained mostly by an increase 
in fat intake, whilst for the milled whole grain intervention the increase was not 
significant (309 kJ per day increase). These increases in energy intake could be 
due solely to the addition of the rolls into the habitual diets as opposed to 
substitution or could be due to the participants adding additional foods (such as 
spreads or jam) to the products to increase the palatability, as this was found to 
be low for all the rolls in the taste test (Chapter 5).
When treatment effects between interventions were compared there was no 
significant difference between the interventions for average daily energy, 
carbohydrate or protein intake. There was however a significant difference
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between the interventions for fat intake, which decreased with both whole grain 
interventions and increased with the control intervention. This increase in fat 
intake agrees with the findings from the subjective appetite ratings where those 
on the control intervention had a greater desire for fatty foods at the end of the 
intervention compared with the start. The reason for this finding is unclear, but 
may be due to the control rolls themselves, which were less well liked according 
to the hedonic ratings in the taste test (Chapter 5), which could have resulted in 
more addition of other products to the rolls thereby increasing fat intakes.
During all three interventions DF intake increased, but the increase was greatest 
in the intact whole grain group and smallest in the control group. This was not 
surprising as the rolls were included in the analysis, when stated by the 
participants, and the whole grain rolls had a greater DF content than the control 
rolls. It is not the most ideal measure of compliance (for this study or for the 
crossover study in Chapter 5), as the participants may just have included them 
in the diaries as opposed to in their diets. Recent studies have shown that 
changes to plasma concentrations of alkylresorcinols maybe a useful biomarker 
of whole grain intake (Landberg et al., 2009, Linko-Parvinen et al., 2007), and 
this should be considered for future studies to confirm compliance.
The 21 participants were randomly allocated to one of the three breads, with 5 
males and 2 females in each group. At baseline the three groups’ 
anthropometries were well matched with no significant differences between the
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groups. The changes to anthropometries during each intervention were 
compared, with no differences arising in the intact whole grain and control 
groups, and only a mean decrease in waist circumference of 1.8 cm from start to 
end of the intervention in the milled whole grain group. This decrease in waist 
circumference could just be due to variations in where the measurement was 
taken, although this was standardised as much as possible between visits.
A recently published parallel study by Katcher et al (2008), compared the effects 
of a 12 week hypocaloric diet with inclusion of whole grains encouraged in one 
group and avoided in another group (control group). This study had similar 
anthropometric outcomes to ours (waist circumference, weight, blood pressure 
and percentage body fat) and found that weight decreased significantly in both 
groups (unsurprisingly due to the hypocaloric diet), but that there was a greater 
decrease in the refined grain group. They also found a significantly greater 
decrease in percentage abdominal body fat in the whole grain group compared 
with the control group. The differences in findings between our study and the 
study by Katcher et al could be explained by the longer duration or greater 
participant numbers (24 in whole grain group and 23 in control group) of the 
Katcher study or due to the fact that the participants in their study were 
encouraged to consume all grain products from whole grain sources and 
therefore consumed on average 5 servings of whole grain per day, compared 
with our participants just consuming the whole grain rolls which provided an 
equivalent of 3 servings. Whilst this intervention study and our study did not find
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significant effects of whole grain intake on body weight, there is much 
epidemiological evidence that does propose an effect of higher whole grain 
intake on weight regulation, as discussed in Chapter 1. However, the 
epidemiological evidence does need to be interpreted with caution and cannot 
prove cause and effect.
At baseline and during the interventions there were no significant differences in 
systolic blood pressure between the groups. However, at baseline diastolic 
blood pressure was significantly lower in the intact whole grain group compared 
with the milled whole grain group. For the milled whole grain and control 
interventions, whilst diastolic blood pressure did decrease during the study, this 
was not significant, but there was a significant increase of 7.7 mmHg during the 
intact whole grain intervention. This increase in diastolic blood pressure was 
significantly different to the decrease in diastolic blood pressure observed in the 
other two groups. However, at the start of the study the intact whole grain 
group’s diastolic blood pressure was significantly lower and therefore the 
increase observed during the intervention resulted in a blood pressure that was 
similar to that of the other groups. The blood pressure finding from this study did 
not confirm the finding that we observed in the short-term crossover study 
(Chapter 5) where there was a reduction in systolic blood pressure following the 
milled whole grain intervention. The reason for the difference in findings is 
unclear, but may be due to differences between the participants included in each 
study (normal weight individuals in the short-term crossover study compared
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with overweight/obese individuals in this study) and their habitual diets, activity 
levels or the adaptation to their normal lifestyle of including the rolls into their 
diets.
At the start of the study there were no significant differences between the three 
groups for any of the fasting blood concentrations measured (total cholesterol, 
HDL-cholesterol, LDL-cholesterol, glucose, insulin, NEFA or TG) or for fasting 
insulin sensitivity (HOMA %S) or (3-cell function (HOMA %B), suggesting that 
although the participants were not randomised based on these characteristics 
they were in fact well matched and any differences observed between the 
groups at the end of the study would be unlikely to be due differences between 
the groups at the start of the study. There were however, no significant 
differences between the three groups for any of the fasting parameters at the 
end of the intervention period.
There was a significant increase in total cholesterol (average increase of 0.39 
mmol/l) during the intact whole grain intervention, accompanied by a trend 
towards a significant increase for HDL-cholesterol (average increase of 0.09 
mmol/l) and LDL-cholesterol (average increase of 0.26 mmol/l). A decrease was 
observed for all three types of cholesterol during the milled whole grain 
intervention (average decrease of 0.23 mmol/l for total cholesterol, 0.05 mmol/l 
for HDL-cholesterol and 0.21 mmol/l for LDL-cholesterol) although these did not 
reach significance and virtually no change was observed with the control
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intervention. The difference observed between the two types of whole grain 
could be due to the small participant numbers in each group and further 
investigation with larger participant numbers (as the study was originally 
designed for) or a cross-over design study should be conducted before 
conclusion relating to the effects of whole grains on cholesterol can be drawn. In 
the study by Katcher et al (2008) described above, effects of the whole grains 
compared with the control group on blood lipids were assessed. They found that 
whilst total, LDL and HDL cholesterol and TG concentrations decreased 
significantly in each group, this difference was not significant between the 
groups and that the decreases were due to the changes in weight that were 
observed.
The postprandial metabolite data indicated mixed results for each metabolite 
measured, but it needs to be borne in mind that these postprandial 
concentrations were in response to a nutritionally balanced low-fibre preload 
(hot chocolate) rather than to the whole grains themselves. These mixed 
findings again could be explained due to the small participant numbers and the 
parallel nature of the study. Whilst there appeared to be no effects of treatment 
on the postprandial glucose concentrations, there were effects of treatment on 
the postprandial insulin responses. For both types of whole grain there appeared 
to be a decrease in the postprandial insulin response at the end of the 
intervention (moderately in the milled whole grain group and more noticeably in 
the intact whole grain group), whereas in the control group the postprandial
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insulin response appeared to increase during the intervention. The lowered 
insulin response observed in our study with the intact whole grain rolls would 
agree with published data showing that whole grains with an intact structure 
produce lower glucose and insulin responses compared with whole grains that 
have been processed in some manner resulting in the disruption of the structure 
of the grain and therefore making the carbohydrate within the grain more 
accessible to digestion and absorption (Bjorck et al., 1994). The lower insulin 
response resulted in a significantly higher oral insulin sensitivity for the intact 
whole grain group at the end of the intervention. This finding agrees with some 
previous data that has shown improvements in insulin sensitivity with high whole 
grain intakes, as discussed in Chapter 1, the studies by Steffen et al (2003) 
(insulin sensitivity assessed by an euglycaemic insulin clamp), Liese et al (2003) 
(insulin sensitivity assessed by insulin modified FSIVGTT) and Pereira et al 
(2002) (insulin sensitivity assessed by an euglycaemic-hyperinsulinaemic 
clamp). The effect of the whole grains on the insulin response in our study could 
be due to the differences in Gl of the products, especially as more of an effect 
was observed with the intact whole grain rolls which had the lower Gl (medium 
Gl of 60.7), although the insulin responses in the Gl study, and the Gl values 
themselves, were not significantly different between the three breads. As 
discussed in Chapter 1 there are mixed findings in previous studies of an effect 
of whole grains on insulin sensitivity, when measured by clamps. The studies by 
Steffen et al (2003) and Pereira et al (2002) found improved insulin sensitivity 
with whole grains, whilst Andersson et al (2007) found no improvement in insulin
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sensitivity. In light of this and our findings further investigation with well defined 
protocols (clamp or IVGTT) to specifically investigate the effect of whole grains 
on insulin responses would be required.
In our study there appeared to be little effect of the 8 week interventions on the 
postprandial NEFA concentrations. For all three interventions the TG 
concentrations where higher at the end of the study compared with the 
beginning, although this was not significant either within or between 
interventions. Whole grains have been proposed to possibly have beneficial lipid 
lowering effects as they contain high amounts of phytosterols, which are known 
to lower blood cholesterol concentrations, and high levels of DF (Slavin, 2004). 
An inverse association between whole grain intake and total and LDL 
cholesterol was reported in a study by McKeown et al (2002). However, a recent 
crossover intervention study where a diet rich in whole grains was compared 
with a diet a rich in refined grains found no effect of 6 week intervention on blood 
lipid concentrations (Andersson et al., 2007). Due to the mixed findings of an 
effect of whole grains on blood lipids, further investigation would be required to 
confirm or deny any beneficial effects.
6.6.3 Overall conclusions
Consumption of whole grains, either in the intact or milled form, did not alter 
food intake, subjective appetite ratings or postprandial metabolite 
concentrations, when consumed at a single meal, compared with refined grains.
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There was also little effect on energy intake, subjective appetite ratings or 
postprandial metabolite concentrations between the interventions, in response to 
the fibre-free meal, after the rolls were consumed for 8 weeks. The findings from 
this study do not agree with the epidemiological evidence that suggests a 
beneficial role of whole grains in appetite and weight regulation. This may be 
because it is acknowledged that those who habitually consume high whole grain 
intakes also have other healthier lifestyle habits (such as not smoking, high 
activity levels and high fruit and vegetable intakes) and therefore it may not be 
the whole grains alone that have beneficial effects, but all these factors working 
together to confer the beneficial effects observed in the epidemiological studies. 
Therefore the lack of significant findings on food intake in our study could 
indicate that whole grains do not exert an effect on food intake regulation. 
However, our study findings were affected by the small participant numbers and 
therefore further investigation would be required, either with more participants or 
with a study with a crossover design, to determine whether whole grains affect 
appetite and food intake when ingested chronically.
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7.1. Summary
With the global increase in obesity rates and its associated risk of other health 
issues, such as a higher prevalence of insulin resistance and T2DM, various 
strategies have been investigated to determine how this problem could be 
tackled to prevent a further rise and potentially assist with weight loss. These 
strategies have included investigations into individuals’ diets and specific dietary 
components that could be altered to subsequently impact on weight, insulin 
resistance and T2DM. One such component that has provoked considerable 
interest is DF, which has been proposed to increase satiety and therefore may 
have a beneficial role in weight management and potentially weight loss. RS, a 
type of DF, and whole grains (in which RS is a major component of the DF) have 
been proposed to affect satiety. The aims of this research were therefore to 
elucidate the effects of RS and whole grains on appetite and food intake, with 
the view that, if positive effects on food intake could be proven, these could be 
beneficial for combating the rising obesity problem. Both acute and chronic 
consumption effects were investigated in normal and overweight individuals.
Despite there being consistent positive evidence of an effect of RS on appetite 
in rodent studies, the data from direct human studies are mixed. In both of our 
studies using RS, the RS was compared with an energy and available 
carbohydrate matched placebo, therefore providing an identical amount of 
glycaemic carbohydrate between the supplements. Differences in glycaemic 
carbohydrate have been a confounding factor in some of the previous work 
investigating the effects of RS on appetite. Our work has shown that when RS
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was ingested acutely (24 hours) at a high dose (48 g) there was a reduction in 
food intake, although no effect on subjective appetite ratings. This effect was not 
reproduced in the chronic study (40 g RS daily for 4 weeks), although the study 
was underpowered. A novel finding from the acute study was a lower 
postprandial insulin response with the RS, possibly explained by increased 
hepatic insulin clearance. This finding was therefore further explored in the 
chronic study using a FSIVGTT. The raw data from the FSIVGTT indicated 
significantly higher glucose, insulin and C-peptide concentrations with the RS 
compared with the PL, possibly explained by improved first-phase insulin 
response, although the parameters obtained from modelling the data were not 
significantly different. However, again, the study was underpowered and 
therefore potential effects may have been masked, so further investigation 
would be required. If consumption of RS does indeed have beneficial effects, not 
only on the postprandial response, but also on the first-phase insulin response, 
this could be beneficial for the management of weight, insulin resistance and 
diabetes.
There is epidemiological evidence for an effect of whole grains on weight 
regulation and therefore a role in satiety has been proposed, but there is little 
intervention data to confirm this. Bread rolls containing 48 g whole grain (the 
minimum amount recommended to be consumed in America) were specially 
developed for use in a chronic intervention study. These rolls provided whole 
grains in both the intact and milled form to determine whether differences in 
grain structure affected the outcome measures. Prior to the chronic intervention
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three studies were conducted. The taste test revealed that whilst the 
experimental breads were rated less highly than the commercially available 
breads, the three developed breads were not perceived as too dissimilar to each 
other in terms of liking and on the properties of the rolls assessed. Therefore 
differences in the organoleptic properties of the breads would be unlikely to 
influence any observed effects on appetite in an intervention study. Although the 
Gl of the rolls resulted in two products having a Gl in the high category (milled 
whole grain and control) and one in the medium category (intact whole grain) the 
difference was not statistically significant. As the Gl, glucose and insulin 
responses in this study were not significantly different, this is unlikely to be a 
contributing factor if any differences were observed on the glucose and insulin 
responses in a chronic intervention study. The short-term crossover (3 week) 
study comparing the milled whole grain rolls and the control rolls revealed no 
significant difference between the two rolls on appetite and food intake. A 
significantly lower systolic blood pressure was observed following the milled 
whole grain intervention compared with the control. The participants in this study 
were healthy, of normal weight and had high fibre diets before the study, which 
may have masked potential effects of increased whole grain intake on food 
intake and appetite.
Acute ingestion of the rolls at a single meal (study morning 2 of the 8 week 
intervention study), by overweight and obese participants, did not alter food 
intake, subjective appetite ratings or postprandial metabolites. The chronic (8 
week) whole grain intervention found no difference between the three rolls for
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subjective appetite ratings or energy intake (at the ad libitum test meal and from 
intakes calculated from the diet diaries), but there did appear to be moderate 
effects on energy and macronutrient intakes within each treatment group 
(energy intake increased in all three groups). Similarly, for the cholesterol 
concentrations and the postprandial metabolites there appeared to be little 
difference between the interventions, but some effects within the different 
treatments. These findings would require further investigation with more 
participants and/or in a crossover designed study, to confirm whether these are 
true effects of whole grain consumption or are incidental findings. Both whole 
grain interventions appeared to improve the postprandial insulin responses, 
more so with the intact than with the milled whole grains, which could be 
explained by the lower Gl of intact whole grains compared with the Gl of the 
milled whole grain and control rolls, although this is unlikely.
Overall these studies have shown that when ingested acutely RS may have a 
role as a satiating ingredient. Whilst this finding was not observed in the chronic 
intervention, the study was underpowered and there appeared to be a lower 
energy intake at the ad libitum test meal which may have reached significance 
with more participants. Although the role of RS in satiety is still not completely 
defined, a clear and novel finding from our two studies, was an effect of RS 
consumption, both acutely and chronically, on insulin responses. More 
participants would be required to determine exactly what the mechanism for an 
effect on the insulin response is, but our data appear to indicate an improvement
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in first-phase insulin secretion or increased hepatic insulin clearance. Our 
studies using whole grains appeared not to agree with the epidemiological 
evidence suggesting a role of whole grains in satiety and therefore weight 
regulation. When ingested in the short-term (3 weeks) there was a beneficial 
effect of the milled whole grains on blood pressure regulation; this finding was 
not confirmed in the chronic intervention (8 weeks) in overweight/obese 
participants. Whist the whole grain study was underpowered the lack of 
significant findings on appetite and food intake may indicate that whole grains do 
not actually affect food intake/weight. It may in fact not be the whole grains 
alone that confer beneficial effects, as suggested from epidemiological studies, 
but instead it is the overall healthier lifestyle habits, that those who habitually 
consume high whole grain diets follow, which provides beneficial protective 
effects.
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7.2. Conclusions
• Acute (24 hour) consumption of 48 g RS reduced energy intake at an ad 
libitum test meal at the end of the 7 hour postprandial period and over the 
whole 24 hour period in healthy, young adult males, compared with an 
energy and available carbohydrate matched placebo.
• Acute (24 hour) consumption of 48 g RS reduced the postprandial insulin 
response in healthy, young adult males compared with an energy and 
available carbohydrate matched placebo, possibly explained by an 
increase in hepatic insulin clearance.
• 40 g RS per day for 4 weeks in overweight/obese participants did not 
affect food intake or subjective appetite ratings compared with an energy 
and available carbohydrate matched placebo.
• Following 40 g RS per day for 4 weeks in overweight/obese participants 
there were significantly higher glucose, insulin and C-peptide 
concentrations, measured during an FSIVGTT, with the RS compared 
with the placebo. However, parameters obtained from the modelling of 
the data were not significantly different.
• 3 week daily consumption of 48 g milled whole grain in healthy young 
adults did not significantly affect appetite or food intake compared with 
refined grain intake, although food intake increased during the refined 
grain intervention and remained fairly constant during the milled whole 
grain intervention.
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• 48 g milled whole grain per day for 3 weeks may have a beneficial role in 
blood pressure regulation compared with refined grain in healthy young 
adults.
• Acute ingestion of 48 g whole grains (intact or milled) or control rolls by 
overweight/obese at a single meal resulted in no significant differences 
between the breads in food intake, subjective appetite ratings or 
postprandial metabolites.
• 8 week daily consumption of either 48 g whole grains (in both the intact 
and milled form) or refined grain in overweight/obese participants did not 
affect subjective appetite and had little effect on energy intake.
• There was little effect of 8 week daily whole grains consumption (in the 
intact and milled form) on postprandial metabolites in overweight/obese 
participants.
Overall conclusions:
o RS appears to be a possible candidate as a satiating ingredient when 
consumed acutely. Although the chronic study did not confirm this effect, 
the subject numbers were small and therefore could mask a potential 
beneficial product in weight management.
o Intervention with 48 g whole grains, in either form, has little effect on 
appetite or food intake compared with refined grain and therefore these 
studies do not agree with epidemiological evidence.
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7.3. Future work
The work conducted in this thesis has been interesting and informative. Whilst 
the RS work has indicated that inclusion of a high dose of RS in the diet may 
have acute appetite effects, as well as interesting metabolic effects, the work 
with whole grains has shown less positive effects on appetite and food intake, 
potentially disproving the epidemiological evidence. In both instances further 
areas of research have been highlighted and would be interesting to pursue 
given more time.
• Continue with the long-term RS and appetite and FSIVGTT study with 
more participants which would provide valuable information on both the 
metabolic effect, but also on any effects on appetite and food intake 
from which further research could progress.
• Inclusion of normal weight individuals to the long-term RS and appetite 
and FSIVGTT study would allow the determination of whether there are 
effects on appetite that are overridden in the overweight population.
• If the long-term consumption of RS indicates an improvement in the 
first-phase insulin response then another long-term crossover 
intervention (of a longer period of time 8-12 weeks) in individuals with 
clinically diagnosed impaired glucose tolerance and/or diabetes, as the 
target group for a clinical improvement, would be conducted to 
determine whether a beneficial effect could be achieved
• Conduct an appetite and RS study for longer time periods to allow for 
adaptation for fermentation and monitor effects on fermentation
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(changes to SCFA in blood or urine) to determine if this is the 
mechanism for an effect on appetite. The effects on blood lipids could 
be further explored in this study. This study could be conducted as a 
dose response study, with increasing amounts of RS being given to 
determine the optimal amount needed to affect 
fermentation/appetite/blood lipids. Alternatively this could be conducted 
as a longer-term study (for example 16 weeks), with study days 
conducted every 4 weeks to determine the minimum length of time 
needed for an effect on fermentation/appetite/blood lipids to occur, and 
whether adaptation occurs at a point at which further consumption at 
that dose does not have a continuing effect.
• Carry out a long term whole grain crossover intervention in 
overweight/obese individuals, using commercially available whole grain 
products to determine overall intake effects on appetite from 
commercially available products and incorporate a biomarker to assess 
compliance.
• Carry out a whole grain study further investigating the blood pressure 
effect, utilising 24 hour monitoring and other vascular markers to 
determine whether whole grains do beneficially affect blood pressure. 
This could be conducted in two population groups, those with and those 
without hypertension, to determine where the beneficial effect would lie.
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An example of the Health and Lifestyle Questionnaire (self-certificate medical 
questionnaire) used in the studies. Each questionnaire was tailored from this to 
suit the particular study.
Self-Certificate Medical Questionnaire 
Study:
Name:.................................................... Date of Birth:...........................
Address:..........................................................................................................
Contact Telephone Number:.........................................................................
GP Name:......................................................................
GP Address:.................. ....................................................................................
Please tick all/any of the following that apply:
□  I have no prior or present history of Coronary Heart Disease, Angina or 
Stroke
□  I have no prior or present history of Type 1 or Type 2 diabetes
□  I have no prior or present history of anaemia
□  I have no prior or current history of gastrointestinal diseases (for example
Crohn’s disease, Coeliac disease, Irritable Bowel Syndrome)
□  I have no prior or present history of liver disease
□  I have no prior or present history of endocrine disorders
□  I have no prior or present history of, nor am I currently being treated for, 
clinical depression and/or other psychological disorders
□  I have no prior or present history of eating disorders, including anorexia or 
bulimia nervosa
□  I have no prior or present history of drug or alcohol abuse within the last 2 
years
A p p e n d ix  1
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□  I am not currently taking or have taken any regular medication prescribed by 
my GP in the last 6 months (if you are please state what you are taking)
□  I am not currently taking or have taken any supplements in the last 6 
months
Have you had any other medical conditions or recent hospital visits?
YES / NO
If you answered yes, could you provide details?
Are you currently on a weight-reducing diet or other dietary restriction?
YES / NO
If yes, please provide details.
Are you allergic to any foods?
YES / NO
If yes, please state what foods you are allergic to.
Do you have any religious dietary requirements?
YES / NO
If yes, please provide details.
Have you been involved in a clinical trial in the last 3 months?
YES / NO
Do you smoke?
YES / NO
If yes, how many per day?
Do you drink alcohol?
YES / NO
If yes, how many units per week? (See below)
Alcohol Measure Unit
Ordinary strength lager (4%) e.g. Carling, Fosters Pint 2.3
Strong lager (5.2%) e.g. Stella Artois, Kronenburg Pint 3
Strong lager e.g. Stella Artois, Carlsberg Export, Grolsch 440ml can 2.2
Beer/ordinary strength Ale e.g. John Smith’s, Guinness Pint 2.3
Red/White Wine Std 175ml 2
Red/White Wine Lg. 250ml 3
Spirits Std 25ml 1
Spirits Lg. 35ml 1.4
Alcopop e.g. Smirnoff Ice, Bacardi Breezer, Reef 275ml 1.5
Signed___________________ . Date I I
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The Dutch Eating Behaviour Questionnaire completed at screening. The 
coloured asterisks indicate the questions relating to external eating (green), 
emotional eating (blue) and restrained eating (red).
A p p e n d ix  2
in  C3 S
a !  & $
s 1 1 1 S -l<L> O O£  TO TO O  >  2 :
1. If you have put on weight, do you eat less than you usually do? *
2. Do you have a desire to eat when you are irritated? *
1
3. If food tastes good to you, do you eat more than you usually do? *
4. Do you try to eat less at meal times than you would like to eat? *
5. Do you have a desire to eat when you have nothing to do? *
6. Do you have a desire to eat when you are depressed or discouraged? *
7. If food smells and looks good, do you eat more than you usually eat? *
8. How often do you refuse food or drink offered because you are concerned about your 
weight? *
9. Do you have a desire to eat when you are feeling lonely? *
10. If you see or smell something delicious, do you have a desire to eat it? *
11. Do you watch exactly what you eat? *
12. Do you have a desire to eat when somebody lets you down? *
13. If you have something delicious to eat, do you eat it straight away? *
14. Do you deliberately eat foods that are slimming? *
15. Do you have a desire to eat when you are cross? *
16. Do you have a desire to eat when you are approaching something unpleasant to 
happen? *
17. If you walk past the baker do you have a desire to buy something delicious? *
18. When you have eaten too much, do you eat less than usual the following days? *
19. Do you get a desire to eat when you are anxious, worried or tense? *
20. If you walk past a snack bar or cafe, do you have a desire to buy something delicious? *
21. Do you deliberately eat less in order not to become heavier? *
22. Do you have a desire to eat when things are going against you, or things have gone 
wrong? *
23. If you see others eating, do you have also the desire to eat? *
24. How often do you try not to eat between meals because you are watching your weight?*
25. Do you have a desire to eat when you are frightened? *
26. Can you resist eating delicious food? *
27. How often in the evening do you try not to eat because you are watching your weight?$
28. Do you have a desire to eat when you are disappointed? *
29. Do you eat more than usual when you see other eating? *
30. Do you take your weight into account when you eat? *
31. Do you have a desire to eat when you are emotionally upset? *
32. When preparing a meal are you inclined to eat something? *
33. Do you have a desire to eat when you are bored or restless? *
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Visual Analogue Scale (VAS) questions used in this research. Each of the 
questions was presented to the participants on a separate page of a booklet, 
and a fresh booklet was given to the participants at each time point. Participants 
marked the line according to how they felt at the time and were told to regard the 
ends of the lines as the most extreme sensation they have ever felt.
A p p e n d ix  3
How hungry do you feel?
I am not hungry 
at all
I have 
never more 
hungry
How much do you think you can eat?
Nothing at all A lot
How full do you feel?
Not at all full Extremely
full
How thirsty do you feel?
Extremely
thirsty
Would you like to eat something sweet?
No, not at all Yes, very 
much
Would you like to eat something salty?
No, not at all Yes, very 
much
Would you like to eat something savoury?
No, not at all Yes, very 
much
Would you like to eat something fatty?
No, not at all Yes, very 
much
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Appendix 4
An example page from the 7 day diet diary given to participants, to show how 
the diaries should be completed.
Example diary pages 
What did you eat?
D ate_______ 2 3 /7 /2 0 0 3 _____Day of the Week____________Ttte&deiy
Time of day Food & Drink (Please describe in detail, including brand 
names where appropriate)
Amount Eaten
8.00am MaesCi - Sains Burys - no addedsugar MeddowC - pic 5a
Semi skimmed milk zoornC
(Brown sugar 1 heaped tsp
Toast - Cjranary dread- thick sdced 2 sheas
margarine (ffora) Thinly spread
honey 1 taBCespoon
tea 1 mug
semi-skimmedmiCk (in tea) Splash - 1 tdlsp
white sugar (in tea) 1 heaped tsp
10.30am Coffee with whole milk (in coffee) 1 mug
packet of crisps (IVatkers) 25g
1.00pm Lunch from canteem sandwich (white dread) 2 medium sCices
margarine (drand unknown) thick
egg mayonnaise 3 tdsp
■mustard and cress Jfandfid
cucumder 6 sCices
'.Bfackdem/ andappCe pie Tic 3a - Large
Custard Tic 8d - Medium
orange ft Ice 250V1C
3-3opm Tea. with whoCe milk & white sugar 1 mug (as Before)
Twix 2 finger
6.00 pm Tea with wfxoCe milk & white sugar Mug (as Before)
dodeddrown rice Tic 4a - Large
chicken curry Tic 4d - Large
mineraCwater (Sainsdury’s) Yi pint
Straw Berry yoghurt (SainsOury's Cow fat) isog
10.30pm Cager (Brandunknown) 33omCdotlCe
Notes/comments/recipes:
Chicken curry - 702 chicken, 1 viecConion, 1 tdBpnpoCyunsaturatedmargarine, 
ltdlspn currypowder, 3/ 4pint chicken stock, itdfspn mango cfiutney,
3 tdfspns sultanas, 1/4 pint Cow - fat yoghurt, 1 tbCspnpCainfCour.
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Food preference questionnaire completed in the Effects of Acute Consumption 
of Resistant Starch on Appetite
Food Preferences Questionnaire
Study: The Acute Effects of Resistant Starch on Appetite and Satiety
1. a) Are you a vegetarian?
□  YES □  NO
b) If you answered yes to question 1.a), do you eat -
A p p e n d ix  5
Cheese □  YES □  NO
Eggs □  YES □  NO
Milk □  YES □  NO
2. Do you usually have breakfast?
□  YES □  NO
3. a) Are you allergic to any foods?
□  YES □  NO
b) If you answered yes to question 3.a), please state what foods you are 
allergic to -
4. a) Do you have any religious dietary requirements?
□  YES □  NO
b) If you answered yes to question 4.a), please state -
260
An
 
ex
am
ple
 
pa
ge
 
fro
m 
the
 
7 
da
y 
bo
we
l 
ha
bit
 d
iar
y 
us
ed
 
in 
the
 
RS
 
st
ud
ie
s.
 P
ar
tic
ip
an
ts
 
we
re 
re
qu
ire
d 
to 
an
sw
er
 t
he 
st
ar
t
CO>.
03*o
h-
<D
O
CD
0
0O)
CD
CL
T 3 
C  O 
Q  
0 a>
0
£0
CL
Eoo
c
0
TJc
CD
CO£=O
CO
0
=JCT
Mu <5
5 E « e !V. (D fa O
I I I I  I 
I ? 1 I !
<D ~CL
_ ro .2 o ©' ® Q. 
_  ' ©  O ©tn w © oJ
©
a  «  "
~ lu E <  |  •o o S xi » xs a _  © n- © _  _
3 £8© cd J5 T> T>
«  N
i  1 c
O *  - T ±3 ©
E
 ^(0 73 O> £ S a, a c 
(H o ®  Ido roa 0) X3Ol Co +- ©
c - Eo £>©© -2 ^
,  o «1 13
.fa ^  £> © ®
l l “!§3» g a C S' 3 © 9 - 0jr © >. © © -C > -C .2
CO
CM
©e
g> £
©
i [Hi© S _fa
<5 F ® E .£ 5
1 ■*= © o
£  O’ © m _  
o E a f  ° ? 
3 c 5o w >. © >, 
S . r  CIS © © » 
© Q) ©3 -a 52
&8 Ior n 3 ® o 
© « c  > ©>  n 2=
oc T>
JN 0Ui© c"0 <0JC© o
§ 00
c
coJZ
a0>> £0iZ
■O
© Q)
§ So 0
o 0H— 03 00 0>> a0 *.> 0(0 c
X ±:
N © fa 'JC
52 ©
> T3° scO D)
-D ~5 © u£ s> &£ © ro ■©
m © © *n
tO >
H
av
e 
yo
u 
m
en
st
ru
at
ed
 
in 
the
 
pa
st
 
7 
da
ys
 
? 
If 
ye
s,
 p
le
as
e 
sp
ec
ify
 
d
at
es
Fo
od
 
list
 q
ue
st
io
nn
ai
re
 
us
ed
 
to 
m
ea
su
re
 
ha
bi
tu
al
 w
ho
le 
gra
in 
int
ak
e 
an
d 
to 
ex
clu
de
 
tho
se
 
wh
o 
re
gu
lar
ly 
co
ns
um
ed
 
hi
gh
U)(1)
cc
c
'2O)
0)o
Ne
ve
r
Ye
ar
ly
Q
ua
rte
rly
On
ce
 
a 
m
on
th
Fo
rtn
ig
ht
ly
1 X
 
we
ek
2 
x 
we
ek
4 
x 
we
ek
Da
ily
CM
CO
ro
Q
ft
5+
Ho
w 
m
an
y 
sp
oo
ns
/s
lic
es
 
of 
the
 
foo
d 
do
 
you
 
ha
ve
 
pe
r 
po
rti
on
?
Fo
od
 
(1 
po
rti
on
)
Br
an
fla
ke
s
Ch
ee
rio
s
Co
rn
fla
ke
s
Cr
un
ch
y 
Nu
t 
Co
rn
fla
ke
s
Fr
os
tie
s
M
ue
sli
Ric
e 
Kr
isp
ie
s
Sh
re
dd
ed
 
wh
ea
t
Sp
ec
ial
 K
W
ee
ta
bi
x
W
ee
to
s
O
th
er
Gr
an
ar
y 
Br
ea
d
W
ho
lem
ea
l B
re
ad
Br
ow
n 
Br
ea
d
Wh
ite
 
Br
ea
d
W
ho
lem
ea
l R
oil
W
hit
e 
Ro
ll
W
ho
lem
ea
l P
itta
 
Br
ea
d
Wh
ite
 
Pit
ta 
Br
ea
d
W
ho
lem
ea
l B
ag
el
26
2
Wh
ite
 
Ba
ge
l
W
ho
lem
ea
l E
ng
lis
h 
M
uf
fin
Wh
ite
 
En
gli
sh
 
M
uf
fin
Ric
e 
Ca
ke
s
Ce
re
al 
Ba
rs 
j
Cr
isp
br
ea
ds
Eoo
CLo
CL W
ho
lem
ea
l S
co
ne
s
Pla
in 
Sc
on
es
W
ho
lem
ea
l P
as
ta
Br
ow
n 
Pa
sta
Wh
ite
 
Pa
sta
W
ho
ieg
ra
in 
Ri
ce
Br
ow
n 
Ri
ce
Wh
ite
 
Ri
ce
26
3
